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FULL TITLE OF THESIS DEVELOPMENT OF RODENT IN VIVO MODELS: 
NEUROINFLAMMATION AND NEURODEGENERATION 
RELEVANT TO ALZHEIMERS DISEASE
STUDENT ID NUMBER: 0325956
SUMMARY OF THESIS:
Alzheimer’s disease (AD) is characterised by Ap plaque formation, neuroinflammation and 
neurodegeneration. Current therapies for AD do not modify disease progression; therefore, 
putative anti-inflammatory and neuroprotective agents need to be assessed in rodent in vivo 
models that demonstrate robust and reproducible markers of neuroinflammation and 
neurodegeneration. This thesis interrogated the development of in vivo models comprising 
markers of neuroinflammation and neurodegeneration in rodent brain. The overview 
describes innate immunity focusing on lipopolysaccharide (LPS) as a standard 
immunostimulant followed by a review of AD and beta amyloid (Ap). Current rodent in vivo 
models of LPS or AP-induced neuroinflammation or neurodegeneration are also examined. 
Chapters 2 and 3 describe the novel application of Luminex® suspension bead array systems 
for the detection of LPS-induced cytokine and other intracellular proteins in brain tissue. 
Intraperitoneal LPS modulated interleukin (IL)-lp, phosphorylated (p)-IicBa, p-p38 kinase 
and p-JNK protein and intracerebroventricular LPS increased IL-ip, IL-la and tumour 
necrosis factor (TNF) -a  protein in rat brain. Cytokine protein in rat brain was abrogated by 
dexamethasone and the a2-adrenoceptor antagonist, fluparoxan. Subsequent chapters 
investigate more disease relevant models of Ap-induced neuroinflammation and 
neurodegeneration detected by immunohistochemistry, Taqman or Luminex® techniques. 
Chapter 4 discussed the assessment, by western blotting, of Ap forms expelled from 
apparatus commonly used to inject solutions into rodent brain tissue and identifying the most 
consistent method of Ap delivery. Subsequent studies revealing inconsistent neurotoxicity 
but robust neuroinflammation following intra-hippocampal injection of Ap were described. 
Final chapters focus on neuroinflammation and neurodegeneration following peripheral 
insult (LPS or the noradrenergic neurotoxin, DSP-4) to amyloid precursor protein (APP) / 
presenilin 1 (PS1) transgenic mice. Peripheral administration of LPS or DSP-4 modulated 
markers of neuroinflammation and did not initiate neurodegeneration. The implications of 
the current data on the future development of in vivo models are discussed in the final 
chapter.____________________________________________________________________
Abstract
Neuroinflammation and neurodegeneration in brain tissue are prominent features in 
the progression of Alzheimer’s disease (AD). In the assessment of putative therapies 
for AD, rodent in vivo models that demonstrate robust markers of neuroinflammation 
and neurodegeneration are crucial. Previous detection of neuroinflammation in vivo 
has largely relied upon immunohistochemical evidence of microglial and astrocytic 
activation or measurement of cytokine mRNA in rodent brain. Observing 
neurodegeneration in response to beta amyloid protein (AP) in vivo is limited. 
Reports of exogenous Ap induced neurotoxicity are inconsistent and a majority of 
APP and APP/PS1 mutant mouse lines, unless presenting intraneuronal Ap 
deposition, do not exhibit overt neurodegeneration. This thesis explores the 
development of rodent in vivo models of neuroinflammation and degeneration and, 
the investigation of markers of neuroinflammation and neurodegeneration in brain 
tissue following intraperitoneal (IP) or intracerebroventricular (ICV) injection of 
lipopolysaccharide (LPS), intra-hippocampal (IH) injection of synthetic Api-42 or 
IP administration of LPS or the noradrenergic neurotoxin DSP-4 to the APP/PS1 
mutant mouse line, TASTPM.
(fi)Novel application of a Luminex suspension bead array system for the detection of 
LPS-induced proteins in brain tissue found that IP LPS induced increases in IL-ip, 
p-bcBa, p-p38 and p-JNK protein and ICV LPS induced increases in IL-ip, IL -la 
and TNF-a protein in rat brain tissue, which was abrogated by dexamethasone and 
the a2-adrenoceptor antagonist, fluparoxan. IH Api-42 injection via Hamilton 
syringe, confirmed by western blotting to provide consistent delivery of Api-42 into 
brain tissue, resulted in a small but variable increase in neurodegeneration but 
significant neuroinflammation. In TASTPM mice, IP injection of LPS or DSP-4 
altered cytokine protein levels and DSP-4 modulated expression of GFAP and Ap 
plaque load. Neither challenge induced neurodegeneration in TASTPM brain tissue. 
These data and recent published reports suggest peripheral insults such as LPS or 
DSP-4 to APP or APP/PS1 mice may only affect pre-existing neuropathology, a 
possibility that merits further investigation. Variability in Api-42-induced
1
neurotoxicity following IH injection indicates that damage caused by exogenous Ap 
may not provide a sufficient window of neuronal cell death suitable for screening 
neuroprotective agents. The data described here has implications on future 
development of models of neuroinflammation and neurodegeneration for screening 
putative therapeutic strategies for AD.
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CHAPTER 1 
General Introduction
1.1 Overview of thesis
Neuroinflammation and neurodegeneration is evident in the brain tissue of patients 
with the chronic neurodegenerative disorder Alzheimer’s disease (AD). Current 
symptomatic therapies for AD focus on alleviating impairments in learning and 
memory but do not alter underlying neuropathology. Hence, there is an unmet need 
for disease modifying agents that can slow the progression of AD. Putative anti­
inflammatory or neuroprotective therapies need to be adequately characterised using 
mechanistic and disease relevant preclinical in vivo rodent models that provide 
markers of neuroinflammation and neurodegeneration relevant to AD. This thesis 
aims to interrogate the development of rodent in vivo models of neuroinflammation 
and neurodegeneration that can be used in the preclinical assessment of disease 
modifying therapies for AD.
This introduction will introduce the innate immune system, specifically focusing on 
the role of cytokines in mediating innate immunity and a description of LPS, a well 
characterised immunostimulant used to induce inflammation in vivo. This section 
will finally discuss the detection of cytokine protein by xMAP technology on 
Luminex® systems, an approach not yet reported for the detection of proteins in 
rodent brain tissue following LPS treatment. Following this, the epidemiology and 
neuropathology of the progressive neurodegenerative disorder AD will be described. 
This will include an overview of proposed mechanisms for beta amyloid (Ap) 
peptide induced neuroinflammation and neurotoxicity and evidence for anti­
inflammatory treatment as a putative disease modifying therapy for AD. This 
introduction will finally discuss the current evidence for LPS and Ap-induced 
neuroinflammation and neurodegeneration in rodent in vivo models.
1.2 Innate immunity
Present from birth, the innate immune system is important in the recognition and
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removal of invading pathogens and is well conserved between invertebrates and 
vertebrates (reviewed by Kimbrell & Beutler, 2001). It is responsible for mounting 
an antigen non-specific defence against infectious stimuli, either immediately or 
within a very short period after infection. The response does not increase in intensity 
with each subsequent exposure or rely upon previous recognition of the antigen 
(reviewed by Kimbrell & Beutler, 2001). The innate immune system can recognise a 
diverse range of pathogens namely by the recognition of well-conserved pathogen- 
associated molecular patterns (PAMPs) present in many different pathogenic 
organisms (Janeway, 1989) by pathogen recognition receptors (PRRs) located on the 
cell surface of immune cells. PRRs include members of the transmembrane signal 
transducing toll-like receptor (TLR) family (Gordon, 2002), which recognise 
PAMPS present on specific organisms such as LPS from the cell wall of gram 
negative bacteria (toll-like receptor 4 (TLR4)) (Miyake, 2004). Surveillance by the 
innate system continues throughout an organism’s lifetime but ageing causes 
diminished function of immune cells that result in a compromised innate response 
(Plackett et al, 2004). Elements of innate immunity occur in a number of chronic 
neurodegenerative disorders including AD (McGeer & McGeer, 2002) and this will 
be described in more detail in section 1.3.6.
1.2.1 Effector cells o f innate immunity
The innate immune system comprises of a variety of phagocytic cells including 
macrophage (reviewed by Gordon, 1998), neutrophil (reviewed by Kobayashi et al, 
2005), dendritic (reviewed by Foti et al, 2004; Rossi & Young, 2005) and natural 
killer (NK) cells (reviewed by O’Connor et al, 2006). These cells engulf foreign 
pathogen and use intracellular vacuoles containing toxic reactive oxidants such as 
nitric oxide (NO), superoxide and degradative enzymes to destroy the microbe 
(Lowenstein et al, 1994). Immune cells are also responsible for the release of soluble 
proteins including those of the complement cascade and cytokine families to enhance 
uptake of pathogen, recruit further cells to the site of invasion and control initiation 
of an antigen-specific response via binding of innate and adaptive immune cells (van 
Rossum & Hanisch, 2004; reviewed by Liew & Mclnnes, 2002). Immune cells, 
particularly macrophage and dendritic cells, act in antigen presentation to initiate 
adaptive immunity by processing engulfed antigen and displaying fragments on the 
cell surface combined with class I or class II major histocompatibility complex
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(MHC). MHC binding, alongside interaction of costimulatory molecules such as 
CD28 on the T cell and CD80 or CD86 on antigen presenting cells (APCs), activates 
subpopulations of T cells. CD4 T helper (Th) or CD8 cytotoxic (Tc) cells 
differentiate into effector subsets depending on the combination of costimulatory 
molecules and cytokines present during activation. Recruitment of effector cells of 
the innate immune system and subsequent activation of cells involved in antigen- 
specific adaptive immunity is controlled and maintained by circulation of cytokines 
(Hoebe et al, 2004; Blach-Olszewska, 2005) (fig 1.1).
Invading pathogen
Chemokines Mannose binds lectin 
(MBL): increase C3 
convertase.
IL1
IL1/IL12
Acute phase 
proteins
IFNy
GMCSF, TNFo, ELI 
IL6, IL10, MCP1, 
MIPla, RANTES
IL1
Neutrophils 
chemoattracted 
to site
Activation of 
complement pathway
PAMPs recognised by 
opsonins
HP A axis 
induction; release 
of endogenous 
glucocorticoids
Neutrophils enter tissue 
from bloodstream via 
diapedesis
Activated cells phagocytose 
antigen present via specific 
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PAMP recognition by 
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primed macrophage & 
dendritic cell
Macrophage and dendritic 
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the invading pathogen
Figure 1.1: Schematic representation o f innate immune system
1.2.2 Cytokines
Potent short acting protein (15-25kDa) mediators generically termed cytokines 
mediate the inflammatory response. Cytokines include lymphokines, interleukins, 
tumour necrosis factors, chemokines (reviewed by Esche et al, 2005; Coelho et al, 
2005) and interferons (reviewed by Kunzi & Pitha, 2005) secreted by a wide variety 
of immune cells (Moller et al, 2005). Cytokines are pleiotrophic and function to
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regulate the intensity and duration of an inflammatory response by regulating 
haematopoiesis and mediating cell growth, differentiation and activation (reviewed 
by Cohen & Cohen, 1996). Due to their role in the maintenance of inflammation, 
cytokine proteins have a short half-life enabling rapid degradation to control the 
immune response. Hence, rapid production of these potent proteins remains transient 
and at low concentration to allow management of inflammation. A single cytokine 
can initiate a cascade of cytokine production from a multitude of immune cells and 
may demonstrate autocrine, paracrine and possibly endocrine actions. Furthermore, 
cytokines act both synergistically and exhibit redundant activity to rapidly initiate an 
adequate immune response (reviewed by Asadullah et al, 2002).
1.2.2.1 Cytokine Families
Since many cytokines have over-lapping actions and few share sequence similiarity 
(reviewed by Turnbull & Rivier, 1999), functional attributes, target receptors or cells 
of origin of cytokines have allowed a classification of cytokines into families (Table 
1.1).
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Cytokine 1 Origin Actions
COLONY STIMULATING FACTOR (CSF)
Granulocyte
Macrophage-CSF
T cells
Macrophage
Endothelium
Induces growth of granulocytes and macrophage colonies 
Activates macrophage, neutrophils and eosinophils
INTERFERONS (IFN)
IFN-y Thl cells 
Tc cells 
NK cells
Primes macrophage & induces MHC I/II
Antagonises some IL4 actions
Induces B cell antibodies, inhibits viral replication
TUMOUR NECROSIS FACTOR (TNF)
TNF-a Monocyte 
Macrophage 
Neutrophils 
T & B cells 
NK cells 
Astrocytes 
Mast cells
Activates primed macrophage and NK cells.
Anti-tumour activity 
Promotes neuronal survival
Recruitment & activation of neutrophils & monocytes 
Mediates septic shock, cell proliferation & apoptosis 
Induction of chemokines, IFNy, TNFa, ELI, GM CSF, 
IL6
Induces acute phase proteins
INTERLEUKINS (IL)
IL-1 
(a & |3)
Monocyte 
Macrophage 
Fibroblasts 
B cells
Dendritic cells
Fever induction
Induces macrophage PGE2/cytokines 
Induces neutrophil adhesion molecules 
B and T cell proliferation 
Induction of acute phase proteins
IL-2 Thl cells Stimulates T & NK cell proliferation
IL-4 B cells 
Th2 cells 
Mast cells
Initiates B cell antibody production
Stimulates cytokine release & antigen presentation
Stimulates T cell growth
IL-6 Th2 cells 
Macrophages 
Mast cells 
Fibroblasts
B & T cell differentiation & T cell growth 
Induces IL2 & IL2 receptor expression on T cells 
Initiate and regulate acute phase proteins 
Involvement in tissue repair
IL-10 Macrophage 
Th2 cells 
B cells
Anti-inflammatory, immunosuppressive 
Down regulates IL1, TNFa and IFNy 
Alters microglia receptor expression.
IL-12 | Macrophage Induction of T cell and Thl cytokines
CHEMOKINES
Monocyte 
Chemoattractant 
Protein (MCP) -1
Macrophage, T 
cells
Chemotactic for T cells
Macrophage 
Inflammatory 
Protein (MlP)-la
Macrophage, T 
cells
Chemotactic for T cells
Regulated on 
Activation, Normal 
T Expressed and 
Secreted 
(RANTES)
Macrophage, T 
cells
Chemotactic for T cells
Table 1.1: Overview of selected cytokine origin and roles (adapted from Kuby, 1997)
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1.2.3 Cytokine transcription
Specific extracellular cytokine receptors and toll-like receptors (TLRs) mediate 
cytokine transcription via two distinct MyD88-dependent and MyD88-independent 
intracellular pathways (reviewed by Gillis, 1991).
Figure 1.2: Schematic representation of TLR4 signalling cascade (Figure taken from 
Palsson-McDermott & O’Neill, Immunology, 2004)
Translocation of the transcription factor nuclear factor-KB (NF-kB) (reviewed by 
Saklatvala et al, 2003; Goodridge & Harnett, 2005) occurs via activation of 
intracellular adaptor proteins, myeloid differentiation factor 88 (MyD88), MyD88 
adaptor-like protein (TIRAP) also known as Mai, TIR-containing adaptor molecule 
(TRIF) also known as TIC AM-1 and TRIF-related adaptor molecule (TRAM) also 
known as TICAM-2. These communicate signals from transmembrane receptors (fig 
1.2). The translocation of NF-kB from the cytoplasm to the nucleus depends on 
phosphorylation of the inhibitory factors IkBoc and/or IkBP resulting in the induction 
of target gene transcription (Krappmann et al, 2004). The MyD88/IRAK/TRAF6
i i  1 1 1 1  m i  i  i t  1 1 1 1 1 1 1  m  1 1 1 1 1 1 1 1 1 1 1 1 1 1  ■ 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
I *1 ) I I *  A  M l  m m b f i M
m * D 3 *
MyD88-independent
MyD88-dependent
t r a f b
, 7BK»
P M
TRAFfi
■ KKI^KKZ
JxFuB binding 
motif
E arly  p n a s o
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complex can also activate the MAPK cascade. Translocated transcription factors bind 
to response elements located on the promoter regions of target genes to induce 
transcription of selected DNA.
1.2.4 Signal transducing pathways
The mitogen-activated protein (MAP) kinase cascade (reviewed by Karin, 2004; 
Woodgett et al, 1996; Dong et al, 2002) mediates and controls target gene 
transcription as a direct response to the extracellular environment of the cell. The 
hierarchical organisation of a multitude of specific intermediary kinases allows the 
control of transcriptional regulatory proteins via amplification and diversification of 
the initial signal (reviewed by Seger & Krebs, 1995). This is subsequently managed 
at each kinase level by the action of phosphatases (Zhang et al, 2002).
Evidence supports a role for MAP kinases in a plethora of cellular functions 
including cell survival (reviewed by Matsuzawa et al, 2005), apoptosis (reviewed by 
Sumbayev & Yasinska, 2006) and inflammation (Karin, 2005). Signal transducing 
pathways influence the expression of a number of mediators including 
proinflammatory cytokines (reviewed by Pocock et al, 2001), nitric oxide synthase 
(NOS) (reviewed by Guzik et al, 2003), matrix metalloproteinases (Reuben & 
Cheung, 2006) and cyclo-oxygenase 2 (COX2) (Akundi et al, 2005). The key 
function of MAP kinases in the immune response has led to intensive research into 
kinases as potential therapeutic targets for chronic inflammatory diseases (Karin,
2004). The vast number of kinases involved in each pathway suggests targeting 
individual kinases may not provide a sufficient anti-inflammatory effect owing to 
compensation by other kinase pathways and manipulating dual or multiple kinases 
may compromise the vast array of kinase functions (Karin, 2005). There are three 
well-characterised groups of MAP kinases recently shown to be present in 
mammalian cells that are activated by dual phosphorylation at a tripeptide motif, 
Thr-Gly-Tyr, Thr-Pro-Tyr and Thr-Glu-Tyr for p38, c-Jun amino-terminal kinase 
(JNK) and extracellular signal-regulated kinase (ERK) respectively (Dong et al,
2002) (fig 1.3). The role of these three MAPK cascades in inflammation is outlined 
below.
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Figure 1.3: Overview of the MAP Kinase cascade (Taken from Clark & Lasa, 2003) 
1.2.4.1 Involvement o f p38 pathway in inflammation
A wide variety of stimuli can activate p38 kinase including stress, pathogens such as 
lipopolysaccharide, cytokines, growth factors and some catecholamines (reviewed by 
Ono & Han, 2000). P38 kinase can phosphorylate or activate both transcriptional and 
non-transcriptional factors including activating transcription factor 2 (ATF2), sap-la 
and GADDI53 and alternative targets such as the mitogens activated protein kinase 
activated protein kinases (MAPKAPKs -2, -3, -5) & MAPK interacting kinase 
1(MNK1). Direct phosphorylation of transcription factors or activation of 
downstream kinases such as mitogen activated protein kinase 1 (MSK1) results in the 
post-transcriptional regulation of proinflammatory cytokines, iNOS, c-Jun (a 
component of the transcription factor complex activator protein-1 (AP-1)) and the 
monocyte chemoattracting protein-1 (MCP-1) via MAPKAPK2 (Ono & Han, 2000). 
Kotlyarov et al (1999) demonstrated that following intraperitoneal LPS injection, the
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attenuation of the proinflammatory cytokine TNF-a was evident in the serum of 
MAPKAPK2 KO mice supporting the role of MAPKAPK2 in regulating cytokines at 
the post-transcriptional level (reviewed by Saklatvala, 2004). The anti-inflammatory 
cytokine IL-10 can also attenuate TNF-a by inhibiting MAPKAPK2 mediated 
activity on AU-rich elements in TNF-a transcripts. TNF-a possesses AU-rich 
elements in the 3’ untranslated region making the mRNA unstable and short lived 
(reviewed by Saklatvala, 2004). Inflammation incurs phosphorylation of AU-binding 
proteins occupying AU-rich elements via a p3 8-dependant pathway involving 
MAPKAP2 (Neininger et al, 2002; Frevel et al, 2003) resulting in release, 
stabilisation and translation of cytokine mRNA.
1.2.4.2 Involvement o f JNKpathway in inflammation
JNK kinases can bind and phosphorylate transcription factors including ATF2, 
SMAD3, Elk-1, serum response factor accessory protein la (sap-la) and c-Jun 
(Tibbies & Woodgett, 1999). The transcription factors, AP-1 and ATF2 increase 
cytokine mRNA expression that consequently results in JNK mediated TNF-a- 
induced AP-1 activity and, along with p38 MAPK and NF-kB, TNF-a-induced 
upregulation of cell adhesion molecules (Herlaar & Brown, 1999). T cell and antigen 
presenting cell (APC) binding also activate the JNK pathway and, in conjunction 
with ERK, induce expression of the promoter and enhancer element of IL-2, a 
cytokine important in T cell proliferation (reviewed by Dong et al, 2001).
1.2.4.2 Involvement o f  ERK pathway in inflammation
ERKs are responsible for post-transcriptional control of immune mediators, 
activation of eosinophils and the positive selection and lineage commitment of 
thymocytes (Tibbies & Woodgett, 1999). Despite some understanding of the role of 
the ERK pathway in T cell activation and proliferation, there is relatively little 
information on the role of ERK in inflammation (Karin, 2004). More recent reports 
have suggested the role of MAP3K tpl2/cot in ERK-mediated LPS-induced 
activation of macrophages. Tpl2 knockout mice displayed abrogated LPS-induced 
ERK activation and TNF-a release (Dumitru et al, 2000). ERK activation appears to 
modulate translocation of TNF-a mRNA from the nucleus to the cytoplasm rather 
than affecting transcription or stabilisation of TNF-a mRNA (Dumitru et al, 2000).
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1.2.5 The hypothalamic-pituitary-adrenal (HPA) axis
Cytokine expression in brain tissue can activate the HP A axis (Morand et al, 1999; 
Beishuizen & Thijs, 2003). The adrenal gland is located above each kidney and 
comprises two distinct regions, the adrenal cortex and adrenal medulla. The adrenal 
cortex can release a variety of steroid hormones derived from cholesterol, namely 
glucocorticoids, mineralocorticoids and androgens. The hormone, 
adrenocorticotrophin (ACTH), produced by the anterior lobe of the pituitary is 
responsible for regulating the release of steroid hormones from the adrenal cortex. In 
turn, the release of corticotrophin-releasing factor (CRT) and vasopressin (AVP) via 
the median eminence modulates ACTH production (reviewed by Campeau et al, 
1998). The most abundant endogenous glucocorticoid (GC) released in humans is 
cortisol, which has potent anti-inflammatory properties (Sweep et al, 1991).
1.2.5.1 Cytokine-induced glucocorticoid production
Studying the role of cytokine-induced glucocorticoid production in vivo is difficult 
and the relative significance and precise mechanism of peripherally and centrally 
derived cytokines in HPA stimulation remains unclear (Beishuizen & Thijs, 2003, 
Angeli et al, 1999). However, studies have provided evidence to support a role for 
IL-1 p. There was an early suggestion that central IL-ip can activate noradrenergic 
neuronal terminals found within the hypothalamus, which modulate the 
hypothalamic CRF secretion but there remains conflicting evidence both supporting 
(Gwosdow et al, 1992) and arguing against (Cambronero et al, 1992) the 
involvement of catecholamines in IL-ip-induced CRF secretion. Subsequent data 
suggested the involvement of the vagal nerve in communicating the peripheral 
immune response to the hypothalamus (Hosoi et al, 2000) since CRF and IL-1 p 
mRNA expression was increased in the hypothalamus after vagal stimulation, which 
increased plasma ACTH and corticosterone levels. More recently, it has been shown 
that the rapid induction of the HPA axis by IL-lp may be mediated by cyclo- 
oxygenase 2 (COX2) since COX inhibitors prevent IL-lp induced HPA activation 
(Dunn, 2000). The chronic activation of the HPA axis may; however, be mediated by 
multiple mechanisms as this occurs independently of COX2 expression (Dunn, 
2000).
Intravenous (IV) and intracerebroventricular (ICY) injection of IL-1 p can dose-
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dependency increase plasma ACTH and induce hypothalamic CRT secretion (Uehara 
et al, 1987; Brown et al, 1991). A pre-injection of rabbit antiserum against rat CRT 
attenuated IL-1 p-induced ACTH (Uehara et al, 1987; Payne et al, 1994). IL-ip also 
upregulates glucocorticoid receptor (GCR) mRNA expression in hypothalamic CRF- 
secreting cells (Angeli et al, 1999). Attenuation of the IL-1 p-induced CRF secretion 
occurs with treatment of the glucocorticoids, corticosterone and Dexamethasone 
(DEX), (Cambronero et al, 1992; Betancur et al, 1995). The HPA axis can regulate 
IL-ip secretion via IL-1 receptor antagonist (IL-IRa) production (Kovalovsky et al, 
2000) and via modulation of IL-1 receptors (Goujon et al, 1997). Post infection, 
glucocorticoids and IL-IRa reach a maximum in the plasma simultaneously, 
preventing chronic IL-1 action (Arzt et al, 1994).
1.2.5.2 Glucocorticoid (GC) modulation o f cytokine induction
GCs act via numerous mechanisms of which the molecular-mediated effects on 
cytokine release are most widely studied (Refojo et al, 2003: 2001; Ray, 1992: 1990; 
Bailey, 1991). The actions of GCs can be biphasic; firstly, GCs may reduce cytokine 
synthesis by macrophage and monocytic cells by preventing transcription and 
translation of target genes. GCs can, due to their lipophilic nature, diffuse into the 
cell and bind to receptors that act as specific ligand-induced transcription factors, 
which are localised throughout most of the body, to form a GC-receptor complex 
(reviewed by Schleimer, 1993). The complex translocates from the cytoplasm to the 
nucleus where it undergoes a variety of structural changes to aid its interaction, via 
zinc fingers (Miesfeld, 1990), with the GC response element (GRE) located in the 
promoter region of target DNA (Schmidt et al, 1994). The GRE has a conserved 
palindromic sequence with each half-palindrome binding one subunit of the 
glucocorticoid receptor. Evidence suggests that GREs and other transcription factor 
DNA binding sites are in close proximity so that, on binding of the GC-receptor 
(GCR) complex, other transcription factor binding sites cannot be used, thus 
preventing the transcription of target genes (Schmidt et al, 1994). GREs can have 
either positive or negative roles during transcription so that GCs can induce or reduce 
the transcription of specific target genes on a tissue-specific basis (Kovalovsky et al, 
2000).
Post-transcriptionally, GCs may destabilise the resulting mRNA by rapidly reducing
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half-life, thus limiting its translation to a protein product. However, this theory 
remains contested (Brattsand et al, 1996). Whilst limiting the production of cytokines 
centrally, GCs also act by up-regulating cytokine receptor expression that enhances 
cytokine effects on target cells and control the further release of proinflammatory 
cytokines (Wiegers et al, 1998).
The GCR can also repress lipopolysaccharide or cytokine-induced NF-kB activation 
by protein-protein interaction between NF-kB and the GCR or by inducing FcBa/p 
expression, which acts to further inhibit the actions of NF-kB (Caldenhoven et al, 
1995; Van de Saag, 1996; Brostjan et al, 1996; De Bosscher et al, 1997; Vanden 
Berghe et al, 1999). Inhibiting NF-kB allows GCs to attenuate cytokine production 
and inhibit T cell proliferation (Ayroldi et al, 2001).
1.2.6 Lipopolysaccharide (LPS)
LPS is derived from the outer membrane of gram-negative bacteria such as 
Escherichia coli. LPS molecules consist of two main components: a well-conserved 
hydrophobic biphosphorylated lipid (lipid A) and a hydrophilic polysaccharide (PS). 
The PS has two regions, a non-repeating core oligosaccharide and a polysaccharide 
chain known as the O-chain (Caroff et al, 2002; Raetz & Whitfield, 2002; Dixon et 
al, 2005). The O-chain confers serotype specificity on a species or strain of bacteria.
The lipid A moiety binds to a variety of receptors including CD 14 that can initiate
activation of the innate immune system.
1.2.6.1 LPS: Mechanism o f action
LPS-binding protein (LBP), a 65kDa protein, binds LPS circulating in the 
bloodstream via the lipid A moiety (Ulevitch & Tobias, 1995). LBP behaves as a 
lipid transfer protein (Gallay et al, 1994) acting to convert aggregates of LPS to 
monomers to accelerate the binding of LPS to CD 14 (Hailman et al, 1994).
Soluble CD 14 (sCD14) aids activation of cells that do not express the membrane 
glycosylphosphatidylinositol-anchored CD 14 (Bazil et al, 1989; Fenton et al, 1998). 
Membrane-bound CD 14 (mCD14) lacks a cytoplasmic domain and in order to induce 
intracellular signals, CD 14 forms a complex recognised by TLR4 (Dobrovolskaia et 
al, 2002; Triantafilou et al, 2002; Heumann & Roger, 2002).
The adaptor protein MD-2, expressed by dendritic cells and monocytes, was
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originally identified by Shimazu et al, 1999. Co-expression of MD-2 is essential for 
the binding of LPS and translocation of the TLR receptor to the cell surface 
(Fujimoto et al, 2004; Miyake, 2004). Studies using radiolabelled LPS have 
illustrated a physical interaction between LPS, MD-2 and TLR4 can only occur in 
the presence of CD 14 (da Silva Correia et al, 2002) irrespective of the role of MD-2 
in complexes with LPS (Kennedy et al, 2004) or TLR4 (Visintin et al, 2001; 
Fujimoto et al, 2004). Although the CD14/MD-2/TLR4 complex is well recognised, 
LPS may also activate CD64, CD 16, CD32, CD36, CD55 (Heine et al, 2003) and 
CD 11 c/CD 18 (Ingalls & Golenbock, 1995) cell surface receptors, depending on cell 
type and activation state.
1.2.6.2 Communication between periphery and CNS
Peripheral inflammation may be sensed by the brain via two pathways, namely the 
neural and humoral mechanisms. Evidence supports a major role for humoral 
pathways during systemic inflammation (Szelenyi, 2001; Rivest et al, 2000). Blood- 
borne cytokines can bind to endothelial receptors in brain tissue or cross the blood- 
brain barrier (BBB) through a saturable carrier-mediated mechanism that is most 
likely to initiate when very high cytokine concentrations exist in the blood (Pavlov et 
al, 2003). Much of the communication from periphery to brain occurs via the 
circumventricular organs (CVOs), areas of minimal BBB, since cytokines in the 
blood can initiate the synthesis and release of soluble mediators including 
prostaglandins and nitric oxide at CVO sites. Circulating LPS can bind to TLR4 
located on endothelial cells of the circumventricular organs (CVOs), leptomeninges 
and choroid plexus (ChP) of the brain and on the surface membrane of monocytes, 
mast cells and neutrophils. TLR4 activation causes transcription of cytokine target 
genes within immune cells, particularly microglia, firstly at the CVOs, choroid 
plexus and leptomeninges and then eventually throughout the brain tissue (Nadeau & 
Rivest, 1999; Ericsson et al, 1995, Herkenham et al, 1998; Vallieres & Rivest, 1997). 
Expression of mCD14 also increases dramatically in microglia, CVO regions and 
then throughout the brain following intravenous (IV) or intraperitoneal (IP) LPS 
(Lacroix et al, 1998). This leads to NF-kB translocation and proinflammatory 
cytokine production, firstly at areas easily reached by the systemic circulation and 
then subsequently throughout the brain tissue. IP LPS injection induces rapid IL-6
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expression in the CVOs and ChP, however, IV injection of pro-inflammatory 
cytokines IL-lp and TNF-a fail to stimulate IL-6 transcription (Vallieres & Rivest, 
1997). There is also evidence to suggest that intraperitoneal LPS may cause mild 
breakdown of the microvasculature allowing diffusion of LPS through the barrier 
(Singh et al, 2004). Entry of molecules into the brain following breakdown of the 
BBB is molecular weight dependent with molecules of approximately <340Da 
entering brain tissue (Singh et al, 2004). The molecular weight of LPS is lOkDa so it 
is possible, but unlikely, that sufficient LPS can enter the brain to elicit a central 
response.
The neural pathway, consisting of the cytokine-mediated activation of vagus nerve 
afferent fibres, links the sympathetic nervous system and the hypothalamic-pituitary- 
adrenal axis (HPA) that ultimately modulates inflammatory processes. Vagal 
afferents terminate in the dorsal vagal complex located in the medulla oblongata and 
comprising the nucleus tractus solitarius, the dorsal motor nucleus of the vagus and 
the circumventricular organ, area postrema. The paraventricular nucleus of the 
hypothalamus, important in releasing corticotrophin releasing hormone as part of the 
HPA axis, interacts with the nucleus tractus solitarius. Evidence from vagotomy 
studies suggests that the neural pathway is more important in mediating mild 
inflammation since preventing input from the vagus nerve can inhibit activation of 
the HPA axis (GayKema et al, 1995) whilst failing to attenuate cytokine expression 
in brain tissue following high doses of LPS (Ishizuka et al, 1997). Humoral 
mechanisms may have more of a role during a rapid and strong peripheral response 
to infectious stimuli.
1.2.7 Detection o f cytokine expression
Cytokine mRNA expression can be detected using polymerase chain reaction 
techniques (reviewed by O’Garra & Vieira, 1992). The detection of mRNA 
expression provides valuable information on gene activity but does not take into 
account post transcriptional events that may affect subsequent protein production. 
Thus, detection of cytokine protein products in addition to the quantification of 
intermediary mRNA expression may provide a more valuable approach to assessing 
the magnitude of an inflammatory response (reviewed by Lockhart & Winzeler, 
2000). Initial detection of cytokine protein employed molecular hybridisation
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techniques or cell-based bioassays (Beckmann & Morrissey, 1991) and the use of 
radio-labelled or enzyme-linked antibodies directed against the protein of interest 
allowed the generation of more frequently used, easier and quicker, immuno-based 
assays (reviewed by Thorpe et al, 1992).
Initially, much standardisation was required between immuno-assay kits to establish 
specific recognition of antibodies for the target protein to prevent cross-reactivity and 
false results (reviewed by Mire-Sluis et al, 1995; Whicher & Ingham, 1990; Tsang & 
Weatherbee, 1996). Further development of highly specific antibodies and 
appropriate standards has allowed immuno-based assays to become highly successful 
as a sensitive and reliable method of detecting cytokine protein in samples (reviewed 
by Mire-Sluis, 1999; Lai et al, 2005; Delarche & Chollet-Martin, 1999). A 
disadvantage of enzyme-linked immunosorbant assays (ELISAs) is the need to 
analyse a single protein at one time which makes profiling of a range of cytokines in 
a single tissue both expensive and low throughput. The advent of multiplexed 
particle-based flow cytometric assays that use beads as the solid base, akin to a 
conventional immuno-assay, now allow detection of multiple analytes in a single 
sample (reviewed by Vignali, 2000; Kellar & Iannone, 2002).
1.2.7.1 Cytokine protein detection using xMAP® technology 
Luminex® suspension bead array systems utilise xMAP® (multi-analyte profiling) 
technology (Luminex Corp, Austin, USA) to allow the multiplexing of up to 100 
different assays within a single sample. The flow cytometers, FACSCalibur™ or 
Luminex® 100™, analyse a liquid suspension placed in each well of a standard 96- 
well plate comprising 5.5 micron polystyrene microspheres internally dyed with 
different ratios of two spectrally distinct fluorophores (red and infrared) that code the 
beads into 100 distinct sets (fig 1.4).
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Colour coded bead with 
specific spectral address 
(ratio of internal dyes)
Figure 1.4: Luminex® polystyrene microsphere beads (Images derived from www.Bio-
rad.com)
Each bead set can be coated with a reagent able to capture and bind a specific analyte 
present in a sample. The microsphere can be coated with a wide variety of reagents 
including antigens, antibodies, receptors, enzyme substrates or DNA (fig 1.5).
To quantify the captured analyte a biotinylated detection antibody followed by a 
fluorescently labelled reporter molecule such as Streptavidin-E is added to the 
suspension and following incubation, each well is read using a Luminex® array 
reader.
Colour coded bead with 
specific spectral address 
(ratio of internal dyes)
arget analyte
iotinylated detection 
antibody
  Streptavidin-PE
Figure 1.5: Detection of analyte by Luminex® bead suspension array (Image derived from
www.Bio-rad.com)
Precision fluidics within the reader aligns the beads into single file, allowing each 
bead to move through a flow cell containing two lasers. A red classification laser 
excites the specific colour coding internal dyes in each microsphere allowing 
identification of the bead. The green reported laser excites the reporter dye attached 
to each bead allowing detection and quantification of the captured analyte (fig 1.6).
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Digital signal processors and software record the fluorescent signals for each bead 
translating them into data for each assay.
Red and green 
classification 
lasers detect 
internal and 
reported dyes
Figure 1.6: Detection of analyte-bead complex by Luminex® 100™ system (Image derived
from www.Bio-rad.com)
1.2.7.2 Advantages o f using xMAP technology
Assessing multiple analytes in a single sample provides greater throughput in data 
collection and ensures reduced variability within the data set by performing 
simultaneous readings (up to 1000 events) on each bead set within a sample. A small 
sample of 12.5 pi can be used per multiplex assay allowing the sample to be utilised 
in further assays and is particularly useful where original sample volumes are small, 
often a problem with samples obtained from mice. As multiple analytes are assessed 
within the same sample, a direct correlation can be made between analytes indicating 
patterns in cytokine profiles more clearly i.e. decreased pro-inflammatory cytokines 
correlating with increased anti-inflammatory cytokine release.
1.2.7.3 Detection o f LPS-induced cytokine protein in brain tissue
LPS can increase the mRNA expression of inflammatory cytokines in plasma and 
brain compartments, particularly following intracerebroventricular injection (Gayle 
et al, 1998; Gayle et al, 1999; Turrin et al, 2001; Plata-Salaman et al, 1998; De 
Simoni et al, 1995). Cytokine mRNA expression also occurs to a lesser degree in 
brain tissue post IP administration in both mice and rats (Jacobs et al, 1997; Kakizaki 
et al, 1999; Laye et al, 1994; Pitossi et al, 1997; Satta et al, 1998; Goujon et al, 1997; 
Castanon et al, 2004). LPS-induced cytokine protein induction in plasma was 
confirmed via the use of immuno-based assays such as ELISAs and, although central 
protein changes have been detected in mouse brain (Goujon et al, 1996) this has not
Individual beads 
■analysed in single 
file within flow cell
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been established in rat. Recent utilisation of xMAP® technology on Luminex® 100™ 
suspension bead array systems has provided further profiling of LPS-induced plasma 
cytokine protein responses, however, quantification of central cytokine levels post 
LPS treatment remains more focused on mRNA expression (Bobrowski et al, 2005). 
Detection of LPS-induced cytokine proteins in the brain using Luminex® 100™ 
suspension bead array systems has yet to be described in the literature. In the present 
studies, I chose to apply the Luminex® 100™ suspension bead array system to 
detecting cytokine protein in rodent brain tissue post intraperitoneal or 
intracerebroventricular LPS administration.
1.3 Alzheimer’s disease (AD)
1.3.1 Epidemiology
During 1906, the German doctor, Dr Alois Alzheimer, noted the presence of 
abnormal tissue and tangled fibre bundles in post mortem brain tissue of a woman 
who had suffered dementia. The associated disease was named Alzheimer’s disease 
(AD) (Alzheimer A, 1907). AD is a chronic neurodegenerative disorder characterised 
by the presence of Ap plaques, neurofibrillary tangles (NFTs), cell loss and 
associated activated microglia and astrocytes (Blennow et al, 2006). Clinical 
manifestations of AD often begin with gradually worsening cognitive impairments, 
particularly in learning and memory (Blennow et al, 2006). As the disease 
progresses, memory loss is associated with neuropsychiatric symptoms including 
anomalous motor behaviour, depression, anxiety, weight loss, irritability and 
agitation (Weiner et al, 2005). In the western world, neurodegenerative disorders 
have become more prominent due to an aging population, with increasing age being 
the greatest risk factor for AD (Barranco-Quintana et al, 2005). 1% of people aged 
<65 years and 24-33% of people aged >85 years are affected by the disease 
(Blennow et al, 2006).
A further important risk factor for AD is an individual’s genetic background 
(Blennow et al, 2006) but many believe that the disease in a majority of sufferers is 
due to a close interaction between genetic and non-genetic factors (Tol et al, 1999). 
The number of Americans alone who have AD has doubled since 1980 to 
approximately 4.5 million, costing at least $100 billion in care giving
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(www.alz.org/AboutAD/statistics). This is despite at least 70% of patients living at 
home where a large percentage of the care they receive comes from relatives and 
friends. This corresponds to an increased cost to businesses to account for lost 
productivity, absenteeism and worker replacement for working individuals who also 
care for an AD sufferer (www.alz.org/AboutAD/statistics). In America, this costs 
business approximately $61 billion per year (www.alz.org/AboutAD/statistics). A 
treatment able to delay the onset of the disease by 5 years could potentially reduce 
the number of patients suffering severe stages of AD by 50% in 50 years 
(www.alz.org/AboutAD/statistics). It is clear that a treatment able to delay the 
progression of the disease pathology is crucial to diminishing the impact of this 
disease on both a social and financial scale. Current drugs act solely as symptomatic 
treatments and can improve or stabilise symptoms in many patients but management 
of the underlying degenerative pathology with disease modifying drugs now requires 
more focus in order to control disease progression more successfully.
h 3.2 Early-onset Familial AD (FAD)
FAD is an uncommon form of AD accounting for <5% of all AD cases (Rocca et al, 
1991; Rocchi et al, 2003). The disease is inherited as an autosomal dominant trait 
and is linked with fully penetrant (causal) mutations in genes coding for APP, 
presenilin 1 (PS-1) and presenilin 2 (PS-2) located on chromosomes 21, 14 and 1 
respectively (Price & Sisodia, 1998). FAD presents early in life (30-60 years of age) 
and the age of onset depends on the presented mutations. PS-2 mutations are rare, to 
date there are only 10 mutations established in PS-2 (Sherrington et al, 1996) whilst 
142 mutations have been identified in PS-1 (Cruts & Van Broeckhoven, 1998). 
Mutations in PS-1 and PS-2 can significantly reduce age of onset. PS1 mutations are 
associated with more aggressive forms of AD and age of onset can occur as early as 
25 years of age (Campion et al, 1999) with disease duration lasting 5 years (Russo et 
al, 2000). FAD PS mutations influence processing of APP resulting in higher ratios 
of extracellular Apl-42 deposition (reviewed by Morishima-Kawashima & Ihara, 
2002).
1.3.3 Sporadic AD (SAD)
The clinical and pathological phenotypes of SAD are indistinguishable from those
44
displayed in FAD cases (Price & Sisodia, 1998) and SAD is the most common form 
of AD, accounting for approximately 95% of all cases (Panza et al, 2002). SAD 
pathogenesis is associated with a number of risk factors and the apolipoprotein E 
(ApoE) e4 allele of the ApoE gene located on chromosome 19 is well documented as 
a partially penetrant genetic risk factor (Pericak-Vance et al, 1991; reviewed by 
Roses, 1996). Although presence of ApoE4 is neither required nor sufficient to cause 
AD it has been strongly associated with reducing the age of onset in SAD cases since 
homozygous carriers demonstrate a younger onset age than patients carrying a single 
copy (Blacker et al, 1997; Meyer et al, 1998). The mechanism of action of ApoE4 
remains unclear, however, increased Ap plaques in E4 carriers and changes in Ap 
deposition in APP overexpressing mice with presence or absence of human ApoE 
provides evidence that presence of ApoE4 can influence Ap accumulation (Poirier et 
al, 2000).
Additional genes have been considered as risk factors for SAD (Sandbrink et al,
1996) including the alpha 1-antichymotrypsin allele A (ACT-A), the 5-repeat allele 
of the VLDL-receptor (VLDL-R) gene, the A2 allele of the HLA-A locus and the 
oestrogen receptor alpha gene (Urakami et al, 2001). Genes studied in case-control 
studies of sporadic AD patients range from those involved in Ap metabolism, 
oxidative stress and inflammation and are extensively reviewed by Combarros et al, 
(2002).
Although there is strong support for the amyloid hypothesis of AD due to close 
association between APP, PS1 and PS2 mutations, the contribution of environmental 
risk factors to onset and progression of SAD have been considered (reviewed by 
Brown et al, 2005). Studies investigating the correlation of aluminium, lead or 
mercury exposure (Gauthier et al, 2000; Cornett et al, 1998; Mutter et al, 2004), diet 
(Luchsinger & Mayeux, 2004) and pesticide exposure (Baldi et al, 2003) with 
incidence of AD have provided controversial data. It remains likely that sporadic AD 
is a culmination of genetic vulnerability and environmental exposures (Jansson,
2005).
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1.3.4 Beta Amyloid (A fi)
Ap is defined as a fibrillar protein comprising extracellular fibrils forming parallel P 
sheets. Ap has an affinity with Congo red and its presence can be determined by 
staining with Congo red, which under polarised light produces a green birefringence 
dependent upon positioning of the Congo red molecules along the fibrils (Nilsson, 
2004). Amino acid sequencing of cerebrovascular amyloid took place in 1984 
(Glenner & Wong, 1984). The subsequent characterisation of cerebral plaque Ap 
revealed that it was similar to cerebrovascular Ap and to Ap present in the brains of 
Down's syndrome patients (Masters et al, 1985). Plaques consist of extracellular 
deposits of Ap comprising aggregated Ap peptides up to 43 amino acids in length. 
Plaques can form a dense core of aggregated Ap protein that appear as a beta-pleated 
sheet when stained with Congo red and viewed under polarised light. Plaques of a 
diffuse nature lacking a dense core are present in greater abundance than core 
plaques and require staining with antibodies raised against Ap. The most common 
forms of amyloid protein usually present in human cerebrospinal fluid are Api-40 
(50-70%) and Apl-42 (5-20%) (Murphy et al, 1999). Apl-42 possesses two 
hydrophobic residues, isoleucine and alanine, that encourage aggregation into 
plaques (Selkoe, 1998) and is the most abundant soluble Ap fragment evident in AD 
brain tissue (Tambaton & Gamgetti, 2006).
1.3.4.1 Amyloid precursor protein (APP)
Isolation of Ap led to the cloning and localisation of the APP gene on chromosome 
21 (Tanzi et al, 1987; St.George-Hyslop et al, 1987). Down’s syndrome patients, 
known to produce cerebral Ap deposits and develop Alzheimer’s disease (AD), 
possess three copies of chromosome 21 (Trisomy 21) suggesting that increased 
production of APP and Ap may underlie the neuropathology (Folin et al, 2003). This 
remains controversial, however, since recent studies have challenged the theory that 
amyloid plaque pathology in Down’s syndrome patients is due to the presence of 
trisomy 21 (Argellati et al, 2006). APP comprises a family of glycosylated 
transmembrane proteins that are ubiquitous and present throughout the body (Hardy,
1997). Alternative splicing of the APP gene codes up to 770 amino acid residues 
(Kosik, 1994) including APP751, APP770 and APP695, the isoform most commonly 
expressed by neurons (Goedert, 1987). The derivation of Ap from APP can occur via
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a non-amyloidogenic (a-secretase) pathway or an amyloidogenic (p-secretase) 
pathway (Kowalska et al, 2004) (fig 1.7). Cleavage by a-secretase precludes 
formation of the amyloid domain and releases the N-terminal portion of APP as 
soluble APPa (sAPPa) and a C-terminal membrane bound fragment of 83 amino 
acids (c83). APP cleavage via the p-secretase pathway forms an N-terminal secreted 
APPp (sAPPP) and a C-terminal peptide comprising 99 amino acids (c99) that 
contains the Ap fragment. C83 or c99 cleavage by y secretase results in the formation 
of a 3kDa fragment (p3) or Ap. Ap is a normal product of neuronal cells released in 
low concentrations and usually found in the CSF and plasma (Selkoe, 1993).
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Figure 1.7: Schematic representation of APP processing (Figure taken from Canevari et al,
2004)
1.3.4.2 Ap: mechanism o f action
The mechanism by which Ap induces inflammation and cell death is unclear but may 
involve a complex cascade of biochemical events resulting in the imbalance of 
intracellular ions, production of inflammatory mediators and free radicals, and 
finally, apoptotic cell death that culminates in massive atrophy of susceptible areas 
(reviewed by Holscher, 2005) (fig 1.8).
The discovery that Ap can activate formyl chemotactic receptors (Lorton et al, 2000) 
or the Receptor for Advanced Glycation Endproducts (RAGE) provided insight into
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a potential mechanism for Ap-induced neurotoxicity (Lue et al, 2001; Sasaki et al, 
2001; Du Yan et al, 1997; Yan et al, 1996). Glycoxidation of free amino groups 
located on the surface of proteins can produce Advanced Glycation Endproducts 
(AGE) and increased expression of RAGE is evident in microglia and neurons of AD 
patients (Yan et al, 1996). RAGE has properties of a signal transduction receptor 
with sites for the transcription factor NF-kB at its promoter. Persistent translocation 
of NF-kB may occur from binding of Ap to RAGE resulting in alteration of gene 
expression in neurons and microglia (Huttunen et al, 1999).
In vitro studies have demonstrated that Ap stimulates glial cells (Kopec & Carroll, 
1998; Akama et al, 1998; Barger et al, 1997; Hu et al, 1999) to release potent 
inflammatory proteins (Meda et al, 1999; Yates et al, 2000; Del Bo et al, 1995; Apelt 
& Schliebs, 2001). Ap can stimulate the production of the proinflammatory 
cytokines IL-lp, TNF-a and IL-6 from neuronal cultures, microglial cultures 
(Szczepanik et al, 2001; Gitter et al, 1995) and astrocyte cultures (Hu et al, 1998). In 
addition, the chemokines monocyte chemotactic protein-1 (MCP-1) and macrophage 
inflammatory protein-la and -lp  (MIP-la and -ip) can be stimulated in human 
monocytes. Cell surface binding of microglia with core plaques may either cause or 
exacerbate neurotoxicity (reviewed by Bamberger & Landreth, 2001) by increasing 
the release of cytokines and reactive oxygen species (ROS). Release of such 
molecules can recruit more immune cells to the area and initiate uptake and 
degradation of deposited Ap (reviewed by Tabet et al, 2000; Varadarajan et al, 2000; 
van Rossum & Hanisch, 2004). Excessive activation of microglia can initiate a 
vicious cycle in which immune cells recruited to the site release toxic agents that 
harm surrounding neurons, which further release factors attracting further microglial 
migration (Ralay Ranaivo et al, 2006).
Ap induces the production of ROS directly via oxidative stress mechanisms 
(reviewed by Mattson, 1997; Hensley et al, 1994) and proto-fibrillar and fibrillar Ap 
cause ROS toxicity by disturbing the membrane environment of metabolic pathway 
enzymes and by causing leakage from redox chains (Goodman & Mattson, 1994; 
Behl & Holsboer, 1998). Antioxidants such as oestrogen (Dykens et al, 2005) and 
vitamin E (Munoz et al, 2005) have been reported to exert neuroprotection against 
amyloid-induced oxidative stress suggesting involvement of oxidative stress in the 
neurodegeneration evident in AD brain tissue. Api-42 or AP25-35 treatment of
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mixed hippocampal cultures reduced intracellular astrocytic and neuronal levels of 
glutathione, a reducing agent that forms part of an antioxidant system in the CNS, 
indicating a role for oxidative stress in AP-induced neurotoxicity (Abramov et al,
2003). Evidence from in vitro studies suggests Ap can alter intracellular calcium 
levels via the modification of voltage-gated ion channels (Green & Peers, 2001; 
Kasparova et al, 2001; Rovira et al, 2002) or through induction of membrane 
leakiness and oxidative stress (Huang et al, 2000). Ap-induced free radical 
generation may also occur via its binding and reducing of reactive metals such as 
copper (Bush et al, 2003) and iron to provoke hydroxyl radical production.
Neurons in post mortem tissue from AD patients display signs of apoptosis (Su et al, 
1994, Mattson et al, 1998). Ap may induce apoptosis in surrounding neurons via the 
p53-Bax cell death pathway (Zhang et al, 2002) although the exact mechanism is 
unknown. Fibrillar Ap may also form large voltage-independent non-selective ion 
channels (reviewed by Kagan et al, 2002) or bind to a mitochondrial endoplasmic 
reticulum (ER)-associated protein called amyloid p-peptide binding protein alcohol 
dehydrogenase (ABAD) (Yan et al, 1997). Increased expression of ABAD is evident 
in aged and AD brain and may potentiate Ap-induced apoptosis and free radical 
generation in neurons (Lustbader et al, 2004). In vitro and immunohistochemical 
studies have revealed that neurons undergoing Ap mediated cell death exhibit classic 
characteristics of apoptosis (Cotman & Anderson, 1995; Kusiak et al, 1996) which, 
correlates with the presence of aggregated Ap forms (reviewed by Iversen et al, 
1995).
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Figure 1.8: Schematic representation of the postulated mechanisms of AP-mediated
neurodegeneration
1.3.4.3 Role o f different A pforms in neurotoxicity
The original ‘amyloid hypothesis’ assumed that extracellular deposition of Ap is 
necessary for cell death (Hardy & Allsop, 1991) and evidence for Ap as a causative 
agent in AD was derived from genetic mutations of APP (Selkoe, 2000). Early 
literature suggested the extracellular fibrillar form of Ap to be the most neurotoxic 
(Simmons et al, 1994; Howlett et al, 1995; Jarrett et al, 1993) and that that the 
neurotoxicity induced by the Apl-42 fragment relates to its readiness to aggregate
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into beta sheets in contrast to the Api-40 fragment, which spontaneously produces a  
helix formations. However, recent evidence of intraneuronal soluble Api-42 as an 
early neurodegenerative change in AD (Femandez-Vizarra et al, 2004) and Down’s 
syndrome brain tissue (Gyure et al, 2001) supports findings that soluble amyloid may 
be first deposited intraneuronally (Masters et al, 1985) suggesting that intracellular 
monomeric and oligomeric amyloid generation may significantly contribute to cell 
death (Wirths et al, 2004). Further evidence has indicated soluble oligomeric Ap 
forms can induce toxicity (Chromy et al, 2003; Walsh & Selkoe, 2004; Lacor et al,
2004) and that core plaques of amyloid fibrils may be neuroprotective and sequester 
toxic Ap fragments from cells (Yan et al, 1996). It remains unclear how the balance 
between extracellular fibrillar Ap and intracellular monomeric or oligomeric Ap 
contributes to neurotoxicity.
1.3.5 Neurodegeneration in AD
Post mortem analyses of the pathology of AD brains have revealed more prominent 
brain weight reduction, cortical atrophy and ventricular enlargement in AD patients 
relative to age-matched controls (Kril et al, 2004; Karas et al, 2003; Skullerud et al, 
1985). Histopathological changes occur in limbic areas and the medial part of the 
temporal lobe and with specific regions of neuronal loss associated with large 
numbers of NFTs and neuritic amyloid plaques in the entorhinal cortex, 
hippocampus and amygdala (Scott et al, 1991; Armstrong, 2006). This manifests 
primarily as a loss of cholinergic neurons in the medial septum, nucleus basalis of 
Meynert (nBM) and vertical band of Broca (VDB) (Vogels et al, 1990; Boissiere et 
al, 1996). Extensive neurodegeneration is also evident in central noradrenergic 
neurons projecting from the locus coeruleus (LC) (Lyness et al, 2003; Engelborgh & 
De Deyn, 1997), the main site of NA synthesis innervating terminal regions 
including the cortex and hippocampus (Mann et al, 1982; Mann &Yates, 1983). LC 
degeneration correlates with duration of illness (Zarow et al, 2003) and duration and 
severity of dementia (Bondareff et al, 1987). Loss of noradrenergic specific neurons 
or NA is also associated with the incidence of depression in patients suffering from 
AD or PD (Chan-Palay & Asan, 1989). Remaining LC neurons may compensate for 
degeneration via neuronal sprouting (Szot et al, 2006; Hoogendijk et al, 1999) 
however; alpha 2C adrenoceptors remained significantly reduced in the hippocampus
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of AD patients (Szot et al, 2006).
1,3.6 Neuroinflammation in AD
1.3.6.1 Cell-mediated inflammation
Although neuroinflammation is evident in a number of CNS disorders such as stroke, 
Parkinson’s disease and multiple sclerosis, it is uncertain whether the inflammatory 
response predisposes to or subsequently exacerbates the neuropathology. 
Neuroinflammatory changes observed in AD sufferers, of both sporadic and familial 
cases of AD, occur early on in disease progression (Sasaki et al, 1997). The 
inflammatory state is characterised by the presence of activated microglia and 
reactive astrocytes within degenerating brain regions (McGeer et al, 1988; Meda et 
al, 1995; Akiyama et al, 2000). Microglia, resident macrophage cells in the brain, 
appear to localise around senile plaques in AD tissue (McGeer et al, 1994; Itagaki et 
al, 1989; Uchihara et al, 1997; Kalaria et al, 1999) and produce toxic agents that 
damage neurons (Siman et al, 1989). The activated state of the glial cells can be 
determined immunohistochemically with antibodies directed against specific proteins 
expressed on the cell surface such as major histocompatability complex (MHC) II 
glycoproteins and integrins such as the CD1 lb receptor.
Additional resident CNS glial cells, astrocytes (Tanaka et al, 1999), can also become 
reactive and have a defensive role in the neuropathology of AD (Aschner, 1998, 
DeWitt et al, 1998). Reactive astrocytes are characterised by their hypertrophic 
morphology and localised by immunohistochemical staining for the astrocytic 
marker, glial fibrillary acidic protein (GFAP). Astrocytes are located around senile 
plaques and appear to create a barrier between plaque and healthy tissue. Astrocytes 
also have a key role in maintaining the integrity of the blood-brain barrier (BBB) 
since the astrocytic foot sits alongside the endothelial wall of blood vessels that 
comprise the microvasculature separating brain tissue and circulating blood (Kim et 
al, 2006). Discrete BBB breakdown in AD patients, as exemplified by reduced 
cerebral blood flow and endothelial cell degeneration (Kalaria et al, 1995), suggests 
compromised cerebrovasculature in the brain may contribute to intense astrocytic 
activation.
It is difficult to determine whether the localisation of microglia with senile plaques is 
to enhance clearance of the insoluble plaque or to mediate aggregation of soluble
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amyloid. Although aggregated amyloid can induce inflammatory processes and 
cellular toxicity, it is unclear whether senile plaque production may be a protective 
mechanism to prevent the neurotoxic effects of precursor amyloid forms. In AD 
tissue, microglia can assist the conversion of diffuse soluble amyloid to aggregated 
plaques (Cotman et al, 1996; Griffin et al, 1995, Mackenzie et al, 1995; Sasaki et al,
1997) but also, as phagocytes, internalise plaques (Shaffer et al, 1995; DeWitt et al,
1998).
1.3.6.2 Cytokines
Astrocytes and microglia respond to injury or tissue damage by releasing an array of 
cytokines capable of recruiting further macrophage and neutrophils (reviewed by 
Mrak et al, 1995). Proinflammatory cytokines such as IL-lp (Griffin et al, 1989; 
Griffin et al, 1995; Shaw et al, 2001), TNF-a (Dickson et al, 1993; Grammas et al, 
2001; Tarkowski et al, 1999; Tarkowski et al, 2000) and IL-6 (Luterman et al, 2000) 
have been detected in post-mortem AD brain tissue. These cytokines are localised in 
plaque-associated microglia suggesting their involvement in either promoting 
clearance or modulating formation of aggregated amyloid deposits. IL-ip modulates 
plaque formation (Sheng et al, 1995; Grilli et al, 1996; Rogers et al, 1999) and APP 
production (Forloni et al, 1992; Rogers et al, 1999; Goldgaber et al, 1989) 
implicating amyloid-induced IL-ip in further increasing amyloid levels. IL-ip and 
TNF-a also appear essential for amyloid induced neurotoxicity (Viel et al, 2001) 
further exacerbating disease pathology.
Polymorphisms located in promoter and non-coding regions of cytokine genes 
appear to increase the risk of developing AD (Ravaglia et al, 2006). Their presence 
is, however, unlikely to initiate the disease alone (reviewed by Griffin, 2006; 
Cacquevel et al, 2004). Polymorphisms for several cytokines including the IL-6 gene 
promoter (Licastro et al, 2003), TNF-a (Alvarez et al, 2002), IL -la (Combarros et 
al, 2002), IL-lp (Sciacca et al, 2003) and the anti-inflammatory cytokine IL-10 (Lio 
et al, 2003) have been associated with AD. Polymorphism for a specific IL -la  gene 
can increase the risk of developing AD by three fold and this risk increases if 
combined with an IL-ip polymorphism (Mrak & Griffin, 2001). Genetic 
polymorphisms occur more frequently in AD patients compared with age-matched
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controls resulting in increased expression of inflammatory mediators, potentially 
affecting the progression of AD pathology (McGeer & McGeer, 2001).
1.3.6.3 Chemokines
Chemokines are a structurally and functionally related family of proteins expressed 
by astrocytes, microglia and endothelial cells. Chemokines act on receptors located 
on neurons, microglia and leukocytes to recruit inflammatory cells to the site of 
injury (Biber et al, 2006). The family includes IL-8, macrophage inflammatory 
protein (MIP)-l, monocyte chemoattractant protein (MCP)-l and RANTES 
(regulated upon activation, normal T-cells, expressed and secreted). Chemokines 
have been localised throughout the AD brain (Xia et al, 1999).
1.3.6.4 Other markers o f neuroinflammation
Prostaglandin 2 (PGE2), a proinflammatory mediator, is elevated in cerebral spinal 
fluid (CSF) from AD patients relative to controls (Ho et al, 2000; Montine et al,
1999). Post mortem, analysis of AD brain has also established the presence of 
markers of oxidative stress (Aslan & Ozben, 2004; Luth et al, 2005) and evidence of 
NOS (Luth et al, 2002; Femandez-Vizarra et al, 2004). Markers of nitric oxide 
production, 3-nitrotyrosine (Tohgi et al, 1999) and nitrate (Navarro et al, 1996; 
Kuiper et al, 1994) were also altered in the CSF of AD patients.
1,3.7 Anti-inflammatory agents as disease modifying therapy for AD
The incidence of AD in populations with inflammation-associated diseases such as 
rheumatoid arthritis has provided greater understanding of the potential role of anti­
inflammatory therapies for AD (Naccari, 2003). Epidemiological studies suggest 
patients on non steroidal anti-inflammatory drug (NSAID) therapy have a decreased 
risk of AD and delayed disease onset (Breitner, 1996; McGeer et al, 1996; 
McDowell, 2001). The Baltimore Longitudinal Study of Aging confirmed that 
NSAID use, particularly ibuprofen, was beneficial in preventing AD (Stewart, 1997) 
and effects were dependent on duration of treatment. Stewart et al, 1997 found that 
for individuals using NSAIDS for less than 2 years there was a risk reduction of one 
third. Patients using NSAIDS for > 2 years reduced their risk by 60% whilst in a 
larger cohort of individuals this length of treatment demonstrated an 80% reduction
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in AD incidence (In‘t Veld et al, 1998). NSAID treatment appears to be more 
successful if administered before disease onset or early on in disease progression. 
Hence, patients would need to take treatment before onset of any overt AD- 
associated symptoms. Additionally, treatment duration will also increase the 
incidence of gastrointestinal toxicity due to the unwanted peripheral effects of 
NSAIDS (Rogers et al, 1993; Tabet et al, 2002). Despite epidemiological evidence 
suggesting NSAIDS may be beneficial in AD, the results obtained from controlled 
clinical trials in AD patients have not demonstrated any beneficial effect of NSAID 
treatment (Firuzi & Pratico, 2006). The method by which NSAIDS may halt disease 
progression remains unclear but it is postulated that NSAIDS may influence the 
metabolism of APP or alter disease progress by activating peroxisome proliferator- 
activated receptors (Aisen et al, 2002).
1.4 Neuroinflammation and neurodegeneration in animal models
The mechanisms by which LPS and Ap may cause neuroinflammation and 
neurodegeneration have been described previously in this introduction. In this 
section, I will outline current reported evidence for neuroinflammation and 
neurodegeneration following the administration of LPS or Ap in vivo or in APP and 
APP/PS1 transgenic Ap models.
1.4.1 LPS -  in vivo models
1.4.1.1 LPS-induced neuroinflammation
Administration of LPS either centrally (Gayle et al, 1998; Gayle et al, 1999; Plata- 
Salaman et al, 1998; De Simoni et al, 1995; Gottschall et al, 1992; Muramami et al, 
1993; Szczepanik & Ringheim, 2003; Kelehua et al, 2000; Song et al, 1999; Finck et 
al, 1997; Sanna et al, 1995; Di Santo et al, 1995; Nicholson & Renton, 2001; Chen et 
al, 2000) or peripherally (Ghezzi et al, 2000; Sironi et al, 1992; Turrin et al, 2001; 
Castanon et al, 2004) to rodents can induce both pro- and anti-inflammatory cytokine 
production.
Intracerebroventricular (ICV) injection of LPS induces pro-inflammatory cytokine 
mRNA expression in the brain (Gayle et al, 1998; Gayle et al, 1999; Plata-Salaman 
et al, 1998; De Simoni et al, 1995) via direct action on brain tissue. Peripheral
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administration of LPS can also induce proinflammatory cytokine mRNA expression 
in the brain albeit to a lesser magnitude (Jacobs et al, 1997; Kakizaki et al, 1999; 
Laye et al, 1994; Pitossi et al, 1997; Satta et al, 1998; Goujon et al, 1997; Castanon et 
al, 2004).
Despite previous reports describing LPS-induced cytokine mRNA expression in 
rodent brain tissue in vivo, reports of LPS-induced cytokine protein, particularly 
following peripheral administration of LPS, are limited (Goujon et al, 1996; 1997). 
Reports focus primarily on intraperitoneal (IP) LPS-induced cytokine protein 
changes in blood or plasma (Sironi et al, 1992; Purswani et al, 2002; Bobrowski et al, 
2005) and the literature does not comprehensively describe the detection of a 
multitude of central cytokine proteins in brain tissue within the same animal 
following LPS administration.
1.4.1.2 LPS-induced neurodegeneration
Some studies have revealed an increase in the number of terminal deoxynucleotidyl 
transferase-mediated dUTP nick-end labelling (TUNEL) stained cells in various 
brain regions post IP LPS injection of rats (Nolan et al, 2000; Semmler et al, 2005). 
This suggests that peripheral administration of LPS may result in limited apoptosis in 
brain tissue. ICV injection of LPS may cause oxidative damage to the brain, despite 
the absence of overt neuronal loss. ICV LPS administration to C57BL6/J mice 
resulted in an acute transient increase in F4-isoprostanes (prostaglandin-like products 
of free radical-catalysed docosahexaenoic acid peroxidation) (Milatovic et al, 2003). 
Significant neurodegeneration can also be obtained by the direct injection of LPS 
into brain regions including the hippocampus (Ambrosini et al, 2005) and the 
substantia nigra (Li et al, 2004). Neurodegeneration was evident as a substantial loss 
in NeuN positive neuronal cell bodies or tyrosine hydroxylase-immunoreactive (TH- 
ir) neurons respectively.
Administration of an additional insult to LPS-treated animals appears to enhance the 
probability of inducing neuronal death. For example, mice receiving the 
glucocorticoid receptor inhibitor, RU486, alongside intracerebral LPS, detectable 
brain damage was evident after 3 days (Soulet & Rivest, 2003). Additionally, 
BALB/cJ mice administered with an IP dose of LPS before the induction of hypoxia- 
ischaemia (HI) suffered axonal and neuronal loss in the corpus callosum not evident 
in control HI mice (Lehnardt et al, 2003).
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1.4.2 Aft-Exogenous in vivo models
1.4.2.1 Exogenous AP-induced neuroinflammation
Injection or infusion of Ap peptide into brain tissue causes neuroinflammation. 
Injection of fibrillar Ap, but not soluble Ap, resulted in astrocytic and microglial 
activation in rat striatum (Weldon et al, 1998) with astrocytes surrounding the 
fibrillar deposits and providing a ‘wall’ to protect adjacent tissue whilst activated 
microglia phagocytosed the deposit. Further data support the presence of this 
pathology in rodent in vivo models (Frautschy et al, 1991; O’Hare et al, 1999; Scali 
et al, 1999; Stephan et al, 2001; Jantaratnotoi et al, 2003; Ryu et al, 2004; Frautschy 
et al, 2001).
The activation of microglia and astrocytes and the associated release of inflammatory 
cytokines, iNOS and COX2 can be potentiated by further insult to the animal. N - 
(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) induced noradrenergic 
depletion rendered rat brain tissue more susceptible to Ap-induced 
neuroinflammation (Heneka et al, 2002). Weldon et al, 1998 suggested that the 
separation of an Ap deposit from surrounding neuropil by astrocytes means it is 
unlikely that neurotoxicity occurs as a result of direct contact between Ap and 
neurons. The toxic mediators released by microglia, particularly NO molecules, may 
act as intermediary factors to induce neurodegeneration in surrounding neuronal 
populations, a hypothesis supported by in vitro evidence (Giulian et al, 1996); but it 
may also be the case that microglia phagocytose the Ap deposit. A recent study 
described the clearance of Api-42 following Ap injection into the hippocampus of 
Wistar rats suggesting phagocytosis of the deposit by surrounding microglia (Takata 
et al, 2004).
1.4.2.2 Exogenous Ap-induced neurodegeneration
Early studies have focused on the influence of the ICV administration of Ap on 
pathology associated with a cognitive impairment (Nakamura et al, 2001; Yamada et 
al, 1999). ICV infusion of Ap in vivo causes a reduction in the enzyme choline 
acetyltransferase (ChAT) usually responsible for degrading acetylcholine, a key 
neurotransmitter involved in learning and memory systems (Nabeshima & Nitta, 
1994). Reduced ChAT may indicate a compensatory mechanism to enhance the level
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of acetylcholine in the brain and hence, administration of Ap into CNS tissue may 
impair the activity of important neurotransmitter systems and associated neuronal 
circuits (Verhoeff, 2005). Reduced ChAT activity may underlie the cognitive deficits 
demonstrated in Ap treated animals. ICV injection of Ap results in learning and 
memory impairments in rodents when assessed in spontaneous alternation, passive 
avoidance and Morris water maze assays (Yamada, 1999). Animals infused with Ap 
plaques derived from AD patients displayed impairments in the watermaze and 
ChAT loss in the hippocampus and frontal cortex (Nitta et al, 1994). At 2 weeks post 
amyloid infusion, a reduction in ChAT activity in frontal cortex and hippocampus 
was associated with memory deficit in watermaze and passive avoidance tests 
(Nabeshima, 1994).
There are published reports of ICV Ap-induced cell loss (Nakamura, 2001) and 
diffuse amyloid deposition in rodent brain tissue, particularly in the presence of 
transforming growth factor (TGF) ~p (Frautschy et al, 1996). It remains difficult, 
however, to consistently achieve Ap deposition and resulting neurodegeneration 
using this method of administration. Much work by Frautschy et al (2001) has 
demonstrated that injection of Ap into rodent brain tissue results in diffuse Ap 
deposition in brain regions pertinent to AD, especially in rats. However, the co- 
administration of TGF-p or high-density lipoprotein (HDL) with Ap significantly 
improves Ap deposition (Frautschy et al, 2001; Harris-white et al, 2004) and results 
in a reduction in synaptophysin (a protein present in synaptic vesicle membranes) 
(Craft et al, 2004). In addition to the inconsistent Ap deposition following injection 
of exogenous Ap into brain tissue, recent work has also revealed that Ap injected 
ICV may remain in the ventricular systems and be removed by phagocytic cells, thus 
Ap peptide may not diffuse into brain tissue sufficiently to cause overt 
neurodegeneration (Nakagawa, 2004).
Direct injection into discrete brain areas, particularly those usually susceptible to 
degeneration in AD, may afford an alternative method of eliciting Ap-induced cell 
death in vivo. Some authors have not demonstrated Ap-induced neurodegeneration in 
vivo using this method (Games et al, 1992; Cleary et al, 1995) and suggest that 
microglia can phagocytose Ap deposits (Shin et al, 1997; Bishop et al, 2003). Others 
demonstrate cell loss that is adjacent to the injection site only (Frautschy et al, 1991;
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Emre et al, 1992; Giordano et al, 1994; Wang et al, 1994; Miguel-Hidalgo et al, 
1998; Stephan et al, 2001; Nakamura et al, 2001; Jantaratnotai et al, 2003; Ryu et al, 
2004) or is evident in specific neuronal populations (Weldon et al, 1998). Ap 
deposits may remain in the tissue even up to 6 months post surgery (Giovannelli et 
al, 1998; Weldon et al, 1998).
Early studies demonstrated that Ap-induced toxicity may depend upon the solvent 
used to dissolve Ap. Particular attention focused on acetonitrile, an organic solvent 
used as a vehicle for exogenous amyloid application (Kowall et al, 1991). It is clear 
that acetonitrile alone is toxic to neurons, either via its conversion to cyanide through 
the actions of cytochrome P450 (Freeman et al, 1998) or via its toxic effect on cell 
membranes, allowing calcium-mediated neurotoxicity (Mattson et al, 1992). Ap may 
enhance toxicity induced by the acetonitrile solvent by potentiating calcium- 
mediated neurotoxicity. The intra-hippocampal injection of human Apl-40 or rat 
Api-40 enhanced the toxicity of 35% acetonitrile whilst Ap in water or phosphate 
buffered saline (PBS) demonstrated little effect (Waite et al, 1992). In contrast, Apl- 
40 dissolved in 35% acetonitrile and injected into the neocortex of rhesus monkeys 
did not potentiate neurotoxicity relative to acetonitrile alone (Podlisny et al, 1992).
1.4.3 A f}-  Endogenous in vivo models — Transgenic mice
1.4.3.1 Endogenous amyloid-induced neuroinflammation
APP or APP/PS1 overexpressing transgenic mice exhibit neuroinflammation, 
exemplified by age-dependent activated microglia and astrocytes. APP (V717I) 
transgenic mice display activated glia in hippocampal and cortical regions at 3 
months, which became pronounced by 16 months of age (Heneka et al, 2005). 
Similarly, the PS APP model comprising APP and PS1 mutations shows a robust age- 
dependant increase in amyloid plaques surrounded by activated microglia and 
associated with reactive astrocytes, which increased with age and amyloid burden 
(Matsuoka et al, 2001). A small number of activated microglia was observed in the 
absence of amyloid plaques, most appeared to associate mainly with diffuse and 
fibrillar deposits. Analysis of the microglial phenotype in Tg2576 APP 
overexpressing mice indicated microglia may sustain plaque development whilst 
astrocytic degradation of Ap and separation of Ap from surrounding neurons
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suggests astrocytes aid neuroprotection (Wegiel et al, 2001). Alteration of the 
expression of pro- and anti-inflammatory cytokines is also evident in APP and 
APP/PS1 transgenic mice. Abbas et al, 2002, reported elevated cortical IFNy and 
IL12 mRNA and protein expression that peaked by 17-19 months and was associated 
with reactive microglia and astrocytes surrounding plaque deposits in Tg2576 mice. 
Anti-inflammatory treatment of APP or APP/PS1 transgenic mice using NSAIDs 
(Yan et al, 2003; Weggen et al, 2001; Lim et al, 2001), curcumin (the active 
ingredient in the curry spice turmeric) (Lim et al, 2001) or pravastatin (a 
hypolipidemic agent used for lowering cholesterol) (Chauhan et al, 2004) has 
demonstrated reduction of either soluble Ap 1 -42 or plaque burden. These findings 
demonstrate the key role inflammatory mediators possess in modulating amyloid 
production.
1.4.3.2 Endogenous amyloid-induced neurodegeneration
Many of the initial APP and APP/PS1 overexpressing transgenic mouse lines that 
were constructed did not exhibit overt neurodegeneration despite extensive plaque 
deposition in the hippocampus, cortex and amygdala (Stein & Johnson, 2002; 
Higgins & Jacobsen, 2003). Evidence suggests that, particularly in models of slow 
amyloid deposition such as Tg2576, amyloid may be sequestered via increased 
transthyretin, a sequestering protein upregulated by sAPPa (Stein & Johnson, 2002) 
as part of a neural mechanism to cope with widespread accumulation of aggregated 
amyloid. Chronic infusion of an antibody against transthyretin leads to increased 
amyloid and tau phosphorylation with apoptosis and neuronal loss in the CA1 
hippocampal field in Tg2576 mice. This further suggests sAPPa driven 
neuroprotective gene expression may protect APP transgenic mice from 
neurodegeneration (Stein et al, 2004). APP23 mice demonstrate hippocampal and 
cortical neurodegeneration, which can be exacerbated by the noradrenergic 
neurotoxin, DSP-4 (Heneka et al, 2006). The APP (SL) PS1KI model appears to be 
the best documented transgenic model presenting extensive neuronal loss (>50%) in 
the CA1/2 pyramidal hippocampal layer associated with intracellular Ap and 
astrogliosis that develops in correlation with the neuronal loss (Casas et al, 2004). 
Recent data described a reduction of about 30% in pyramidal hippocampal neurons 
in APP751/PS1 transgenic mice that did not correlate with extracellular Ap plaque
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load, suggesting multiple mechanisms of Ap neurotoxicity (Shmitz et al, 2004). 
Rockenstein et al, 2005 compared high levels of human beta-secretase (BACE) -1, 
with and without hAPP. hBACEl/hAPP double transgenic and hBACEl transgenic 
mice exhibited neurodegeneration in the neocortex and hippocampus despite reduced 
Ap levels. These recent reports provide evidence that neurodegeneration may 
correlate with the accumulation of intraneuronal Ap as the neurodegeneration 
observed in APP (SL) PS1KI and APP751/PS1 mice correlates with increased 
intraneuronal Ap immunoreactivity (Games et al, 2006).
1.5 Thesis Objectives
Presently, therapeutic agents for AD primarily provide symptomatic relief and do not 
modify the progression of disease pathology. The limitations of current in vivo 
rodent models of neuroinflammation and neurodegeneration make preclinical 
screening of putative anti-inflammatory and neuroprotective agents for AD difficult. 
Quantification of markers of neuroinflammation following LPS, as a commonly used 
immunostimulant, or Ap, the peptide associated with AD, administration relies on 
the detection of cytokine mRNA expression, which may not translate to the final 
protein product. Current models of exogenous or endogenous Ap induced 
neurodegeneration do not demonstrate reproducible and quantifiable neuronal cell 
death. This thesis explores the development of rodent in vivo models using 
exogenous LPS and Ap injection approaches and endogenous Ap transgenic models 
and discusses their suitability for screening novel agents.
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CHAPTER 2
Peripheral administration of LPS -  an in vivo model of 
neuroinflammation ?
2.1 Introduction
Despite a number of reports describing the expression of proinflammatory cytokine 
mRNA in rodent brain (Jacobs et al, 1997; Castanon et al, 2004) there are currently 
only limited reports of cytokine protein detection in rodent brain tissue (Goujon et al, 
1996; 1997) following IP administration of LPS. Previous literature has reported the 
use of Luminex® for detecting a wide range of cytokine proteins within a single 
rodent plasma sample (Bobrowski et al, 2005). I describe the application of this 
technology to the detection of LPS-induced cytokine protein in rodent brain tissue. It 
is important to also establish that the expression of cytokines in brain tissue is a 
centrally derived response and not due to infiltration of blood bome cytokines. The 
detection of other proteins by Luminex® has not yet been documented but kits have 
been developed to detect phosphorylated proteins. Phosphorylated proteins are 
involved in LPS-mediated intracellular signalling and their detection by Luminex® 
may confirm the presence of a brain response to peripheral LPS administration. I 
describe the application of Luminex® for assessing phosphorylated proteins 
including Ik B oi, JNK, ERK and p38 in rodent brain tissue. The induction of cytokine 
mRNA expression in brain tissue is also assessed using Taqman PCR techniques. 
Finally, to illustrate pharmacological modulation of LPS induced cytokines in the 
rodent brain, the changes in LPS induced central and peripheral cytokine expression 
following administration of the glucocorticoid dexamethasone and the a l  
adrenoceptor antagonist, fluparoxan, will be examined.
2.L I Glucocorticoid (GC) modulation and inflammation
Circulating cytokines can induce endogenous glucocorticoid production via 
activation of the HPA axis (Buckingham et al, 1994). Levels of serum corticosterone 
rise rapidly in LPS challenged mice, initially rising in a profile similar to that of
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serum TNF-a but remaining elevated for up to 24 hours after LPS administration, 
well after TNF-a levels have returned to baseline (Eskay et al, 1990). 
Adrenalectomised animals demonstrate increased expression and production of 
inflammatory mediators in models of inflammatory disease (Perretti et al, 1989; 
Calignano et al, 1985; Bertini et al, 1989; Smith et al, 2002) that can be reversed by 
administration of glucocorticoids. The glucocorticoid receptor inhibitor, RU486, can 
also increase the inflammatory reaction observed in animals injected intracerebrally 
with LPS, demonstrating glucocorticoids may protect the brain from inflammatory 
insult (Nadeau & Rivest, 2003). Systemic glucocorticoids including prednisolone and 
dexamethasone are strong immunosuppressants that can alleviate symptoms in 
inflammatory based disorders including asthma and arthritis but their use is limited 
to a short duration of therapy due to severe adverse effects (Roumestan et al, 2004). 
Although the attenuation of IP LPS-induced plasma cytokine production by 
glucocorticoid treatment has been previously described in rodent (Sironi et al, 1992, 
Mengozzi et al, 1994), the effect of dexamethasone treatment on IP LPS-induced 
plasma and brain cytokines has not yet been reported. Studies 3 through to 5 of this 
thesis investigate the effect of the strong anti-inflammatory agent dexamethasone on 
IP LPS-induced cytokine protein in rodent brain tissue and plasma detected by 
Luminex® suspension bead array system.
2.1.2 P38a inhibition and inflammation
P38a, an isoform of the p38 MAP kinase, has a well defined role in inflammation 
and its involvement in the expression of cytokines such as ILl-p and TNF-a is well 
documented (reviewed by Adams et al, 2001).
P38a inhibitors potently inhibit cytokine production in vitro (Lee et al, 1994; Dean et 
al, 1999) and in vivo (Barone et al, 2001) and demonstrate anti-inflammatory 
properties in models of chronic inflammatory based neurodegenerative and 
peripheral disorders, infection, cancer and autoimmune disease (reviewed by 
Kaminska, 2005). A number of companies began to develop potent, orally 
bioavailable p38a inhibitors after the publication of pyridinyl imidazole compounds 
(Lee et al, 1994) as inhibitors of cytokine production. Currently, the assessment of a 
number of molecules is taking place in the clinic (reviewed by Lee & Dominguez, 
2005; reviewed by Dominguez et al, 2005), particularly for treatment of rheumatoid
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arthritis (reviewed by Schieven, 2005).
P38MAPK inhibitors are able to reduce cytokine production by controlling gene 
transcription and translation and by destabilising cytokine mRNA (Lee et al, 1994). 
These agents are suitable compounds to assess attenuation of LPS-induced cytokine 
protein in vivo. There is evidence of central p38 phosphorylation post IP LPS (Kelly 
et al, 2003) but there is no published literature describing the effect of p38MAPK 
inhibitors in an IP LPS in vivo model of central and peripheral cytokine protein. 
Study 5 examines the effect of the p38a inhibitor, GW569293, on IP LPS-induced 
cytokine protein in rat brain tissue and plasma detected via Luminex® suspension 
bead array system.
2,1,3 a2-adrenoceptor antagonism and inflammation
Early evidence supported the involvement of monoamines such as serotonin (5-HT) 
and noradrenaline (NA) in the regulation of inflammation. In a model of 
carregeenan-induced paw oedema, whole brain and hypothalamic concentrations of 
NA were augmented during acute peripheral inflammation (Bhattacharya et al, 
1988). Intraperitoneally (IP) administered LPS significantly increased hippocampal 
and preoptic NA levels in rat (Linthorst & Reul, 1998). Denervation of NA fibres in 
a model of arthritis resulted in earlier onset and increased severity of inflammation 
and arthritic pathology (Felton et al, 1992) whilst carregeenan-induced inflammation 
in rabbit demonstrated an increase in a2 receptor affinity or numbers in articular 
blood vessels (Gray & Ferrell, 1992). Cytokine modulation through control of 
intracellular cAMP levels appears to occur via a l  adrenoceptor mediated inhibition 
and beta-adrenoceptor activation of adenylate cyclase demonstrating the role of a l  
receptors in cytokine production.
NA acts via G-protein linked alpha (a) or beta (P) adrenoceptors. There are two 
subtypes of a  receptor, a l  and a l  which, when activated, can either stimulate 
release of intracellular calcium (a l)  or decrease adenylate cyclase activity (a2). The 
three subtypes of p receptor (p i, 2 and 3) can increase adenylate cyclase activity 
resulting in induction of intracellular cAMP. a l  adrenoceptors are further subdivided 
into three isoforms, a2A, a2B and a2C localised primarily at synaptic junctions 
where their role is to control neurotransmitter release, a l  receptors act as inhibitory
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autoreceptors by inhibiting the release of NA. NA or synthetic agents such as the 
agonists clenbuterol or clonidine (Boyd, 2001) or the antagonists yohimbine or 
fluparoxan act at a2 receptors (Maes et al, 2000; Halliday et al, 1991). Antagonists 
of a2 adrenoceptors antagonise the inhibitory effect of the receptor on NA release 
resulting in an increase in synaptic NA. a2 adrenoceptors are widely distributed 
throughout the rat brain (Scheinin et al, 1994) and are localised at synapses (Aoki et 
al, 1994) and on the cell surface of macrophage and monocytes (Spengler et al, 
1990).
The anti-inflammatory effect of NA (reviewed by Galea et al, 2003) is mediated by 
down-regulating the expression and release of pro-inflammatory cytokines (Kaneko 
et al, 2005; Hu et al, 1991; Willis & Nisen, 1995) and inhibiting microglial activation 
(Lee et al, 1992; Loughlin et al, 1993; Chang & Liu, 2000) evident in AD. Recent 
reports describing the role of NA in CNS pathology are controversial. Wenk et al, 
2003 demonstrated a lack of DSP-4 mediated potentiation of neuroinflammation or 
cholinergic neurodegeneration; however, noradrenergic depletion in APP 
overexpressing mice exacerbated neuroinflammation and neurodegeneration (Heneka 
et al, 2006) and potentiated Ap-induced cortical cytokine and iNOS expression in rat 
in vivo (Heneka et al, 2002). Increasing NA levels via the antagonism of a2 
adrenoceptors may inhibit the expression of IP LPS-induced cytokine protein in brain 
tissue or plasma and attenuate LPS-induced iNOS expression in plasma. Study 5 
investigates the effect of the a2 adrenoceptor antagonist, fluparoxan, on IP LPS- 
induced cytokine protein in rat brain tissue and plasma detected by Luminex 
suspension bead array system and plasma nitrite, a marker of iNOS production.
2.1.4 Chapter Aims
This series of studies sought to establish a high-throughput model of 
neuroinflammation by evaluating:
1. The detection of IP LPS-induced plasma and brain-derived cytokine protein 
using the Luminex® suspension bead array system.
2. The involvement of a brain-derived response to IP LPS by assessing 
cytokine mRNA and phosphoprotein expression in brain tissue.
3. The suitability of the peripheral LPS model for screening putative anti­
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inflammatory therapies by investigating the effects of dexamethasone as a 
standard anti-inflammatory treatment and via p38 inhibition or alpha2 
adrenoceptor antagonism.
2.2 Materials & Methods
2.2.1 Materials
The p38 inhibitor GW569293 and the a l-  adrenoceptor antagonist fluparoxan were 
synthesised at GSK, Harlow. Methylcellulose was prepared at GSK, Harlow. 
Phosphate buffered saline (PBS) was prepared using PBS tablets obtained from 
Sigma, UK. Lipopolysaccharide (0111:B4, L2630) and the glucocorticoid 
dexamethasone were purchased from Sigma, UK.
TMBio-Plex cytokine, phosphoprotein and total target assay kits containing standards,
primary bead and secondary detection antibody solutions were obtained from Bio-
Rad Laboratories, USA. Bio-plex™ phosphoprotein testing reagent kits, total protein
T T k l
assay solutions and Bio-plex calibration beads were purchased from Bio-Rad 
Laboratories, USA. Streptavidin-PE was obtained from VWR, UK. The Luminex®- 
100™ system was purchased from Luminex® Corporation, USA. 96-well filter plates 
and vacuum manifold apparatus were obtained from Millipore®, USA.
2.2.2 Animals
Specific, pathogen free male CD (caesarean derived from original Charles River 
Laboratories Sprague Dawley colonies) rats (250g, approximately 10 weeks of age) 
were purchased from Charles River, UK housed (4-5 per cage) in an animal facility 
at GlaxoSmithKline Pharmaceuticals, Harlow, Essex, UK. All rats were maintained 
under a controlled temperature of 21-24°C and a 12-hour phase light/dark cycle 
(lights on at 7am) and fed a pellet diet and water ad libitum. All experimental 
procedures were conducted in accordance with the GlaxoSmithKline local ethics 
committee and conformed to the UK Animals (Scientific Procedures) Act 1986.
2.2.3 Drug administration
Dexamethasone, fluparoxan and GW569293 were sonicated in 0.5% 
methylcellulose until completely dissolved and administered orally (gavage) at a
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dose volume of 2ml/kg. Dosing took place according to a timed schedule of 2 rats 
every 15 minutes to account for the time required to sample each rat. LPS 
(lOOpg/kg, 1 ml/kg) was allowed to dissolve in PBS in a falcon tube (VWR 
International, UK) for at least 30 minutes before administration. This dose of LPS 
was chosen from previous studies (Turrin et al, 2001; Pezeshki et al, 1996). LPS 
was injected (i.p) at 30 minutes, 1 hour and 2 hours after oral dosing of fluparoxan, 
(1, 3 & lOmg/kg), dexamethasone (1 mg/kg) or GW569293 (25mg/kg). An in vivo 
pharmacodynamic assay previously run at GSK, Harlow, revealed that oral 
treatment of 1, 3 and lOmg/kg fluparoxan caused reversal of agonist (UK, 14304) 
induced hypothermia. Subsequent PK analysis revealed brain concentrations of
0.592, 1.796 and 3.657pM respectively. Dexamethasone (lmg/kg, oral) and 
GW569293 (25mg/kg, oral) caused a reduction in neuroinflammation and cell 
death following intra-nigral injection of LPS into rat brain tissue (Sunter et al, in 
prep).
2.2.4 Sample collection
Rats were deeply anaesthetised with sodium pentobarbitone (Euthatal® lOOmg kg-1
1.p, Rhone Merieux, Harlow, UK). The right atrium was cut and trunk blood 
collected into a 1.3ml EDTA micro-tube (VWR International, UK). All rats, unless 
otherwise stated, were subsequently transcardially perfused with 120ml ice-cold 
0.9% sterile saline to wash the brain of circulating blood. During this procedure, the 
descending artery was clamped to improve upper-body perfusion. Brain regions 
were microdissected and stored in preweighed labelled eppendorfs (VWR 
International, UK) at -80°C. The blood was spun in a microcentrifuge (Centrifuge 
5415 D, Eppendorf UK Ltd, Cambridge, UK) at 16,1 lOg for 5 minutes and the straw- 
coloured plasma fraction collected into fresh eppendorfs and stored at -80°C.
2.2.5 Cytokine protein determination
2.2.5.1 Sample preparation
Microdissected brain tissue samples were diluted (5ul/mg tissue) with high 
performance ELISA (HPE) buffer (Sanquin Reagents, Amsterdam) and homogenised 
using a hand-held Ultra-Turrax T8 homogeniser (VWR International, UK). Samples
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were spun (16,1 lOg for 2 minutes) in a microcentrifuge (Centrifuge 5415 D, 
Eppendorf UK Ltd, Cambridge, UK). Supernatant was removed and stored in a fresh 
eppendorf at -80°C. Brain supernatant and plasma were defrosted and 50pl aliquots 
of each sample placed into a corresponding well on a standard 96-well plate (Nunc, 
UK) according to a predetermined plate layout. Each 50pl aliquot was diluted with 
150pl assay buffer (1% bovine serum albumin (BSA)-Fraction V, PBS).
(r)2.2.5.2 Luminex suspension bead array -  cytokine analysis
lOOpl of each pre-diluted sample was transferred to a pre-wet (lOOpl of assay buffer 
added to each well and the plate vacuum filtered) 96-well filter plate. A 50,000pg 9- 
plex standard was diluted to a 32,000pg solution and then serially diluted 1:2 using 
assay buffer to provide a 16-point (including zero) standard curve. Each sample was 
incubated in the dark overnight at 4°C with 50pl of a premixed 9-plex anti-cytokine 
conjugated bead solution diluted with assay buffer to lx concentration (250pl stock 
bead solution diluted with 5,750pl assay buffer). The plate was washed three times 
with 200pl of assay buffer and filtered using a vacuum manifold apparatus to 
eliminate unbound protein and prevent cross-contamination. Samples were further 
incubated with 100pi detection antibody (stock 120pl solution diluted with 1 l,940pl 
assay buffer) for 1 hour in the dark at room temperature and then washed three times 
with 200pi assay buffer. 12pl of Streptavidin-PE (stock solution was diluted with 
11,988pl assay buffer) and lOOpl added to each well. The plate was left to shake 
(700rpm) for 30 minutes at room temperature in the dark. The contents of each well 
were analysed by the Luminex®-100™ system to achieve median fluorescence 
intensity (MFI) readings for standard curves and samples. Samples for studies 1 and 
2 were analysed using FACScalibur™, since the Luminex®-100™ system was not 
available at GSK during these early studies.
The Luminex®-100™ system was previously calibrated using Bio-plex™ calibration 
beads at a low RP1 value of 3832. Double discriminator gates were positioned from 
approximately 8,000 to 15,000 to separate singlet and doublet beads. Intensity was 
identified at bead regions 18, 20, 21, 32, 34, 35, 37, 55 and 72 for IL-2, IL-10, IL-la, 
IL-4, IFN-y, IL-ip, GM-CSF, IL-6 and TNF-a, respectively.
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2.2.6 Phosphoprotein determination
2.2.6.1 Sample preparation
Brain samples were placed into preweighed eppendorfs and their weight (mg) 
measured. 500mM phenylmethylsulfonyl fluoride (PMSF) (Sigma, UK) was 
prepared by dissolving 0.436g PMSF in 5ml DMSO and 0.5ml aliquots stored at - 
20°C. 10 ml (40p.l of factor 1 and 20pl of factor 2 to 9.9ml of cell lysis buffer) of 
lysing solution was vortexed gently, 40pi of 500mM PMSF added and the solution 
left to cool on ice. 5 pl/mg tissue of lysing solution was added to each sample, which 
was briefly homogenised until in solution. The samples were stored at -70°C 
subsequently thawed, vortexed and then centrifuged at 3328g for 4 minutes. The 
supernatant was collected and the protein concentration determined. Supernatant was 
further diluted with lysing solution to achieve a protein range of 200-900pg/ml.
2.2.6.2 Total protein assay
BSA (25mg) was dissolved in 2.5ml of lysing solution and protein standards 
prepared from a 1 mg/ml stock BSA solution. Each stock supernatant sample was 
diluted 1 in 20 with lysing solution. 25pi of standards and samples were placed into 
clean dry eppendorfs and 125pi of Reagent I added. All eppendorfs were incubated 
for one minute and a further 125pl of Reagent II added. Following vortexing, all 
tubes were centrifuged at 13,200rpm for 3-5mins. The supernatant was discarded by 
inverting tubes on clean absorbent tissue. 127pl of Reagent A’ (reagent S + reagent 
A) was added to each pellet and the eppendorfs incubated at room temperature for 5 
minutes. Eppendorfs were vortexed and 1ml of Reagent B added to each tube. 
Eppendorfs were incubated at room temperature for 15 minutes. 200pl of each 
sample was placed into a 96-well plate in duplicate and read at 750nm.
2.2.6.3 Luminex® suspension bead array — phosphoprotein analysis
50pl of sample, in duplicate, were placed onto a standard 96-well plate according to 
a predetermined plate layout. An equal volume of assay buffer obtained from a Bio- 
Rad phosphoprotein testing reagent kit was added to each sample. The bead solution 
for each phosphoprotein (180pl) was vortexed and aliquoted into a single vial before 
dilution with 8280pl wash buffer. 50pl of beads were added to each well of a pre­
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washed filter plate and the plate immediately vacuumed and washed (lOOpl wash 
buffer) twice. Sample and control lysates were allowed to thaw and vortexed and 
50pl of each sample or control placed in a predetermined well. Each plate was left to 
incubate in the dark at room temperature for 15-18 hours. Following incubation, the 
plate was vacuum filtered and washed (lOOpl wash buffer) three times. Each 
detection antibody (180pl) was added to a single vial and diluted with 3780pl of 
detection antibody diluent and 25pi of the final solution added to each well. The 
plate was left to incubate in the dark at room temperature for 30 minutes and then 
vacuum filtered and washed (lOOpl wash buffer) a further three times. 50pl of 
Streptavidin-PE (180pl stock diluted with 17820pl wash buffer) was placed in each 
well and left to incubate for 10 minutes in the dark at room temperature. The plate 
was vacuum filtered and rinsed three times using lOOpl of resuspension buffer. 
Resuspension buffer (125pi) was added to each well and left to incubate for 30 
seconds before obtaining MFI readings for phospho- and total protein detected in 
brain homogenate using the Luminex®-100™ system.
The Luminex®-100™ system was previously calibrated using Bio-plex™ calibration 
beads at a high RP1 value of 17435. Double discriminator gates were positioned 
from approximately 8,000 to 15,000 to separate singlet and doublet beads. Intensity 
was identified at regions 34, 36, 38 and 58 for JNK, p38MAPK, ERK2 and I k B oi, 
respectively. Total and phospho protein levels were standardised using total protein 
concentrations for each sample. All samples were corrected to 1 mg/ml total protein 
concentration. The ratio of phosphorylation was calculated by dividing 
phosphoprotein concentrations by total protein concentrations (i.e. p-JNK/total JNK).
2.2.7 Nitric Oxide Assay
Administration of DSP-4 can increase iNOS expression in vivo (Heneka et al, 2002) 
suggesting that modulating NA may result in changes in nitrite, a marker of iNOS 
production. Nitric oxide levels were assessed by quantifying the total nitrite in each 
sample using a Nitric Oxide Colorimetric Assay Kit (Biomol Research Laboratories, 
USA), Standards were prepared and 50pl of each standard added to predetermined 
wells. Sample (25pi) diluted with deionised water (25pi) was plated in duplicate. 
Reconstituted NADH solution (25pl) was added to every well followed by 
reconstituted nitrate reductase (25pl). The plate was gently shaken and then left to
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incubate at 37°C for 30 minutes. Greiss reagent I and Greiss reagent II (50pl each) in 
each well was incubated at room temperature for 10 minutes. Optical absorbency was 
read at 540nm. After adjusting readings for blank wells, a standard curve was 
constructed and sample concentrations determined.
2.2.8 Quantification o f cortical mRNA expression - TaqMan
The left frontal cortex was dissected and placed into a sterile biopur® (RNase-free) 
safe-lock eppendorfs (VWR International, UK) and stored at -80°C for RNA 
quantification. Frontal cortex provided sufficient tissue for TaqMan analysis and 
allowed remaining cortical tissue to be used for Luminex detection of cytokine or 
phosphoprotein detection. Total RNA was isolated using TRIZOL reagent 
according to the manufacturer’s instructions (Invitrogen, USA). The RNA was 
resuspended in ultraPURE distilled water (Invitrogen, life technologies, UK), and 
RNA purity was confirmed by gel electrophoresis, ensuring that A260: A280nm ratio 
was >1.8. Equal quantities of RNA from each tissue sample were used in reverse 
transcription reactions to generate cDNAs (Ginham et al, 2001). First strand cDNA 
was synthesized from 1 pg of each RNA sample in a reaction mixture (0.01 M 
dithiothreitool (DTT), 0.5 mM each dNTP, 0.5 pg oligo (dT) primer, 40 U 
RNAseOUT ribonuclease inhibitor (Life Technologies Inc.), and 200 U Superscriptll 
reverse transcriptase (Life Technologies Inc.)). Triplicate reverse transcription 
reactions were performed and resulting cDNA products were divided into aliquots 
using a Hydra 96 robot (Robbins Scientific, Sunnyvale, CA, USA). Primer (F and R) 
and probe (P) sets were designed from sequences in the Genbank database using 
Primer Express software (Perkin-Elmer, UK) (Table 1.1). All Taqman probes 
contained 6-Carboxyfluorescein at 5’ end and the quencher dye, 6-carboxy- 
tetramethyl-rhodamine at the 3’ end. Taqman PCR was carried out using an ABI 
prism 7700 sequence detector (Perkin-Elmer Applied Biosystems, Foster City, CA, 
USA) on the cDNA sample mixture (2.5 mM MgCL, 0.2 mM dATP, dCTP, dGTP 
and dUTP, 0.1 pM each primer, 0.05 pM Taqman probe, 0.01 U AmpErase uracil-N- 
glycosylase, 0.0125 U Amplitaq Gold DNA polymerase (Perkin-Elmer, UK)). 
Samples were incubated at 50°C for 2 min, 95°C for 10 min followed by 40 cycles of 
95°C for 15 s, 60°C for 1 min. Additional reactions were performed on each 96 well 
plate using rat genomic DNA (Clontech Laboratories Inc., Palo Alto, CA, USA) to
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produce a standard curve (Harrison et al, 2000). Taqman was kindly completed by 
Ainsley Culbert and Florence Guillot, GSK, Harlow, UK.
Gene Reagent Sequences
GAPDH F; GAACATCATCCCTGCATCCA
R ; CCAGTGAGCTTCCCGTTCA 
P; CTTGCC CACAGCCTTGGCAGC
T N F a  F; G G CA TG G A TC TC A A A G A C A A C
R ; G G T G T G G G T G A G G A G C A C  
P ; T  C T  A CT C C C A G G T T  C T C TT  C A A G G G  A CA AG GC
I L - i p  F; C C C A A C T G G T A C A T C A G C A C C
R ; A C A C G G G T T  C CA T G G T  GAAGT C  
P; T C C C G A C C A T TG C TG T TT C C TA G G A A G
EL-6 F; CCCAACTTCCAATGCTCTCCTA
R; GCTTTCAAGATGAGTTGGATG 
P; TGGTCCTTAGCCACTCCTTCTGTGACTCTAACTT
Table 2.1: TaqMan reagent sequences
2.2.9 Data Analysis
Study 1 and 2: Non-linear regression curves of the cytokine standard values were 
calculated using the GraphPad Prism one site hyperbola model. The concentrations 
of unknown samples were determined in GraphPad Prism relative to calculated 
standard curves.
Study 3 and 5: 4/5-parameter logistic regression curves (Hulse et al, 2004) of the 
cytokine standard values were calculated using STarStation Version 2.0 software 
(Applied Cytometry Systems, Sheffield, UK) and the concentrations of unknown 
samples were determined relative to calculated standard curves.
A general linear mixed model approach using the Proc Mixed procedure in SAS 
Version 8 (SAS® Institute, UK) assessed each separate cytokine protein, cytokine 
mRNA and phosphoprotein response using brain region as a repeated measure. 
Univariate tests of significance using Statistica™ Version 6.1 (StatSoft, USA) 
calculated the overall effect of LPS treatment on each separate response in plasma. In 
study 5, due to the unexpected variance across treatment groups and presence of zero 
values within the vehicle and dexamethasone groups for plasma IFN-y and plasma 
TNF-a, a univariate test of significance was applied in the absence of the vehicle and 
dexamethasone groups which were treated as a mean of zero. Planned comparisons
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on the predicted means from the model assessed individual treatment effects within 
plasma and brain compartments. Results are represented as means ± SEM and 
significance was set at P < 0.05. Percentage reduction describes attenuation relative 
to the LPS-induced cytokine response above vehicle levels.
2.3 Protocols
2.3.1 Study 1: Timecourse o f cytokine protein induction
Male CD rats (n=8 per group) were administered with either lOOpg/kg LPS dissolved 
in filtered PBS or filtered PBS alone and euthanased at 2 or 6 hours (based on a 
protocol described by Quan et al, 1994) post LPS administration for plasma and 
brain samples. Whole hippocampus and frontal cortex, brain regions that 
demonstrate significant degeneration in AD (Gomez-Isla et al, 1996), were 
microdissected for cytokine analysis.
2.3.2 Study 2: Cytokine protein detection throughout brain tissue
Study 2 validates the detection of LPS induced cytokine protein throughout different 
brain regions. Male CD rats (n=8 per group) were administered with either lOOpg/kg 
LPS dissolved in filtered PBS or filtered PBS alone. Animals were euthanased at 6 
hours post LPS administration and blood and brain samples removed. The brain was 
microdissected into whole hippocampus, frontal cortex, cerebellum, striatum and 
hypothalamus.
2.3.3 Study 3: Effect o f Dexamethasone on cytokine expression
Male CD rats (n=8 per group) pre-treated with either 0.5% methylcellulose or the 
glucocorticoid dexamethasone (1 mg/kg) were administered 1 hour later with 
lOOpg/kg LPS dissolved in filtered PBS or filtered PBS alone. Animals were 
euthanased at 6 hours post LPS administration; blood and brain were quickly 
removed. Animals were not perfused to prevent potential degradation of mRNA 
integrity caused by the duration time of the procedure. Whole hippocampus was 
microdissected for cytokine analysis by Luminex®. Frontal cortex was hemidissected 
providing left frontal cortex for Luminex® analysis and right frontal cortex of five 
animals for the determination of cytokine mRNA expression by taqman.
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2.3.4 Study 4: Cytokine mRNA and intracellular protein expression
Study 4 further investigates the induction of a centrally derived inflammatory 
response following IP LPS injection. IL-lp, TNF-a and IL-6 mRNA expression was 
assessed in brain tissue at 2 and 6 hours post LPS, the timepoints at which cytokine 
protein was detected in brain tissue. Further to this, phosphorylated IicBa, p38, JNK 
and ERK was detected in cortex and hippocampus using Luminex®. Phosphoprotein 
analysis using Luminex® was based on personal communication with the 
manufacturer since available kits had not previously been used for analysis of animal 
tissue. Male CD rats (n=8 per group) were administered with lOOpg/kg LPS 
dissolved in filtered PBS or filtered PBS alone. Animals were euthanased at 2 or 6 
hours post LPS administration. Blood and brain were removed, the perfused brain 
was microdissected for whole hippocampus and hemidissected left frontal cortex for 
phosphoprotein analysis and hemidissected right frontal cortex for taqman analysis. 
Additional male CD rats (n=4 per group) were terminally anaesthetised with an IP 
overdose of pentobarbitone at 2 and 6 hours post LPS. These animals were not 
perfused but frontal cortex was microdissected for taqman analysis for comparison of 
mRNA integrity and mRNA expression levels with perfused cortical samples.
2.3.5 Study 5: Effect o f p38 inhibition and a2 adrenoceptor antagonism on
cytokine expression
Male CD rats (n=8 per group) pre-treated with 0.5% methylcellulose or the 
glucocorticoid dexamethasone (1 mg/kg, 1 hour), the p38 inhibitor GW569293 
(25mg/kg, 2 hour) or the alpha-2 adrenoceptor blocker fluparoxan (1, 3 or lOmg/kg, 
30 mins) before IP administration with LPS (lOOpg/kg) dissolved in filtered PBS. 
Animals were euthanased at 6 hours post LPS. The brain was microdissected for 
whole hippocampus and frontal cortex.
2.4 Results
2.4.1 Study 1: Timecourse o f cytokine protein in brain and plasma
2.4.1.1 Cytokine protein in brain
Separate repeated measures ANOVA of each individual cytokine indicated that LPS
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treatment specifically increased the pro-inflammatory cytokines IL-la, F (i, 27) = 
8.18, p<0.01, and IL-ip, F (i, 21) = 16.96, p<0.001, in brain tissue (fig 2.1). There 
were additional significant effects of timepoint, F (i? 21) = 5.88, p<0.05, and a 
treatment*timepoint interaction, F (i, 27) =11.98, p<0.01, on IL -la  in brain tissue.
Post hoc planned comparisons revealed a significant increase of IL-ip was evident 
by 6 hours in the hippocampus (p<0.01) with a trend to increase by 2 hours that 
failed to reach significance at the 0.05 level (p=0.06) (fig 2.IB). LPS significantly 
elevated cortical IL-ip by 2 (p<0.05) and 6 (p=0.05) hours (fig 2.1 A).
IL -la  was significantly elevated at 6 hours in hippocampal (p<0.01) and cortical 
(p<0.05) tissue relative to vehicle treatment.
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Figure 2.1: Cytokine protein in the cortex (A) and hippocampus (B) of adult rats (n = 8) by 2 
and 6 hours post IP LPS administration, data represented as cytokine protein (pg) per 
milligram of tissue and shows mean ± SEM. * p <0.05, ** p <0.01 significantly different vs. 
respective timepoint vehicle (repeated measures ANOVA followed by planned comparisons)
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2.4.1.2 Cytokine protein in plasma
Proinflammatory cytokines were detected in plasma at 2 and 6 hours post 
intraperitoneal LPS administration (fig 2.2). Separate univariate ANOVAs revealed a 
significant overall effect of treatment on TNF-a, F (i5 24) = 6.43, p<0.05, IL-6, F (i; 24) 
= 15.86, p<0.001, IL-la, F (i,27) = 10.41, p<0.01, IL-ip, F(i,27) = 19.74, p<0.001, IL- 
2, F (i, 25) = 9.42, p<0.01 and IL-10, F (i, 26) = 10.48, p<0.01. There was also a 
significant effect of timepoint on IL-6 , F (i, 24) = 8.25, p<0.01, IFNy, F (i, 2i )  -  4.31, 
p<0.05 and IL-2, F (i,25) = 4.82, p<0.05.
Post hoc planned comparisons revealed plasma TNF-a (p<0.01), IL-6  (p<0.001) and 
IFN-y (p<0.05) concentrations increased by the greatest magnitude by 6  hours. 
Elevated IL -la  and IL-lp were evident at both 2 (p<0.05, both cytokines) and 6  
(p<0.05 for IL -la, p<0.001 for IL-lp) hours post LPS administration. IL-10 
(p<0.01) and IL-2 (p<0.01) were significantly elevated above vehicle levels by 6  
hours post LPS (fig 2.2).
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Figure 2.2: Cytokine protein in the cortex (A) and hippocampus (B) of adult rats (n = 8) by 2 
and 6 hours post IP LPS administration, data represented as cytokine protein (pg) per 
millilitre of sample and shows mean ± SEM. (* p <0.05, ** p <0.01, *** p <0.001 
significantly different vs. respective timepoint vehicle (univariate ANOVA followed by
planned comparisons)
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2.4.2 Study 2: Cytokine protein throughout brain tissue
2.4.2.1 Cytokine protein in brain
LPS induced cytokine protein in a number of discrete brain regions and demonstrated 
a specific cytokine profile within brain tissue (fig 2.3A & 2.3B).
Repeated measures ANOVA indicated an overall effect of treatment, F (i, 34) = 15.12, 
p<0.001 and brain region, F (4, 31) = 6.34, p<0.001 on the pro-inflammatory cytokine 
TNF-a. Production of TNF-a was significantly increased in the hypothalamus from 
0.039 ± 0.004 to 0.083 ±0.15 pg/mg tissue. There was also an overall effect of 
treatment on IFN-y, F (i, 60) = 5.42, p<0.05, with a significant increase in the 
hypothalamus from 0.052 ± 0.005 to 0.069 ± 0.005 pg/mg tissue (fig 2.3B (D).
There was an overall effect of treatment, F (i, 59) = 38.3, p<0.001, and brain region, F 
(4, 32) = 3.66, p<0.05, on IL-la. IL -la  was significantly elevated in the cortex from 
0.069 ± 0.007 to 0.201 ± 0.04 pg/mg tissue (fig 2.3A (B)), striatum from 0.052 ± 
0.003 to 0.244 ± 0.073 pg/mg tissue (fig 2.3A (C)), and hypothalamus (fig 2.3B (D)) 
from 0.084 ± 0.01 to 0.256 ± 0.054 pg/mg tissue. Although failing to reach statistical 
significance, a post hoc planned comparison also revealed an increase of IL -la in the 
cerebellum from 0.04 ± 0.003 to 0.139 ± 0.041 pg/mg tissue, p=0.089.
There was a significant overall treatment effect on IL-ip, F (i, 51) = 63.04, p<0.001. 
Post hoc planned comparisons indicated that LPS increased IL-ip in all brain regions 
studied. LPS induction of hypothalamic IL-ip (fig 2.3B (D)) resulted in the greatest 
magnitude of response from 0.355 ± 0.02 to 1.40 ± 0.298 pg/mg tissue. The 
cerebellum (fig 2.3B (E)), striatum (fig 2.3A (C)), hippocampus (fig 2.3A (A)) and 
cortex (fig 2.3A (B)) showed significant augmented levels of IL-ip from 0.345 ± 
0.031 to 1.26 ± 0.29, 0.338 ± 0.022 to 1.079 ± 0.218, 0.347 ± 0.006 to 0.606 ± 0.106 
and 0.325 ± 0.01 to 0.861 ± 0.117 pg/mg tissue respectively.
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Figure 2.3A: Cytokine protein in the cortex (A) and hippocampus (B) and striatum (C) of 
adult rats (n = 8) by 6 hours post IP LPS administration, data represented as cytokine protein 
(pg) per milligram of tissue and shows mean ± SEM. * p <0.05, ** p <0.01, *** p <0.001 
significantly different vs. vehicle (repeated measures ANOVA followed by planned
comparisons)
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Figure 2.3B: Cytokine protein in the hypothalamus (D), cerebellum (E) and plasma (F) of 
adult rats (n = 8 ) by 6  hours post IP LPS administration, data represented as cytokine protein 
(pg) per milligram of tissue (D-E) or cytokine protein (pg) per millilitre of sample (F) and 
shows mean ± SEM. * p <0.05, ** p <0.01, *** p <0.001 significantly different vs. 
respective timepoint vehicle (ANOVA followed by planned comparisons)
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2.4.2.2 Cytokine protein in plasma
IP LPS administration resulted in an increase in a multitude of plasma cytokines (fig 
2.3B (F)); only IL-2 demonstrated a reduction relative to vehicle levels from 4.02 ±
2.7 to 1.63 ± 0.28 pg/ml.
Separate univariate ANOVAs indicated an overall effect of treatment on plasma IFN- 
y, F (i, is) = 38.7, p<0.001, IL-ip, F a , i4) = 11.24, p<0.01, IL-6 , F 0, i4) = 9.11, p<0.01, 
IL-la, F (i, 13) = 11.52, p<0.01, TNF-a, F (i, i4) = 12.01, p<0.01 and IL-10, F (i, i4) = 
19.75, p<0.001.
Post hoc planned comparisons revealed IFN-y was increased from 26.54 ± 9.81 to
360.4 ± 96.1 pg/ml (p<0.01) and IL-ip from 58.47 ± 12.53 to 503.83 ± 167.66 pg/ml 
(p<0.01). LPS also significantly increased plasma IL- 6  from 307.02 ± 6.71 to 1504 ±
533.7 pg/ml (p<0.05), IL -la  from 2.35 ± 0.55 to 6.26 ± 1.64 pg/ml (p<0.05) and 
TNF-a from 53.43 ± 0.83 to 265 ±81.7 pg/ml (p<0.05). LPS administration elevated 
levels of the anti-inflammatory cytokine IL-10 from 39.2 ± 3.09 to 133.6 ± 25.7 
pg/ml (p<0 .0 1 ).
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2.4.3 Study 3: Effect o f Dexamethasone on cytokine expression
2.4.3.1 Cytokine mRNA changes in frontal cortex
There were no significant effects of treatment in unperfused brain tissue on 
expression of the endogenous housekeeper gene, GAPDH. This indicates that 
treatment with LPS, vehicle or dexamethasone had no significant effect on RNA 
integrity. In order to control for variations in RNA quality the results were expressed 
as a percentage of the level of GAPDH expression as described previously (Medhurst 
et al, 2 0 0 0 ).
Repeated measures ANOVA revealed an overall effect of treatment on TNF-a, F (3, 
14) = 10.03, p<0.001, IL-lp, F (3? 15) = 4.75, p<0.05, and IL-6 , F ^  14) = 10.13, 
p<0.001, in cortical tissue. Post hoc planned comparisons revealed that LPS 
significantly increased expression of TNF-a from 0.64 ± 0.09 to 2.96 ± 0.2% 
(p<0.01) (fig 2.4A), IL-ip from 57 ± 0.71 to 3.6 ± 1.10% (p=0.01) (fig 2.4C) and IL- 
6  from 0.07 ± 0.08 to 1.25 ± 0.17% (p<0.001) (fig 2.4B). Administration of 
dexamethasone fully attenuated the LPS induction of TNF-a to 0.57 ± 0.18% 
(p<0.001) and IL-ip to 0.6 ± 0.15% (p=0.01). Dexamethasone treatment failed to 
diminish LPS-induced IL- 6  mRNA expression.
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Figure 2.4: Effect of dexamethasone treatment on LPS-induced TNFa (A), IL6 (B) and ILlp 
(C) mRNA expression in the cortex of adult rats by 6 hours post IP LPS administration, data 
represented as cytokine mRNA as a percentage of GAPDH expression and shows mean ± 
SEM. ** p <0.01, *** p <0.001 significantly different vs. vehicle; # p <0.05, ### p <0.001 
significantly different vs. LPS (univariate ANOVA followed by planned comparisons)
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2.4.3.2 Cytokine protein in brain
Cytokine levels in brain regions of vehicle treated animals were of a similar 
magnitude to each other and to that demonstrated in study 1.
Repeated measures ANOVA revealed an overall effect of treatment on IL-lp, F (2,27) 
= 19.55, p<0.001. Post hoc planned comparisons revealed LPS significantly 
increased hippocampal IL-lp from 0.67 ± 0.11 to 2.39 ± 0.35 pg/mg tissue (fig 2.5B) 
and cortical IL-ip from 0.58 ± 0.12 to 2.39 ± 0.37 pg/mg tissue (fig 2.5A) (p<0.001, 
both regions relative to the vehicle group). Dexamethasone pre-treatment attenuated 
both cortical IL-ip to 0.78 ± 0.07 pg/mg tissue (89% reduction, p<0.001) and 
hippocampal IL-ip to 0.74 ± 0.08 pg/mg tissue (96% reduction, p<0.001) relative to 
the LPS group.
Repeated measures ANOVA revealed an overall treatment effect on central IL-la, F 
(2, 27) = 6.31, pcO.Ol. Post hoc planned comparisons revealed that LPS significantly 
induced hippocampal (p<0.05) but not cortical IL -la  from 0.20 ± 0.04 to 0.67 ± 0.24 
pg/mg tissue. Dexamethasone pre-treatment fully attenuated hippocampal IL -la 
(p<0.01) to 0.08 ± 0.04 pg/mg tissue and decreased basal (no significant effect of 
LPS) cortical IL -la  to 0.07 ± 0.03 pg/mg tissue (214% reduction, p=0.01) 
respectively.
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Figure 2.5: Effect of dexamethasone pre-treatment on cytokine protein in the cortex (A) and 
hippocampus (B) of adult rats (n = 8) by 6 hours post IP LPS administration, data 
represented as cytokine protein (pg) per milligram of tissue and shows mean ± SEM. ** p 
<0.01, *** p <0.001 significantly different vs. vehicle; # p <0.05, ## p <0.01, ### p <0.001 
significantly different vs. LPS (repeated measures ANOVA followed by planned
comparisons)
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2.4.3.3 Cytokine protein in plasma
Cytokine levels for both baseline vehicle treatment and post LPS stimulus were of a 
similar magnitude to that demonstrated in study 1 (fig 2.6).
Univariate ANOVA revealed a significant overall treatment effect on IFN-y, F (2,26) = 
8.54, p=0.001, IL-la, F (2, 27) = 4.71, p<0.05, IL-ip, F (2,27) = 23.55, p<0.001, IL-6, F 
(2,24) = 6.37, p<0.01 and TNF-a, F (2,27) = 16.79, pO.OOl.
Post hoc planned comparisons demonstrated LPS significantly increased IFN-y 
(pO.OOl) from 78.78 ± 25.88 to 631.75 ± 138.31 pg/ml, IL-ip from 15.55 ± 8.99 to 
1236.65 ± 223.47 pg/ml, IL -la  from 0.00 ± 0.00 to 19.49 ± 8.98 pg/ml, IL-6 from
0.00 ± 0.00 to 308.55 ± 146.22 pg/ml and TNF-a from 49.62 ± 33.15 to 765.08 ± 
150.71 pg/ml, pO.OOl).
Dexamethasone pre-treatment significantly attenuated the LPS-induced increase of 
IFN-y by 82% to 178.25 ± 94.15 pg/ml (pO.OOl) and fully attenuated IL-la 
(p=0.01). Dexamethasone also attenuated LPS-induced IL-lp by 81% to 238.52 ± 
61.83 pg/ml (pO.OOl), IL-6 by 97% to 8.58 ± 8.58 pg/ml (pO.Ol) and TNF-a by 
77% to 211.84 ± 36.53 pg/ml (pO.OOl).
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Figure 2.6: Effect of dexamethasone pre-treatment on cytokine protein in the cortex (A) and 
hippocampus (B) of adult rats (n = 8) by 6 hours post IP LPS administration, data 
represented as cytokine protein (pg) per millilitre of sample and shows mean ± SEM. * p 
0-05, ** p <0.01, *** p <0.001 significantly different vs. vehicle; # p <0.05, ### p <0.001 
significantly different vs. LPS (univariate ANOVA followed by planned comparisons)
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2.4.4 Study 4: Cytokine mRNA and intracellular protein expression
2.4.4.1 LPS-induced mRNA expression in frontal cortex
There were no significant alterations in GAPDH expression in perfused tissue, 
however, a two fold significant reduction in GAPDH and cyclophilin expression was 
evident in unperfused tissue obtained from LPS treated rats relative to unperfused 
tissue of vehicle treated rats. Further analysis of pro-inflammatory cytokine 
expression therefore took place using perfused brain tissue since LPS treatment had 
no significant effect on RNA quantification and integrity or housekeeper gene 
expression.
Separate univariate ANOVA revealed a significant overall effect of treatment on the 
mRNA expression of pro-inflammatory cytokines TNF-a, F (i, n) = 16.77, p<0.01, 
IL-ip, F (i, ii) = 14.06, p<0.01 and IL-6, F (i, n) = 35.74, p<0.001, in cortical tissue. 
There was also a significant effect of timepoint on TNF-a, F (i, n) = 18.67, p<0.01, 
and a significant treatment*timepoint interaction on IL-6, F(i, n) = 11, p<0.01.
Post hoc analysis revealed that LPS significantly increased expression of TNF-a 
from 1.34 ± 0.42 to 6.40 ± 1.57% (p=0.001) by 6 hours post administration (fig2.7A) 
whilst IL-ip was elevated from 0.44 ± 0.01 to 11.75 ± 6.03% by 2 hours post LPS 
challenge (p<0.01) (fig 2.7C). LPS induced IL-6 from -0.08 ±0.156 to 4.01 ± 0.95% 
at 2 hours post administration (p<0.001) (fig 2.7B).
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Figure 2.7: TNFa (A), IL6 (B) and ILip (C) mRNA expression in the cortex of adult rats by 
2 and 6 hours post IP LPS administration, data represented as cytokine mRNA as a 
percentage of GAPDH expression and shows mean ± SEM. ** p <0.01, *** p <0.001 
significantly different vs. vehicle; # p <0.05, ### p <0.001 significantly different vs. LPS 
(repeated measures ANOVA followed by planned comparisons)
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2.4.1.2 LPS-induced intracellular protein phosphorylation
Repeated measures ANOVA revealed a significant overall effect of timepoint, F (1,27) 
= 16.00, pO.OOl, and brain region, F (1,26) = 9.16, pO.Ol, on percentage 
phosphorylation of p38. Post hoc planned comparisons revealed an increase in p38 
phosphorylation by 6 hours post intraperitoneal LPS (pO.Ol) relative to vehicle 
treated animals (fig 2.8A).
Repeated measures ANOVA revealed a significant effect of timepoint, F (i, 28) = 
15.86, pO.OOl, brain region, F (i, 21) = 54.27, pO.OOl and a 
treatment*region*timepoint interaction, F (i, 27) = 7.11, p=0.01, on the percentage 
phosphorylation of JNK post intraperitoneal LPS treatment. Phosphorylation of JNK 
was increased in the hippocampus relative to cortex and appeared to be increased, 
regardless of treatment, by the 6 hour timepoint. JNK phosphorylation was decreased 
by 2 hours post intraperitoneal LPS (p<0.05) (fig 2.8C).
Repeated measures ANOVA indicated a treatment*timepoint interaction, F 21) = 
5.35, p<0.05, and a treatment*region*timepoint interaction, F (i, 23) = 10.49, p=0.01, 
on the percentage of IicBa phosphorylation post IP LPS treatment. Post hoc planned 
comparisons revealed an increase in IicBa phosphorylation by 2 hours (p<0.05) and a 
reduction in IicBa phosphorylation by 6 hours (p<0.01) post LPS treatment (fig 
2.8B). Phosphorylation of IicBa was higher in hippocampal tissue and by 6 hours in 
the vehicle group whilst LPS treatment caused higher levels of IicBa 
phosphorylation in cortical tissue and at 2 hours.
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Figure 2.8: Phosphorylation of cortical p38, hippocampal IkBa and cortical JNK intracellular 
protein expression in adult rats by 2 and 6 hours post IP LPS administration, data represented 
as percentage phosphorylation of total protein and shows mean ± SEM. * p <0.05, ** p 
<0.01 significantly different vs. vehicle group within timepoint (repeated measures ANOVA
followed by planned comparisons)
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2.4.4.3 LPS-induced plasma nitrite
Univariate ANOVA revealed a significant effect of LPS treatment, F (i, 24) =269.21, 
pO.OOl, timepoint, F (i, 24) =180.92, pO.OOl and a significant treatment*timepoint 
interaction, F (i, 24) =11.22, pO.OOl, on plasma nitrite levels as a measure of plasma 
nitric oxide production (fig 2.9). Post hoc planned comparisons revealed that LPS 
significantly induced nitrite from 17.5 ± 1.15uMole/L to 322 ± 72.78 uMole/L 
(pO.OOl) by 6 hours post IP LPS administration. Nitric oxide levels were not 
significantly increased by 2 hours post LPS.
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Figure 2.9: Plasma nitrite levels in adult rats by 2 and 6 hours post IP LPS administration, 
data represented as nitrite (uMole/L) and shows mean ± SEM. *** p <0.001 significantly 
different vs. vehicle group within timepoint (repeated measures ANOVA followed by
planned comparisons)
2.4.5 Study 5: Effect o f p38 inhibition and a2 adrenoceptor antagonism on
cytokine expression
2.4.5.1 Cytokine protein in brain
Repeated measures ANOVA revealed a significant overall effect of treatment on IL- 
ip, F (6,47) =4.40, p=0.001 in brain tissue. There was also a significant effect of brain 
region on central IL-lp, F (i, 46) =17.07, p<0.001 revealed as a significantly higher 
level of IL-ip protein in the hippocampus relative to the cortex.
Post hoc planned comparisons demonstrated that LPS increased cortical IL-lp (fig
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2.10A) and hippocampal IL-ip (fig 2.10B) from 0.63 ± 0.08 to 1.60 ± 0.35 pg/mg 
tissue (pO.OOl) and from 1.20 ± 0.21 to 2.74 ± 0.20 pg/mg tissue (pO.OOl), 
respectively. Dexamethasone fully abrogated LPS-induced cortical (pO.OOl) and 
hippocampal IL-ip (pO.OOl) to 0.58 ± 0.05 and 1.01 ± 0.14 pg/mg tissue 
respectively (fig 2.10).
Post hoc planned comparisons also revealed a trend for fluparoxan treatment to 
attenuate the effect of LPS on IL-ip in brain tissue. Fluparoxan reduced hippocampal 
IL-ip by 79% to 1.52 ± 0.39 pg/mg tissue at lmg/kg (p=0.01), by 80% to 1.51 ± 0.24 
pg/mg tissue at 3mg/kg (pO.05) and by 88% to 1.38 ± 0.27 pg/mg tissue at lOmg/kg 
(p=0.08) (fig 2.12B) relative to the LPS group. Fluparoxan did not significantly 
decrease LPS-induced cortical IL-lp at lmg/kg (20% to 1.40 ± 0.22 pg/mg tissue 
(p=0.86)), at 3mg/kg (43% to 1.18 ± 0.26 pg/mg tissue (p=0.29)) or at lOmg/kg 
(52% to 1.10 ± 0.12 pg/mg tissue (p=0.37) (fig 2.11). The p38 inhibitor GW569293 
had no effect on hippocampal (p = 0.23) or cortical IL-ip (p = 0.31) (fig 2.12).
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Figure 2.10: Effect of dexamethasone pre-treatment on cytokine protein in the cortex (A) and 
hippocampus (B) of adult rats (n = 8) by 6 hours post IP LPS administration, data 
represented as cytokine protein (pg) per milligram of tissue and shows mean ± SEM. *** p 
<0.001 significantly different vs. vehicle vs. vehicle group; ### p <0.001 significantly 
different vs. LPS (repeated measures ANOVA followed by planned comparisons)
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Figure 2.11: Effect of fluparoxan pre-treatment on cytokine protein in the cortex (A) and 
hippocampus (B) of adult rats (n = 8) by 6 hours post IP LPS administration, data 
represented as cytokine protein (pg) per milligram of tissue and shows mean ± SEM. # p 
<0.05, ## p <0.01 significantly different vs. LPS (repeated measures ANOVA followed by
planned comparisons)
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Figure 2.12: Effect of GW569293 pre-treatment on cytokine protein in the cortex (A) and 
hippocampus (B) of adult rats (n = 8) by 6 hours post IP LPS administration, data 
represented as cytokine protein (pg) per milligram of tissue and shows mean ± SEM 
(repeated measures ANOVA followed by planned comparisons)
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2.4.5.2 Cytokine protein in plasma
Univariate ANOVA revealed a significant overall effect of treatment on plasma IFN- 
y, F (4, 25) =31.00, p<0.001, IL-1|3, F (6, 43) =32.90, p<0.001, IL-la, F (6, 41) =8.12, 
p<0.001, TNF-a, F (4,23) =7.19, p<0.001 and IL-10, F (6,46) =4.09, p=0.01.
Post hoc planned comparisons revealed LPS significantly increased plasma IFN-y 
from 0.00 to 2359.08 ± 655.70 pg/ml (p<0.001) and plasma IL-ip from 10.36 ± 9.76 
to 2844.88 ± 787.61 pg/ml (p<0.001). LPS-induced plasma IL -la and TNF-a from 
8.89 ± 3.54 to 160.56 ± 82.93 pg/ml (p<0.001) and 0.00 to 3154.44 ± 408.19 pg/ml 
(p<0.001) and increased IL-10 from 1125.97 ± 144.35 to 2025.73 ± 434.83 pg/ml 
(p=0.05).
Dexamethasone fully attenuated plasma IFN-y to 0.00 pg/ml (p<0.001) and ILip by 
90% to 305.33 ± 62.74 pg/ml (p<0.001) (fig 2.13). Dexamethasone also fully 
abrogated plasma IL -la  to 8.92 ± 6.89 pg/ml (p<0.001) and fully attenuated TNF-a 
to 0.00 pg/ml (p<0.001) (fig 2.13). Dexamethasone did not significantly attenuate 
LPS-induced IL-10 (p=0.43) similar the profile seen in study 3.
Fluparoxan significantly attenuated LPS-induced plasma IFN-y by 56% to 1031.58 ±
433.00 pg/ml (p<0.05) at lmg/kg, by 67% to 768.64 ± 156.13 pg/ml (p<0.05) at 
3mg/kg and by 73% to 647.40 ± 128.03 pg/ml at lOmg/kg (p=0.01) (fig 2.14). Post 
hoc planned comparisons revealed that treatment with the p38 inhibitor; GW 569293 
potentiated LPS-induced plasma IFN-y by 292% (p<0.001) (fig 2.15).
Fluparoxan did not significantly decrease LPS-induced plasma IL-ip at the p<0.05 
level (at lmg/kg (p=0.19), at 3mg/kg (p=0.26), at lOmg/kg (p=0.52)) (fig 2.14). 
GW569293 had no significant effect on plasma IL-ip (p = 0.43) relative to the LPS 
group (fig 2.15). Fluparoxan did not significantly attenuate LPS-induced plasma IL- 
l a  (at lmg/kg (p=0.64), at 3mg/kg (p=0.53), at lOmg/kg (0.58) (fig 2.14) and 
GW569293 also had no significant effect on plasma IL-ip (p = 0.47) relative to the 
LPS group (fig 2.15).
Fluparoxan decreased LPS-induced TNF-a by 57% to 913.12 ± 203.40 pg/ml at 
lmg/kg (p=0.06), by 65% to 757.97 ± 238.52 pg/ml at 3mg/kg (p=0.01) and by 82% 
to 386.25 ± 118.64 pg/ml at lOmg/kg (p<0.001) (fig 2.14). GW569293 had no 
significant effect on LPS-induced TNF-a (p=0.50) (fig 2.15).
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There was a trend for fluparoxan at lOmg/kg to potentiate LPS-induced plasma IL-10 
by 129% at lmg/kg (p=0.19), by 127% at 3mg/kg (p=0.21) and 141% at lOmg/kg 
(p=0.08) (fig 2.14). GW569293 had no effect on LPS-induced IL-10 production 
(p=0.36) (fig 2.15).
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Figure 2.13: Effect of dexamethasone pre-treatment on cytokine protein in the cortex (A) and 
hippocampus (B) of adult rats (n = 8) by 6 hours post IP LPS administration, data 
represented as cytokine protein (pg) per millilitre of sample and shows mean ± SEM. (***p 
<0.001, **p <0.01, * p <0.05 significantly different vs. vehicle; ### p <0.001, # p <0.05 
significantly different vs. LPS (univariate ANOVA followed by planned comparisons)
97
V eh ic le /L P S
Fluparoxan 1 m g/k g Fluparoxan 3 m g /k g
4000 n
3500 -
£ 3 0 0 0
re 1000
K
Fluparoxan 1 0 m g /k g
L .##  £
G M C SF IFNy IL10 IL1a IL10 IL2 IL4 IL6 TNFa
Figure 2.14: Effect of fluparoxan pre-treatment on cytokine protein in the plasma of adult 
rats (n = 8) by 6 hours post EP LPS administration, data represented as cytokine protein (pg) 
per millilitre of sample and shows mean ± SEM. ### p <0.001, ## p <0.01, # p <0.05 
significantly different vs. LPS (univariate ANOVA followed by planned comparisons)
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Figure 2.15: Effect of GW569293 pre-treatment on cytokine protein in the plasma of adult 
rats (n = 8) by 6 hours post IP LPS administration, data represented as cytokine protein (pg) 
per millilitre of sample and shows mean ± SEM. ### p <0.001 significantly different vs. LPS 
(univariate ANOVA followed by planned comparisons)
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2.4.5.3 LPS-induced plasma nitrite
Repeated measures ANOVA indicated a significant effect of treatment, F (6, 37) 
=49.21, p<0.001, on plasma nitrite levels (fig 2.16). Post hoc planned comparisons 
revealed that LPS significantly induced nitrite from 12.38 ± 0.63 to 482.55 ± 74.53 
uMole/L (p<0.001). This induction was significantly attenuated by dexamethasone 
treatment (98% reduction, p<0.001) to 23.3 ± 3.17 uMole/L.
Fluparoxan significantly reduced LPS-induced nitrite by 77% at lmg/kg (p<0.001) to 
120.54 ± 24.92 uMole/L, 49% at 3mg/kg (p<0.01) to 251.88 ± 74.73 uMole/L and to 
163.27 ± 31.83 uMole/L (6 8 %) at lOmg/kg (p<0.001). The p38 inhibitor, 
GW569293, also significantly attenuated plasma nitrite by 67% (p<0.001) to 166.51 
± 28.16 uMole/L.
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Figure 2.16: Effect of GW569293 or fluparoxan pre-treatment on plasma nitrite levels in 
adult rats by 6 hours post BP LPS administration, data represented as nitrite (uMole/L) and 
shows mean ± SEM. *** p <0.001 significantly different vs. vehicle group; ### p <0.001, ## 
p <0.01 significantly different vs. LPS group (univariate ANOVA followed by planned
comparisons)
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2.5 Discussion
2.5.1 Detection of cytokine protein in brain and plasma
Although published literature details the induction of central cytokine mRNA 
expression post IP LPS (Jacobs et al, 1997; Satta et al, 1998), reports of the detection 
of cytokine protein in brain tissue have been limited (Goujon et al, 1996; 1997). In 
this chapter, I have described the first application of the Luminex® system for the 
detection of cytokine protein in brain and plasma following IP LPS to rats. A 
significant increase of IL -la  and IL-ip protein throughout discrete regions of the 
brain by 2 and 6 hours following LPS treatment was associated with inconsistent 
increases in IL -la  and TNF-a. Throughout the duration of this thesis, alteration in 
IL-ip in brain tissue following peripheral injection of LPS has usually been reported 
as an increase in mRNA expression (Tonelli et al, 2003; Turrin et al, 2001). 
Although the current studies describe the first reported evidence of the application of
(r)Luminex to the detection of cytokine protein changes in brain tissue following 
peripheral LPA administration, very recently, the detection of IP LPS-induced IL-lp 
and TNF-a in rat brain tissue by ELISA has been reported (Roche et al, 2006). This 
evidence supports the current data that an IP injection of LPS can elicit pro- 
inflammatory cytokine production in rodent brain. The substantial increases of TNF- 
a  in brain tissue reported by Roche et al (2006) may be as a result of the timepoint 
investigated by the authors since, by 4 hours, TNF-a protein was not detectable in 
brain tissue. This may explain why, by 6 hours post IP LPS injection, no increase in 
TNF-a has been detected by Luminex® in the current studies. The significant 
increase in a wide range of cytokines in plasma including IFN-y, IL-ip, TNF-a and 
IL-6 indicates the primary induction of cytokine protein in blood before the CNS. It 
is important to determine that cytokine proteins detected in the brain tissue by 
Luminex® are centrally derived and not plasma bome cytokines that travelled 
through the BBB.
2.5.2 Communication o f peripheral inflammation to the brain
Although a wide range of cytokine proteins were evident in plasma following 
peripheral LPS treatment, only IL-ip protein and small increases in IL-la protein 
were detectable in brain tissue. There is much literature describing the possible
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mechanisms behind the communication of a peripheral inflammatory response to the 
brain. For example, Singh et al, 2004 suggest that peripheral administration of LPS 
caused a slight loss of integrity in the BBB that was molecular weight dependent. A 
protein of approximately 342Da may enter the brain, however [14C] dextran at 50- 
90kDa was unable to travel through the BBB. LPS has a molecular weight of 
approximately lOkDa (www.textbookofbacteriology.net). Hence, until further 
analysis using dextran molecules between 1 and 50kDa establishes more clearly the 
range of BBB penetration possible following IP LPS, it is difficult to determine 
whether LPS itself may enter the brain to cause a cytokine response although 
previous reports have suggested that it is unlikely (Quan et al, 1994). Others argue 
that LPS and cytokines circulating within the bloodstream activate specific receptors 
including TLR4, located on the surface of immune cells and endothelial cells of the 
CVOs, as described in section 1.5.1.2 of chapter 1; however, entry of LPS into the 
brain via the BBB would also activate TLR4 receptors on immune cells within brain 
tissue. Regardless of the mechanism by which an LPS-mediated inflammatory 
response in the blood is communicated to the brain, a neuroinflammatory response 
will be evident by the presence of cytokine mRNA expression and the activation of 
NFkB and MAP kinases.
IP LPS injection significantly increased cortical mRNA expression by 2 hours (IL-ip 
and IL-6) and 6 hours (TNF-a) post injection in perfused samples (fig 2.7). Prior 
investigation of cytokine mRNA expression in unperfused brain samples revealed 
significant increases in IL-ip, IL-6 and TNF-a by 6 hours that were similar in 
magnitude to expression in perfused samples (fig 2.4). This supports previous 
literature and indicates that the brain can present an endogenous central cytokine 
response to peripheral infection (Turrin et al, 2001; Goujon et al, 1995; 1996; Laye et 
al, 2000; Jacobs et al, 1997, Kakizaki et al, 1999; Laye et al, 1994). The magnitude 
of IL-ip mRNA expression at 2 hours was greater than TNF-a or IL-6 at either 2 or 
6 hours (fig 2.7). A greater magnitude of mRNA expression may translate into a 
larger amount of protein product, which may explain why IL-ip protein, in the 
absence of TNF-a or IL-6, can be detected in brain tissue by 6 hours following LPS 
administration.
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In accordance with the literature, I have shown that IP injection of LPS increased 
cytokine mRNA expression in brain tissue (Turrin et al, 2001; Laye et al, 2000). In 
addition to this, detection of intracellular protein phosphorylation by Luminex 
revealed that IP LPS treatment altered phosphorylation of IicBa, JNK and p38 in 
brain tissue (fig 2.8). This is the first time that the detection of intracellular protein 
phosphorylation in brain tissue using Luminex® has been reported. IicBa, JNK and 
p38 are intracellular proteins involved in LPS mediated cell signalling pathways 
important in the induction of target gene transcription. LPS can induce the 
translocation of the transcription factor NF-kB (Krappmann et al, 2004) subsequently 
causing the transcription of target cytokine genes, as described in chapter 1. The 
inhibitory factors IicBa and/or IicBp prevent the translocation and DNA binding of 
NF-kB. Stimulus-dependent phosphorylation of IicBa/p releases NF-kB into the 
nucleus to induce transcription of target genes including that of pro- and anti­
inflammatory cytokines (Krappmann et al, 2004). IP LPS caused a significant 
increase in IicBa phosphorylation in the hippocampus by 2 hours post LPS 
administration (fig 2.8). There was also a non-significant trend for an increase in 
IicBa phosphorylation in cortical tissue. Interestingly, analysis of JNK 
phosphorylation by Luminex® also revealed a reduction in JNK phosphorylation by 2 
hours after IP LPS administration (fig 2.8). Previous literature suggests that activated 
NF-kB can exert anti-apoptotic activity by the suppression of JNK phosphorylation 
(Bubici et al, 2006). Together, these data suggest that the translocation of NF-kB 
may be responsible for the increased expression of cytokine mRNA and protein in 
brain tissue, supporting the evidence that peripheral inflammation is communicated 
to the brain to induce centrally derived cytokine production.
LPS can also activate p38, a MAP kinase important in mediating inflammation 
(Nolan et al, 2003). IP LPS induced p38 kinase phosphorylation in the cortex by 6 
hours post treatment (fig 2.8). LPS did not increase p38 phosphorylation in the 
hippocampus at 2 or 6 hours following injection. This suggests that p38 in 
hippocampal tissue is either unaffected by peripheral infection or that the temporal 
profiles of p38 phosphorylation differ between the cortex and hippocampus. 
Pharmacological inhibition of p38 kinase in models of chronic inflammation has 
demonstrated a role for this kinase in modulating cytokine gene transcription. The 
increase in p38 phosphorylation in brain tissue by 6 hours after peripheral
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administration of LPS suggests that p38 has more of a role in later stages of 
inflammation in this in vivo model.
2,5.3 Pharmacological manipulation o f cytokine protein in brain tissue
2.5.3.1 Glucocorticoid treatment - dexamethasone
In accordance with published literature, taqman analysis of central cytokine mRNA 
expression revealed a large increase in cortical IL-ip mRNA at 2 hours that declined 
by 6 hours following IP LPS injection (fig 2.7). Quan et al (1998) described the 
detection, by in situ hybridisation techniques, of IL-ip at the CVOs and BBB by 2 
hours following LPS administration. Sustained (8-12hrs post LPS) IL-ip expression 
was evident in glial cells throughout brain parenchyma that returned to basal levels at 
24 hours. In the current studies, pre-treatment with dexamethasone (DEX) 
significantly attenuated LPS-induced IL-ip mRNA (fig 2.4) and protein expression 
in brain tissue (fig 2.5) and pro-inflammatory cytokine protein in plasma (fig 2.6). 
Previous reports have described the exacerbation of central IL-ip mRNA expression 
in adrenalectomised (inhibiting glucocorticoid release) rats following peripheral LPS 
injection (Quan et al, 2000). Glucocorticoids such as DEX may enter the brain tissue 
to increase IkBgc expression in microglia, firstly at the CVOs and BBB and then 
throughout the brain tissue (Quan et al, 2000). The increased expression of the 
inhibitory factor IkBgc prevents the LPS-mediated translocation of N F -k B  and 
subsequently inhibits the endogenous transcription and translation of cytokines 
including IL-ip in the brain.
Until now, most evidence for the role of glucocorticoids in modulating LPS-induced 
cytokine expression has stemmed from reports of the potentiation of cytokine 
production following a reduction in endogenous glucocorticoids. For example, 
adrenalectomy or administration of the GC type II receptor antagonist RU38486 
resulted in a potentiation in cytokine mRNA and protein expression after peripheral 
LPS challenge (Goujon et al, 1997 & 1996). The lethal effects of LPS or cytokines 
administered to adrenalectomised rats can be prevented by glucocorticoid 
replacement (Kapcala et al, 1995). The effect of the GC methylprednisolone on LPS- 
induced cytokine production in the brain was assessed in rat brain tissue but, in 
contrast to the current studies, analysis was limited to the detection of TNF-a by
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ELISA (Buttini et al, 1997). Hence, there are presently no data published describing 
the effect of IP LPS injection on the expression of a range of cytokine proteins in rat 
brain tissue and plasma or detailing the effect of dexamethasone treatment on 
detectable cytokine protein. In the current study, using Luminex® has provided a 
novel insight into the effect of dexamethasone treatment on central and peripheral 
cytokine protein release in rat brain following IP LPS injection which is yet to be 
comprehensively reported in the literature.
2.5.3.2 a2-adrenoceptor antagonism - fluparoxan
The a2-adrenoceptor antagonist, fluparoxan, exhibited a strong anti-inflammatory 
effect by significantly decreasing cortical IL-la, hippocampal IL-lp and a non­
significant dose-dependent trend to decrease cortical IL-ip (fig 2.11). Fluparoxan 
also significantly attenuated plasma TNF-a and IL-lp and potentiated plasma IL-10 
(fig 2.14). Antagonism of a l  adrenoceptors has previously been shown to inhibit 
plasma TNF-a (Hasko et al, 1995; Fessler et al, 1996; Szelenyi et al, 2000), either 
inhibit (Finck et al, 1997) or increase (Hasko et al, 1995) IL-6 and potentiate IL-10 
(Szelenyi et al, 2000). The data described in this chapter support reported literature 
and confirm that antagonism of presynaptic a l  adrenoceptors using fluparoxan can 
exert an anti-inflammatory effect on LPS-induced cytokine production. Fluparoxan 
and other selective a l  antagonists increase central noradrenaline release (Millan et 
al, 1994) that results in the prolonged activation of p adrenoceptors, p adrenoceptors 
may exert an anti-inflammatory effect by preventing IicBa degradation and 
subsequent NF-kB translocation and activation of target cytokine genes (Farmer & 
Pugin, 2000; Ye, 2000).
The a l  antagonist, idazoxan can reduce nitrite production by macrophages in vitro 
(Shen et al, 1994). There is currently little data describing the effects of a l  
antagonists on nitrite production in vivo. Here, fluparoxan pretreatment attenuated 
LPS-induced plasma nitrite at all doses providing the first in vivo evidence of a2 
modulation of iNOS activity during inflammation (fig 2.16).
2.5.3.3 P38 inhibition -  GW569293
The p38 inhibitor, GW569293, failed to reduce central or peripheral cytokine
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production (fig 2.12 & 2.15) and significantly enhanced plasma IFN-y with a non­
significant trend to increase plasma TNF-a and IL-lp (fig 2.15). The p38 MAP 
Kinase isoforms have a well-established role as mediators of cytokine release and 
p38 inhibitors demonstrate potent inhibition of cytokine production, particularly in 
vitro (Lee et al, 1994; Cuenda et al, 1995; Dean et al, 1999) but also to a lesser 
degree in vivo (Barone et al, 2001; Legos et al, 2001). Other literature has described 
p38 inhibitors cause elevation of cytokine production (T ten Hove et al, 2002) or 
demonstrate a lack of efficacy for cytokine inhibition (Campbell et al, 2004; Zhang 
et al, 1997; Lu et al, 1999; van den Blink et al, 2001). Previous literature suggests 
p38 activity may be cell-specific resulting in potentiation of cytokine release in 
macrophages whilst inhibiting release in other cell types (Van den Blink et al, 2001; 
Zhang et al, 1997). In addition, the p38 kinase may not modulate TNF-a production 
to the degree originally supposed or alternative intracellular pathways may 
compensate for p38-mediated changes in TNF-a levels. In vitro studies also indicate 
that p38 inhibition may have positive or negative effects on cytokine production 
depending upon the stimuli, cell populations and levels of cytokines produced (Rao 
et al, 2002; Salmon et al, 2001; Kim et al, 2004).
Although it is clear LPS can induce phosphorylation of the p38 kinase, TLR4 
receptor signalling also directly activates NF-kB particularly in the early stages of 
the immune response to peripheral LPS injection (Krappmann et al, 2004). Study 4 
described in this chapter indicated increased central p38 phosphorylation by 6 hours 
post LPS, however, phosphorylation of hcBa, an inhibitory factor for NFkB, 
increased by 2 hours (fig 2.8). This demonstrates a strong role for the NF-kB 
pathway early in LPS-induced cytokine production. These data also suggest the early 
phase of cytokine protein induction may be directed more through direct NF-kB 
activation in the absence of activation of a p38 kinase pathway, possibly explaining 
the lack of an acute effect of GW569293 in the IP LPS cytokine model.
LPS or cytokines can cause iNOS activation (Liew et al, 1994; Lazarov et al, 2000) 
and a continuous LPS infusion in rat caused a small elevation in plasma nitrate/nitrite 
by 4 hours that increased considerably by 6 hours (Soszynski, 2002; Hamilton & 
Warner, 1998). An iNOS selective inhibitor, 1400W, prevented LPS-induced 
increase in nitrate/nitrite suggesting nitric oxide production is consistent with
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inducible nitric oxide synthase (iNOS) induction (Hamilton & Warner, 1998). 
Although p38 inhibition exhibited little effect on the cytokines investigated in the 
current study, the release of nitrite by circulating plasma macrophages and 
monocytes was significantly reduced by GW569293 (fig 2.16). These data support 
some in vitro evidence (Guan et al, 1997); however, other studies have indicated p38 
inhibition may enhance NO production (Lahti et al, 2006). It is possible that iNOS 
activity occurs independently of cytokine production and may support a cell-specific 
role for p38 kinase. Variation in the inflammatory stimulus and timepoints 
investigated between studies may also influence the effect of p38 inhibition on iNOS 
activity.
This chapter describes the first report of the application of a Luminex® suspension 
bead array system to the detection of cytokine protein and phosphoproteins involved 
in LPS-mediated intracellular signalling in brain tissue post IP LPS. Importantly, the 
identification of intracellular protein phosphorylation and cytokine mRNA 
expression in brain tissue confirmed an endogenous neuroinflammatory response to 
IP LPS injection. It is evident that IP LPS can induce central inflammatory markers, 
specifically IL-ip and IL -la and that an EP LPS-induced cytokine protein model can 
successfully act as a first-pass screen for putative anti-inflammatory agents. One 
caveat of this model is that the peripheral anti-inflammatory actions of an agent may 
prevent subsequent communication of the presence of inflammation to the brain, 
making it difficult to clearly assess the anti-inflammatory activity of compounds on 
brain tissue. Some agents may also modulate cytokines other than IL-lp or IL-la 
released endogenously within the brain. A model providing a broader central 
cytokine profile is required to provide more in-depth analysis of the effect of a 
compound on neuroinflammation. mRNA expression of inflammatory cytokines in 
plasma and brain tissue is increased to a greater extent following administration of 
LPS directly into the brain in contrast to peripheral LPS injection (Gayle et al, 1998; 
Gayle et al, 1999; Turrin et al, 2001; Plata-Salaman et al, 1998; De Simoni et al, 
1995). The following chapter will describe the measurement of central and peripheral 
cytokine following ICY injection of LPS using Luminex®
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CHAPTER 3
Central administration of LPS — confirming anti­
inflammatory activity in brain tissue
3.1 Introduction
Chapter 2 detailed the validation of a high throughput in vivo model of IP LPS 
induced central and peripheral cytokine protein in rodent brain. Neuroinflammation 
was present as evidenced by alterations in pro-inflammatory mRNA expression, IL- 
1P protein and intracellular proteins in brain tissue indicating the communication of a 
peripheral immune response to the brain. The glucocorticoid dexamethasone and the 
a2-adrenoceptor antagonist fluparoxan attenuated pro-inflammatory cytokine protein 
expression in brain tissue and plasma. The peripheral LPS model, however, does not 
clearly establish anti-inflammatory activity of these agents in brain tissue as 
reduction of LPS-induced cytokines in the blood affect the communication of an 
inflammatory response from blood to brain. An in vivo model in which the 
inflammatory response is initiated in brain tissue first will allow further assessment 
of the efficacy of agents on centrally derived inflammation. I chose to induce a 
neuroinflammatory response to LPS via ICV injection into rat brain and to use the 
Luminex® suspension bead array system, previously validated for cytokine detection 
in chapter 2, to assess the induction of central and peripheral cytokine protein. The 
model will be used to further investigate the anti-inflammatory properties of 
dexamethasone and fluparoxan in brain tissue. Glucocorticoid treatment attenuates 
LPS-induced cytokine production (Sironi et al, 1992, Mengozzi et al, 1994) and 
dexamethasone demonstrated potent anti-inflammatory properties in chapter 2. 
Antagonists of a2 receptors increase synaptic NA, a catecholamine that inhibits the 
release of pro-inflammatory cytokines (Kaneko et al, 2005; Hu et al, 1991) and 
inhibits microglial activation (Lee et al, 1992; Loughlin et al, 1993; Chang & Liu, 
2000).
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3.1.1 Intracerebroventricular (ICV) injection
LPS, at a molecular weight of lOkDa is unlikely to cross the blood brain barrier. In 
order to induce neuroinflammation, LPS must be directly injected into the brain 
tissue. LPS infusion into the ventricular system, via direct injection or implantation 
of a permanent indwelling cannula, initiates a strong time-dependant inflammatory 
response in the brain, ipsilateral to the site of injection (Muramami et al, 1993). 
Following ICV LPS injection, intraventricular macrophages and microglia increase 
the expression of cell-surface proteins including both MHC class I and II (Ling et al, 
1998). Microglia are subsequently activated in hippocampal and thalamic areas 
(Nicholson & Renton, 2001) prompting rapid induction of pro-inflammatory 
cytokines including TNF-a (Zujovic et al, 2001). Evidence suggests that ICV 
administered LPS induces peripheral cytokine production via its dissipation into the 
blood from the brain since bioactive LPS can be detected in the blood as early as 5 
minutes post injection (Chen et al, 2000). The magnitude and range of cytokine 
response evident in the periphery following central LPS administration is, however, 
less than that induced by peripheral LPS challenge.
3.1.2 Evidence o f central cytokine induction by ICV LPS
Acute ICV LPS administration results in the expression of pro-inflammatory 
cytokine mRNA in the brain (Gayle et al, 1998; 1999; Plata-Salaman et al, 1998; De 
Simoni et al, 1998; Muramami et al, 1993; Song et al, 1999). ICV administration of 
LPS may also induce cytokine protein in plasma (Hallenbeck et al, 1991; Gottschall 
et al, 1992; Song et al, 1999; Ghezzi et al, 2000; Chen et al, 2000; Nicholson & 
Renton, 2001; Finck et al, 1997). ELISAs have previously been used to detect a 
small range of cytokine proteins in brain tissue (Szczepanik & Ringheim, 2003; 
Kalehua et al, 2000; Zujovic et al, 2001).
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3.1.3 Chapter A ims
The goals of this chapter are to:
1. Evaluate the anti-inflammatory effect of dexamethasone pre-treatment on 
ICV LPS induced cytokine protein in rat brain tissue and plasma.
2. Assess the anti-inflammatory effect of fluparoxan and GW569293 pre­
treatment on ICV LPS induced cytokine protein in rat brain tissue and 
plasma.
3.2 Materials & Methods
3.2.1 Materials
The p38 inhibitor GW569293 and the a l-  adrenoceptor antagonist fluparoxan were 
synthesised at GSK, Harlow. PBS (Sigma, UK) and methylcellulose were prepared 
in-house. Lipopolysaccharide (0111 :B4, L2630) and the glucocorticoid
dexamethasone were purchased from Sigma, UK.
3.2.2 ICV cannulation
Specific, pathogen free male CD rats (250g, approximately 10 weeks of age) 
(Charles River, UK) were anaesthetised by inhalation of 3% isoflurane in oxygen 
(Merial animal Health Ltd, Essex, UK). The head of each rat was shaved and the skin 
sterilised using a hibitane/alcohol solution. Lacrilube (Allergan, Buckinghamshire, 
UK) was applied to the eyes to prevent them from drying out during surgery. 
Animals were secured in a stereotaxic frame (David Kopf Instruments, USA) (incisor 
bar set -3.2mm below the intra-aural plane) and a midline incision along the sagittal 
suture made in the skin overlying the skull. 0.1ml intra-epicaine (Arnolds, Surrey, 
UK) was injected into the subdermal skin layers to provide post-operative local 
analgesia. Four burr holes were drilled and screws and cannula (Plastics One, 
Roanoke, Virginia, USA) implanted into the skull, secured in place by cyanoacrylate 
gel and gel activator (RS components, Corby, UK). The skin either side of the gel 
was sutured with vicryl rapide 4/0 (Johnson & Johnson, UK) and the animal housed 
in an incubator set at 37°C until the rat had regained consciousness. All animals were 
returned to the home cage with warm bedding and soft mash/baby food. The body 
weights and general health of the rats were monitored daily until pre-operative body
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weight had been reached. Rats were individually housed in an animal facility at 
GlaxoSmithKline Pharmaceuticals, Harlow, Essex UK under controlled conditions 
(temperature: 21-24°C, 12-h light/dark cycle (7am lights on) and fed a pellet diet and 
water ad libitum.
Post ICV cannulation, all animals were tested for cannulae patency by ICV injection 
of human angiotensin II (lOOng/rat) (Sigma, UK) (Johnson & Epstein, 1975). 
Animals that failed to display an acute dipsogenic response were culled by an 
approved schedule one method. All experimental procedures were conducted in 
accordance with the GlaxoSmithKline local ethics committee and conform to the UK 
Animals (Scientific Procedures) Act 1986.
3.2.3 Drug administration
Dexamethasone, GW569293 and fluparoxan were sonicated in 0.5% 
methylcellulose until completely dissolved and administered orally at a dosing 
volume of 2ml/kg. Dosing took place according to a timed schedule of two rats 
every 15 minutes to account for the time required to sample each rat. ICV 
cannulated rats were administered with either 20pg or 5pg LPS (0111:B4 E. coli, 
L2630, Sigma, UK) dissolved in 5pl of filtered PBS. LPS (4mg/lml or lmg/lml) 
was allowed to dissolve in PBS in a falcon tube (VWR International, UK) for at 
least 30 minutes before administration. Initial studies completed at GSK, Harlow, 
assessed cytokine protein induction in plasma following 20pg LPS ICV therefore,
I used this dose for the preliminary study. LPS (5pg) was reported to increase 
hippocampal TNF-a protein; hence, this dose is also reported in this chapter 
(Zujovic et al, 2001). LPS was injected ICV at 30 minutes, 1 hour or 2 hours 
following oral (gavage) treatment with fluparoxan (3mg/kg), dexamethasone 
(lmg/kg) or GW569293 respectively.
3.2.4 ICV administration and cytokine determination
An infusion pump (Harvard PHD 4400 Hpsi, Harvard Apparatus, Kent, UK) was 
loaded with a lOOul Hamilton syringe (Hamilton, Birmingham, UK) attached to PVC 
tubing and tipped with a stainless steel injector (Plastics One, Roanoke, Virginia, 
USA). The tubing and syringe were filled with 0.9% saline and a lOpl air bubble 
drawn up at the distal end to enable separation of the test compound and the saline.
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LPS was injected over the duration of two minutes with a further 30 seconds before 
injector removal to ensure complete diffusion of LPS into the ventricle. Dosing took 
place according to a timed schedule of two rats every fifteen minutes to account for 
the time required to sample each rat. Rats were deeply anaesthetised with sodium 
pentobarbitone (Euthatal® lOOmg kg-1 i.p, Rhone Merieux, Harlow, UK) 2 hours 
post ICV LPS administration. This sampling timepoint was based on evidence in the 
literature (Kalehua e al, 2000; Zujovic et al, 2001) and previous in-house studies 
(GSK, Harlow) demonstrating peak IL-la, IL-ip and TNF-a induction in brain 
tissue by 2 hours post ICV LPS. Plasma and ipsilateral brain samples were obtained 
using the method described in 2.2.4. All samples were prepared for cytokine 
determination as described in 2.2.5.1 and subsequently analysed using the Luminex 
suspension array system using the method described in 2.2.5.2.
3.2.5 Data Analysis
4/5-parameter logistic regression curves (Hulse et al, 2004) of the cytokine standard 
values were calculated using StarStation software and the concentrations of unknown 
samples were determined relative to calculated standard curves.
A general linear mixed model approach using the Proc Mixed procedure in SAS® 
Version 8  (SAS Institute, UK) assessed each separate cytokine response using brain 
region as a repeated measure. Univariate tests of significance using Statistica™ 
Version 6.1 (StatSoft, USA) calculated the overall effect of LPS treatment on plasma 
cytokine responses. Planned comparisons on the predicted means from the model 
assessed individual LPS effects on cytokine levels within plasma and brain 
compartments. Results are represented as means ± SEM and significance was set at P 
< 0.05. Percentage reduction describes attenuation relative to the LPS-induced 
cytokine response.
3.3 Protocols
3.3.1 Study 6: Pre-treatment o f dexamethasone or GW569293: 20ytg ICV
LPS
Male CD rats (n=8-10 per group) were pre-treated with 0.5% methylcellulose, 
dexamethasone (lmg/kg, 1 hour) or GW569293 (25mg/kg, 2 hours) before ICV LPS
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(20|ig/rat) dissolved in filtered PBS. All animals were euthanased 2 hours post LPS 
administration and plasma, ipsilateral hippocampus and frontal cortex were taken for 
cytokine analysis
3.3.2 Study 7: Pretreatment o f dexamethasone: 5jug ICV LPS
Male CD rats (n=4-7 per group) pre-treated with either 0.5% methylcellulose or the 
glucocorticoid dexamethasone (lmg/kg) were administered 1 hour later with 5pg/rat 
LPS dissolved in filtered PBS or filtered PBS alone. All animals were euthanased 2 
hours post LPS administration and plasma, ipsilateral hippocampus and frontal 
cortex were taken for cytokine analysis.
3.3.3 Study 8: Pretreatment offluparoxan or GW569293: 5/jg ICV LPS
Male CD rats (n=6 - 8  per group) pre-treated with 0.5% methylcellulose, fluparoxan 
(3mg/kg, 30 mins) or GW569293 (25mg/kg, 2 hours) before ICV LPS (5pg/rat) 
dissolved in filtered PBS. All animals were euthanased 2 hours post LPS 
administration and plasma, ipsilateral hippocampus and frontal cortex were taken for 
cytokine analysis.
3.4 Results
3.4.1 Study 6: Pre-treatment o f dexamethasone or GW569293: 20pg ICV
LPS
3.4.1.1 Cytokine protein in brain
CD rats (n=8 ) were pre-treated with the glucocorticoid dexamethasone followed by 
ICV 20pg LPS (fig 3.1 A & 3.IB). Separate repeated measure ANOVAs on each 
cytokine indicated an overall effect of treatment, F 29) = 8.04, p<0.001, region, F (i, 
29) = 58.38, p<0.001 and a treatment*brain region interaction, F (3, 29) = 5.47, p<0.01 
on LPS-induced IL-la. There was a significant effect of treatment [F (3, 30) = 7.78, 
p<0.001], region [F (i? 29) = 61.38, p<0.001] and a treatment*brain region interaction 
[F (3, 29) = 5.49, p<0.01] on LPS-induced IL-lp. Repeated measures revealed an 
overall effect of treatment, F (3, 30) = 7.22, p<0.001 region, F (i, 30) = 24.16, p<0.001 
and a treatment*brain region interaction, F (3, 30) = 6.64, p=0.001 on the
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proinflammatory cytokine TNF-a. There was also a significant treatment effect on 
IFN-y, F (3,27) = 4.01, p<0.05.
Post hoc planned comparisons revealed LPS increased cortical IFN-y from 1.13 ± 
0.06 to 1.27 ± 0.07 pg/mg tissue, however, this failed to reach significance at the 
p<0.05 level (p=0.08). (fig 3.1 A & 3.IB).
Post hoc planned comparisons also revealed LPS increased hippocampal IL-la from 
0.76 ± 0.09 to 4.3 ± 1.07 pg/mg tissue (p<0.01) and from 0.77 ± 0.14 to 8.33 ± 1.24 
pg/mg tissue in the cortex (p<0.001). Dexamethasone significantly attenuated 
hippocampal IL -la  to 2.12 ± 0.49 pg/mg tissue (61% reduction of LPS response 
(p<0.05)). ICV LPS also significantly increased hippocampal IL-ip from 2.42 ± 0.03 
to 11.48 ± 2.50 pg/mg (p<0.001) and cortical IL-ip from 2.59 ± 0.69 to 21.45 ± 2.99 
pg/mg tissue. Dexamethasone reduced hippocampal IL-lp by 48% to 7.14 ± 1.40 
pg/mg tissue (p<0.05). LPS augmented hippocampal TNF-a from 2.28 ± 0.08 to 3.51 
± 0.36 pg/mg (p<0.05) and cortical TNF-a from 2.19 ± 0.14 to 5.28 ± 0.39 pg/mg 
(p<0.001). Dexamethasone attenuated hippocampal TNF-a by 83% to 2.48 ± 0.30 
pg/mg (p<0.05) and cortical TNF-a by 53% to 3.65 ± 0.52 pg/mg tissue (p<0.01). 
The p38 inhibitor, GW569293 did not significantly attenuate any LPS-induced 
cytokine protein measure within brain tissue (fig 3.2A & B).
3.4.1.2 Cytokine protein in plasma
Separate univariate ANOVAs revealed overall treatment effect on plasma IL-la, F (3, 
28) = 4.20, p=0.01, and TNF-a, F (3, 30) = 19.21, p<0.001 (fig 3.3). LPS reduced 
plasma IL -la  from 372.43 ± 134.91 to 71.88 ± 14.53 pg/ml (p=0.01) and increased 
plasma TNF-a from 648.83 ± 172.97 to 47460.7 ± 10013.24 pg/ml (p<0.001). 
Dexamethasone attenuated TNF-a by 93% decreasing LPS induced plasma TNF-a 
to 4114.79 ± 1146.03 pg/ml (p<0.0001). GW569293 significantly decreased plasma 
TNF-a by 87% to 6414.03 ± 1552.53 pg/ml (p=0.001) (fig 3.4).
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Figure 3.1: Effect of dexamethasone pre-treatment on cytokine protein in the cortex (A) and 
hippocampus (B) of adult rats (n = 8-10) by 2 hours post ICV LPS (20pg) administration, 
data represented as cytokine protein (pg) per milligram of tissue and shows mean ± SEM. 
***p <0.001, **p <0.01, * p <0.05 significantly different vs. vehicle; ## p <0.01, # p <0.05 
significantly different vs. LPS (repeated measures ANOVA followed by planned
comparisons)
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Figure 3.2: Effect of GW569293 pre-treatment on cytokine protein in the cortex (A) and 
hippocampus (B) of adult rats (n = 8-10) by 2 hours post ICV LPS (20pg) administration, 
data represented as cytokine protein (pg) per milligram of tissue and shows mean ± SEM 
(repeated measures ANOVA followed by planned comparisons)
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Figure 3.3: Effect of dexamethasone pre-treatment on cytokine protein in plasma of adult 
rats (n = 8-10) by 2 hours post ICV LPS (20pg) administration, data represented as cytokine 
protein (pg) per millilitre of sample and shows mean ± SEM. ***p <0.001, **p <0.01 
significantly different vs. vehicle; ### p <0.001 significantly different vs. LPS (univariate 
ANOVA followed by planned comparisons)
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Figure 3.4: Effect of GW569293 pre-treatment on cytokine protein in plasma of adult rats (n 
= 8-10) by 2 hours post ICV LPS (20pg) administration, data represented as cytokine protein 
(pg) per millilitre of sample and shows mean ± SEM. ### p <0.001 significantly different vs. 
LPS (univariate ANOVA followed by planned comparisons)
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3.4.2 Study 7: Pretreatment o f dexamethasone: 5/jg ICV LPS
3.4.2.1 Cytokine protein in brain
Repeated measures ANOVA on each cytokine indicated an overall treatment effect 
on IL-la, F (2, 14) = 14.88, p<0.001, IL-ip, F (2, 9) = 11.21, p<0.01 and TNF-a F (2, 14) 
= 7.33, p<0.01 in brain tissue (fig 3.5A & 3.5B). There was also a significant effect 
of brain region on TNF-a, F (i, 14) = 5.47, p<0.05.
Post hoc planned comparisons revealed LPS significantly increased cortical 
(p<0.001) and hippocampal (p=0.001) IL -la  from 0.31 ± 0.06 to 1.19 ± 0.11 pg/mg 
tissue and from 0.45 ±0.13 to 2.4 ± 0.65 pg/mg tissue respectively. Dexamethasone 
significantly attenuated LPS-induced cortical IL -la  (p<0.01) by 75% to 0.53 ±0.14 
pg/mg tissue and fully attenuated hippocampal IL -la  (p<0.001) to 0.42 ± 0.11 pg/mg 
tissue. LPS significantly increased cortical (p<0.01) and hippocampal (p<0.01) IL-ip 
from 0.72 ± 0.23 to 33.30 ± 4.01 pg/mg tissue and from 1.49 ± 0.84 to 46.85 ± 11.88 
pg/mg tissue respectively. Dexamethasone significantly decreased LPS-induced 
hippocampal IL-ip by 6 8 % (p<0.05) to 15.61 ± 7.49 pg/mg tissue and attenuated 
LPS-induced cortical IL-lp by 43% (p=0.09) to 19.42 ± 9.05 pg/mg tissue. ICV LPS 
administration increased cortical TNF-a (p<0.01) from 0.69 ± 0.37 to 2.35 ± 0.23 
pg/mg tissue and hippocampal TNF-a (p<0.01) from 1.07 ± 0.43 to 3.48 ± 0.81 
pg/mg tissue. Dexamethasone treatment reduced the LPS induction of cortical and 
hippocampal TNF-a by 85% (p<0.01) to 1.17 ± 0.33 pg/mg tissue and 89% (p<0.01) 
to 1.42 ± 0.30 pg/mg tissue respectively.
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Figure 3.5: Effect of dexamethasone pre-treatment on cytokine protein in the cortex (A) and 
hippocampus (B) of adult rats (n = 4-7) by 2 hours post ICV LPS (5pg) administration, data 
represented as cytokine protein (pg) per milligram of tissue and shows mean ± SEM. ***p 
<0.001, **p <0.01 significantly different vs. vehicle; ### p <0.001, ## p <0.01 significantly 
different vs. LPS (repeated measures ANOVA followed by planned comparisons)
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3.4.2.2 Cytokine protein in plasma
Plasma IL-lp was increased (p<0.01) from 0.20 ± 0.20 to 779.67 ± 605.86 pg/ml and 
IL-6 and TNF-a was augmented from 128.00 ± 0.00 to 693.61 ± 162.23 pg/ml 
(p<0.05) and from 0.00 ± 0.00 to 4132.36 ± 1866.86 pg/ml (p<0.001) respectively. 
Dexamethasone attenuated the LPS-induced increase in IL-ip by 98% (p<0.06) to 
14.71 ± 14.71 pg/ml and fully attenuated IL-6 (p<0.01) and TNF-a (p<0.001) to 0.00 
pg/ml (fig 3.6).
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Figure 3.6: Effect of dexamethasone pre-treatment on cytokine protein in plasma of adult 
rats (n = 4-7) by 2 hours post ICV LPS (5pg) administration, data represented as cytokine 
protein (pg) per millilitre of sample and shows mean ± SEM. ***p <0.001, **p <0.01, * p 
<0.05 significantly different vs. vehicle; ### p <0.001, ## p <0.01 significantly different vs. 
LPS (univariate ANOVA followed by planned comparisons)
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3.4.3 Study 8: Pretreatment offluparoxan or GW569293: 5pg ICV LPS
3.4.3.1 Cytokine protein in brain
Separate repeated measure ANOVAs indicated an overall effect of treatment on IL- 
la , F (3; 25) = 3.53, p<0.05, IL-ip, F (3, 25) = 2.85, p=0.06 and TNF-a F (3, 24) = 5.34, 
p<0.01 in brain tissue (fig 3.7A and 3.7B). There were also significant effects of 
brain region on GM-CSF, F (1,24) = 13.84, p=0.001, IFN-y, F (1,25) = 9.12, p<0.01, IL- 
4, F (1,25) = 22.06, pO.OOl, IL-6, F (1,25) = 21.22, p<0.001 and TNF-a, F (1,24) = 4.18, 
p=0.05.
Post hoc planned comparisons revealed LPS significantly increased cortical (p<0.05) 
and hippocampal (p<0.01) IL -la  from 0.85 ± 0.27 to 2.86 ± 1.82 pg/mg tissue and 
from 0.82 ± 0.19 to 2.64 ± 0.79 pg/mg tissue respectively. LPS-increased cortical IL- 
l a  was attenuated by 96% following fluparoxan treatment (p<0.05) to 0.93 ±0.16 
pg/mg tissue. Increased hippocampal IL -la  in response to ICV LPS was also 
reduced by 65% to 1.46 ± 0.34 pg/mg tissue following fluparoxan but this failed to 
reach significance at the p=0.05 level (p=0.09).
LPS significantly increased IL-ip from 8.39 ± 6.21 to 33.48 ± 8.93 pg/mg tissue and 
from 8.72 ± 3.55 to 43.29 ± 20.37 pg/mg tissue in cortex (p<0.05) and hippocampus 
(p<0.05) respectively. Fluparoxan also reduced the production of cortical and 
hippocampal IL-ip by 79% to 13.74 ± 3.64 pg/mg tissue (p=0.05) and 65% to 20.96 
± 5.05 pg/mg tissue (p=0.08) respectively.
LPS induced a significant elevation of TNF-a in cortex from 0.63 ± 0.29 to 2.39 ±
0.81 pg/mg tissue (p<0.05) and hippocampus from 1.04 ± 0.26 to 2.54 ± 0.32 pg/mg 
tissue (p<0.01). This was attenuated by fluparoxan treatment to 0.87 ±0.17 pg/mg 
tissue in cortex (86% reduction, p<0.05) and by 42% to 1.91 ± 0.42 pg/mg tissue in 
hippocampus, however this failed to reach significance at p<0.05 (p=0.19).
The p38 inhibitor, GW569293 did not significantly attenuate any LPS-induced 
cytokine protein measure within brain tissue (IL-1P: cortex -  p=0.11 vs. LPS; 
hippocampus -  p=0.42 vs. LPS) (fig 3.8A & B).
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Figure 3.7: Effect of fluparoxan pre-treatment on cytokine protein in cortex (A) and 
hippocampus (B) of adult rats (n = 6-8) by 2 hours post ICV LPS (5fig) administration, data 
represented as cytokine protein (pg) per milligram of tissue and shows mean ± SEM. **p 
<0.01, * p <0.05 significantly different vs. vehicle; # p <0.05 significantly different vs. LPS 
(repeated measures ANOVA followed by planned comparisons)
121
Vehicle/LPS GW569293/LPS
A
45 - 
o' 40 -
3■
J2 35 -
J 5 30 -
& 25  - <u
|  20 - 
S
S' 15 -
0  1 0  -1
5 5 -
G M CSF IFNy IL10 IL1a IL13 IL2 IL4 IL6 TNFa
B
70
a  20 -
IL6 TNFaGM CSF IFNy IL1(3 IL2 IL4IL10 IL1a
Figure 3.8: Effect o f GW569293 pre-treatment on cytokine protein in cortex (A) and 
hippocampus (B) of adult rats (n = 6-8) by 2 hours post ICV LPS (5pg) administration, data 
represented as cytokine protein (pg) per milligram o f tissue and shows mean ± SEM 
(repeated measures ANOVA followed by planned comparisons)
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3.4.3.2 Cytokine protein in plasma
A univariate ANOVA revealed an overall effect of treatment on plasma IL-10, F (3,25) 
= 3.36, p<0.05, IL-ip, F (3, 25) = 5.47, p<0.01, IL-6 , F (3, i7) = 6.93, p<0.01 and TNF- 
a, F(3, 19) = 8 .8 6 , p<0.001 (fig 3.9 & 3.10).
Post hoc comparisons revealed that ICV administered LPS increased plasma IL-ip 
(p=0.08) and TNF-a (p=0.07) from 81.24 ± 27.76 to 412.12 ± 120.03 pg/ml and 
from 482.62 ± 105.34 to 2513.32 ± 1008.41 pg/ml respectively. Fluparoxan 
treatment fully attenuated plasma IL-10 to 95.28 ± 40.60 pg/ml (p<0.01) and 
attenuated plasma IL-lp by 85% to 132.19 ± 60.20 pg/ml (p<0.01) (fig 3.9). 
Fluparoxan also significantly decreased plasma IL- 6  relative to LPS treatment 
(p<0.001) although LPS did not significantly increase plasma IL- 6  above vehicle 
levels (p=0.10). Plasma TNF-a was significantly attenuated by 93% to 623.60 ± 
298.25 pg/ml (p=0.01) (fig 3.9). GW569293 significantly increased plasma TNF-a 
by 371% to 9343.88 ± 2632.91 pg/ml (p<0.05) (fig 3.10).
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Figure 3.9: Effect of fluparoxan pre-treatment on cytokine protein in plasma of adult rats (n 
= 6-8) by 2 hours post ICV LPS (5pg) administration, data represented as cytokine protein 
(pg) per millilitre of sample and shows mean ± SEM. ### p <0.001 ## p <0.01 significantly 
different vs. LPS (univariate ANOVA followed by planned comparisons)
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Figure 3.10: Effect of GW569293 pre-treatment on cytokine protein in plasma of adult rats 
(n = 6-8) by 2 hours post ICV LPS (5pg) administration, data represented as cytokine protein 
(pg) per millilitre of sample and shows mean ± SEM. # p <0.05 significantly different vs. 
LPS (univariate ANOVA followed by planned comparisons)
3.5 Discussion
3.5.1 Central v s. peripheral cytokine response
The activation of microglia in the endothelial wall of ventricles and hippocampal and 
thalamic areas causes a rapid increase in mRNA expression (Gayle et al, 1998; 1999; 
Plata-Salaman et al, 1998; De Simoni et al, 1998; Muramami et al, 1993) and protein 
(Zujovic et al, 2001) of pro-inflammatory cytokines, particularly TNF-a, in rat brain. 
Using the Luminex® system, modulation of ICV LPS-induced cytokine protein in 
plasma and brain tissue by dexamethasone and fluparoxan was assessed. An initial 
study using 20pg LPS, a dose previously used at GSK Harlow, to assess the anti­
inflammatory activity of compounds, revealed that, in addition to a robust increase in 
central TNF-a protein there was a significant induction of cortical and hippocampal 
IL -la  and IL-lp (fig 3.1). This demonstrates a similar effect of LPS in brain tissue to 
that described in chapter 2 in which IP LPS caused a significant induction in cortical 
IL-ip and TNF-a mRNA expression (fig 2.4) and a detectable increase in cortical 
and hippocampal IL-lp protein (fig 2.5). In general, the hippocampal response to
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ICV administered LPS was greater than that evident in cortical tissue. This is likely 
due to the timecourse of events that occur following administration, since initial 
activation of microglia occurs within the ventricles and hippocampal regions 
(Nicholson & Renton, 2001). Central IL-la, IL-ip and TNF-a protein induction was 
also evident following 5pg ICV LPS but the magnitude of cytokine protein 
production was increased, particularly in the hippocampus, relative to 20pg LPS (fig 
3.5). Interestingly, Zujovic et al, 2001 reported that following completion of a dose 
response curve of LPS, maximal TNF-a production was achieved using lOpg ICV 
LPS, however, in order to observe modulation of cytokine protein by anti­
inflammatory agents, 5pg LPS was used to obtain a sub-maximal TNF-a response in 
brain tissue. This suggests LPS-mediated cytokine production is dose-dependent, 
achieving maximal levels at lOpg and decreasing in magnitude at higher doses of 
LPS (20pg).
The peripheral response to ICV administered LPS did not directly relate to the 
central profile. There was a massive increase in plasma TNF-a protein production in 
the absence of IL -la  and a small associated increase in IL-ip protein (fig 3.4 & 3.6). 
LPS can be detected in the blood approximately five minutes after ICV LPS injection 
(Chen et al, 2000). Hence, plasma cytokine induction may possibly be caused by the 
direct interaction of LPS with immune cells circulating in the blood. However, it 
cannot be discounted that centrally derived cytokines may travel through the 
damaged (due to the surgically implanted cannulae) blood-brain barrier.
3.5.2 Central efficacy o f peripherally administered anti-inflammatory agents
3.5.2.1 Glucocorticoid treatment - Dexamethasone
Chapter 2 described the complete attenuation of IP LPS-induced central cytokine 
mRNA (fig 2.4) and protein (fig 2.5) expression by dexamethasone. Assessing the 
central efficacy of peripherally administered dexamethasone in the model was 
difficult as a reduction of cytokines in the blood by dexamethasone meant reduced 
communication to the brain of peripheral inflammation. Hence, reduced cytokine 
protein production in brain tissue following dexamethasone may be a knock-on effect 
of the agent on cytokine release in blood. The central efficacy of dexamethasone was 
assessed following injection of LPS into the ventricular system to initiate
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inflammation in brain tissue. Dexamethasone significantly attenuated central TNF-a, 
hippocampal IL -la  (61% reduction) and IL-lp (48% reduction) protein increased by 
a 20pg ICV LPS injection (fig 3.1). Interestingly, dexamethasone exhibited greater 
anti-inflammatory activity on cytokine protein induced by a 5pg ICV LPS injection. 
Dexamethasone significantly attenuated hippocampal (100%) and cortical IL-la 
(75%) and hippocampal IL-ip (69%), fully abrogated TNF-a protein and there was a 
non-significant trend to a decrease in cortical IL-ip (43%) protein following ICV 
administration of 5pg LPS (fig 3.5). Lower magnitude of cytokine production, 
particularly IL-ip, after ICV administration of 20pg LPS (hippocampus: 11.48; 
cortex: 21.49 pg/mg tissue) relative to 5pg LPS (hippocampus: 46.85; cortex: 33.30 
pg/mg tissue) may be responsible for the decreased central efficacy of 
dexamethasone. Further research may elucidate the exact reasons why 20pg dose of 
LPS elicits a reduced central cytokine protein response relative to 5pg LPS. It is 
possible that a larger inflammatory stimulus initiates an enhanced endogenous 
glucocorticoid response in brain tissue relative to that caused by an ICV injection of 
5pg LPS. Enhanced glucocorticoid levels in the brain may result in the attenuation of 
cytokine protein production. Subsequent studies to assess the anti-inflammatory 
behaviour of the a2-adrenoceptor antagonist, fluparoxan describe the administration 
of 5pg LPS since the anti-inflammatory activity of the strong immunosuppressant 
agent, dexamethasone was most effective at this dose of LPS.
3.5.2.2 a2 adrenoceptor antagonism - Fluparoxan
Antagonism of presynaptic a2-adrenoceptors can modulate the levels of various 
cytokines including TNF-a, IL-6 and IL-10 (Hasko et al, 1995; Szelenyi et al, 2000; 
Song et al, 2001). Assessment of the anti-inflammatory properties of fluparoxan 
(reported in section 2.4.5) revealed that fluparoxan abrogated the levels of IL-ip in 
brain tissue (fig 2.11) associated with attenuated levels of IFN-y and TNF-a in 
plasma and increased plasma IL-10 levels (fig 2.14) following IP injection of LPS. 
Peripheral administration of fluparoxan (3mg/mg) significantly attenuated the ICV 
LPS induced central production of the pro-inflammatory cytokines, TNF-a, IL-la 
and IL-ip (fig 3.7), abrogated plasma IL-6 and TNF-a and also attenuated ICV LPS 
induced plasma IL-10 by 75% (fig 3.9). ICV administered LPS activates endothelial
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microglia (Nicholson & Renton, 2001) known to possess a2-adrenoceptors (Spengler 
et al, 1990). Antagonism of presynaptic a2-adrenoceptors, as discussed in chapter 2, 
results in an increase of synaptic NA. NA is known to modulate key aspects of the 
immune response, controlling the release of pro-inflammatory cytokines via 
subsequent activation of P-adrenoceptors (Szelenyi et al, 2001). In vitro analysis of 
the effects of p-adrenoceptor agonists on LPS-induced cytokine production has 
revealed that agonism of the p2-adrenoceptor elicits an abrogation of pro- 
inflammatory cytokine release (Verhoeckx et al, 2005), possibly by preventing NF- 
k B  translocation (Farmer & Pugin, 2000).
Fluparoxan pre-treatment caused an increase in plasma IL-10 (fig 2.14) in the IP LPS 
model, in contrast to an abrogation of plasma IL-10 (fig 3.9) in the ICV LPS model. 
In support of published literature, this may suggest a differential role for central and 
peripherally derived NA on cytokine release. Song et al, 1999 reported that depletion 
of NA in mouse brain attenuated ICV LPS induced plasma IL-6 in contrast to a 
significant potentiation of ICV LPS-induced plasma IL-6 following depletion of 
peripheral NA. It is possible that central and peripheral NA levels differ between the 
LPS models described in the current studies, resulting in a disparity between the IL- 
10 response to LPS injected via different administration routes. Overall, the data 
presented here and in chapter 2 of this thesis lends support to the role of NA in 
inflammation. Assessment of the anti-inflammatory activity of fluparoxan using both 
the IP and ICV LPS models has provided the first in vivo evidence that peripheral 
pre-treatment with the a2-adrenoceptor antagonist, fluparoxan, can modulate LPS 
induced neuroinflammation.
3.5.2.3 P38 inhibition - GW569293
The p38 inhibitor GW569293 attenuated plasma TNF-a following ICV LPS (20pg) 
(fig 3.4) but increased plasma TNF-a post ICV administration of 5pg LPS (fig 3.10). 
As discussed in section 2.5.3.3 of this thesis, the modulatory effects of p38 inhibition 
on cytokine production has been previously reported as dependent upon the stimuli, 
cell populations and levels of cytokines produced (Rao et al, 2002; Salmon et al, 
2001; Kim et al, 2004). In vitro studies have demonstrated that inhibition of the p38 
kinase can elevate TNF-a (T ten Hove et al, 2002: Kim et al, 2004). Interestingly, 
the current studies demonstrate p38 inhibition can significantly attenuate a large
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increase in LPS-induced plasma TNF-a levels (approx 47,000 pg/ml) but augments 
lower levels of LPS-induced plasma TNF-a (approx 2500 pg/ml). It is possible that 
there are different cell populations involved in the production of plasma TNF-a at 
different doses of LPS but it is more likely that the modulation of cytokine protein 
production following p38 kinase inhibition depends upon the levels of cytokine 
protein produced during activation of the NF-kB pathway. Further research is 
merited to investigate the exact response of plasma TNF-a relative to increasing 
doses of ICV LPS following administration of a p38 inhibitor.
3.5.3 The limitations o f in vivo LPS-induced neuroinflammation models
The use of LPS to elicit robust and reliable markers of neuroinflammation in vivo 
has been clearly demonstrated in chapters 2 and 3 of this thesis. Detection and 
quantification of inflammatory markers in plasma and brain tissue by Luminex® 
following IP LPS injection provides a model that can be used for the high throughput 
screening of putative anti-inflammatory agents. Novel agents that demonstrate clear 
anti-inflammatory properties using this model can be further screened for central 
efficacy using an ICV LPS model of neuroinflammation. It remains important, 
however, to understand the mechanism of action that results in increased cytokine 
protein release and iNOS activity in these models. Using Luminex®, the assessment 
of intracellular protein phosphorylation following IP LPS indicated the early cellular 
response (by 2 hours post LPS) is mediated by direct NF-kB activation. The later 
phase (6 hours post LPS) of LPS-mediated cell signalling appeared to involve p38 
phosphorylation. Any target of interest must have a role in the acute innate immune 
response to LPS to accurately assess anti-inflammatory properties of agents in these 
models as, demonstrated in this thesis, dexamethasone and fluparoxan can 
significantly alter NF-kB mediated cytokine production whereas the p38 inhibitor, 
GW569293 has demonstrated inconsistent changes in plasma TNF-a. Despite the 
caveat that a reduction in peripheral inflammation by an anti-inflammatory agent will 
prevent communication of infection to the brain in the IP LPS model, the IP LPS 
model appears to be predictive of the subsequent effect of agents following ICV 
LPS.
Screening of novel anti-inflammatory agents for specific neurodegenerative diseases 
may additionally or alternatively require assessment in more disease relevant models.
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Preclinical in vivo models specifically designed to assess compounds for AD may 
involve injection of Ap peptide into brain tissue to induce neuroinflammatory and 
neurodegenerative changes (Nabeshima et al, 1995). Subsequent chapters will 
describe studies intended to determine the successful delivery of Ap into the rodent 
brain and the subsequent induction of Ap-induced neuroinflammation and 
neurodegeneration in vivo.
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CHAPTER 4
Injection of A p i-42 into the brain of the adult rat: 
neurodegeneration & neuroinflammation
4.1 Introduction
Previous chapters have discussed the use of LPS to induce neuroinflammation in the 
rat brain. Using Luminex®, the rapid increase in cytokine protein in brain tissue and 
plasma was detected following either ICV or IP LPS injection. Proinflammatory 
cytokines have been detected in post-mortem AD brain tissue (Shaw et al, 2001). 
However, the AD brain is also characterised by activated microglia associated with 
amyloid plaques within degenerating brain regions such as the hippocampus 
(McGeer et al, 1988; Armstrong, 2006). Hence, the development of in vivo models 
with pathology related to AD is important, particularly the use of Ap fragments to 
induce neuroinflammation and neurodegeneration in rodent brain tissue. There are 
conflicting reports of the neuroinflammatory and neurotoxic effects following 
injection of Ap into rodent brain. Injection of Ap into the hippocampus resulted in 
increased neuroinflammation and cell loss in rats (Miguel-Hidalgo et al, 1998; Ryu et 
al, 2004); however, the absence of a convincing neurotoxic effect of Ap in vivo has 
also been described (Games et al, 1992; Cleary et al, 1995). Much of the reported 
inconsistency in Ap-induced neurotoxicity in rodent brain may be explained by 
variability in Ap fragments used, Ap aggregation state, vehicle and the apparatus 
used for Ap delivery. For example, many different types of apparatus have been used 
to administer Ap into the brain including the minipump (Craft et al, 2004), ICV 
tubing and injector (Nakagawa, 2004) or Hamilton syringe (Jantaratnotoi et al, 2003; 
Ryu et al, 2004).
4.1.1 Delivery o f A p  into the rodent brain
Ap can be delivered into the brain via a number of different routes. Direct injection 
into the ventricular system or a discrete brain region such as the hippocampus using a 
Hamilton syringe (A) can include a number of injections within one surgical 
procedure; however, this method usually involves a single administration at each
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injection point. Administration of Ap via an indwelling cannula using Hamilton 
syringe and tubing (B) allows a controlled number of repeated single injections into 
ventricles or discrete brain regions. An implanted minipump (C) provides constant 
delivery of Ap and, currently is the most convenient method for chronic 
administration of Ap into rodent brain.
A
Figure 4.1: Schematic representation of the methods currently available for delivery of Ap 
into rodent brain: direct injection (A), repeated administration (B) and chronic infusion (C)
4.1.2 A p  aggregation process
Extracellular Ap plaques in the AD brain consist of a dense core of insoluble fibrillar 
Ap protein mainly comprising the Api-42 fragment (Rossor, 1993) and Api-42 is 
considered the most neurotoxic Ap fragment in AD brain tissue (Tabaton et al, 
1994). Fibrillar Api-42 consists of parallel p strands that form p pleated sheets 
(Antzutkin et al, 2002). Under polarised light, Api-42 stained with Congo red 
reveals a green birefringence signifying the presence of p pleated sheets. Api-42 
neurotoxicity has been related to both its fibrillar and oligomeric aggregated states 
(Pike et al, 1993; Tamagno et al, 2006). Soluble Api-42 aggregates easily in 
solution; however, the rate of aggregation is dependent on peptide concentration, pH, 
duration of incubation and the length of the carboxyl terminus (Burdick et al, 1992).
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Initially, Ap exists in a monomeric (random coil) form that can rapidly convert into a 
partial p structure called an Ap dimer (Soreghan et al, 1994). As the amount of dimer 
decreases, the concentration of higher molecular weight aggregates increases, evident 
as spherical particles with the characteristics of protein micelles (Soreghan et al, 
1994). These AP oligomers eventually co-aggregate to form strings of micelles 
named protofibrils (Hartley et al, 1999). These intermediaries undergo a 
conformational change resulting in the exposure of an initially protected C-terminus 
to the surrounding solvent and the formation of mature Ap fibrils (Garzon-Rodriguez 
et al, 2000).
4.1.3 Western blot analysis o f A p i  -42 forms
SDS-polyacrylamide gel electrophoresis enables the detection and assessment of the 
size of a single protein within a sample relative to a molecular weight marker. As the 
proteins move through the gel, they are separated by size and charge as small 
proteins migrate through the gel faster than larger molecules. The protein bands 
present on the gel can then be driven into a nitrocellulose membrane by using 
electrophoresis to push negatively charged proteins onto the positively charged 
membrane. Following incubation with primary and reporter-linked secondary 
antibodies, protein bands can be visualised by a variety of methods depending upon 
the type of reporter molecule. Fluorescent detection methods require the fluorescence 
of a probe when excited by light. The emission of the excitation is detected by a 
photosensor e.g. Odyssey Infrared Imaging System (LI-COR Biosciences, USA) 
which takes a digital image of the blot. This technique is a highly sensitive method 
since infra red detection eliminates variability and gives a high signal to noise ratio 
allowing accurate quantification. I will use SDS-polyacrylamide gel electrophoresis 
and the Odyssey Infrared Imaging System (LI-COR Biosciences, USA) to detect Ap 
protein forms expelled from apparatus used to inject Ap into rodent brain tissue.
4.1.4 Chapter A ims
The series of studies described in this chapter sought to:
1. Assess different Apl-42 delivery systems namely the minipump, Hamilton 
syringe or ICV tubing and metal cannulae.
2. Evaluate subsequent neurodegenerative and neuroinflammatory effects of
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exogenous human Api-42 protein into rat brain dissolved in PBS or 
acetonitrile solvent.
3. Establish Api-42 specific neurotoxicity by comparing neuronal cell death 
and neuroinflammation following intra-hippocampal injection of Apl-42 and 
the reverse peptide AP42-1.
4.2 Materials & Methods
4.2.1 Materials
Apl-42 was obtained from California Peptide Research, USA. All gels, gel reagents 
and buffers used for western blot analysis were obtained from Novex/Invitrogen, UK 
and bovine serum albumin (BSA), Acetonitrile, Tween 20 and 1M Tris was 
purchased from Sigma, UK. Sterile saline was purchased from VWR International, 
UK. Sterile 0.1M PBS and 4% paraformaldehyde were prepared at GSK, Harlow, 
UK. Immunostaining machines, antibody diluent, PAP pens, peroxidase blocking 
solution and LSAB 1, LSAB 2 HRP-conjugate and diaminobenzidine substrate kits 
obtained from DakoCytomation, UK. Optimax buffer was obtained from A.
Menarini, UK. Gills haematoxylin stain was purchased from HD Supplies, UK. The
sources of additional materials are individually stated.
4.2.2 A p i  -42 preparation
Unless otherwise stated, Api-42 was prepared as described by Ryu et al, 2004. Ryu 
et al, 2004 reported significant cell loss in rat brain tissue following intra- 
hippocampal injection of Apl-42.
lmg Api-42 was reconstituted into 443.4pl of vehicle solution to provide 500pM 
solution. The solution was thoroughly vortexed for approximately ten minutes and 
then allowed to incubate at 37°C for 18 hours. Following incubation, the solution 
was aliquoted into sterile biopur® safe-lock eppendorfs (VWR International, UK) and 
stored at -20°C until immediately before use.
4.2.3 Gel analysis o f amyloid samples
Based on an established protocol for the detection of the Ap peptide using western 
blotting (GSK, UK):
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Api-42 solution was drawn up into a Hamilton syringe and expelled into eppendorfs 
containing PBS to produce 0.2pg/pl solution. 5pi was added to 5pi NuPage sample 
reducing agent 10X, 12.5pl NuPage LDS sample buffer 4X and 27.5pl PBS resulting 
in a 0.02pg/pl solution. lOpl sample was loaded onto a gel (NuPage 12% Bis-Tris 
gel -  1mm thick x 12well) secured in a Novex Mini gel system and transfer 
apparatus. 500pl NuPage Antioxidant was added to 200ml IX SDS running buffer 
(50ml 20X NuPage MES running buffer and 950ml deionised water) and used to fill 
the upper buffer chamber. The lower buffer chamber was filled with 600ml IX SDS 
running buffer. The gel was run at 120V for approximately 2 hours until the 
coomassie dye front had almost reached the bottom of the gel. The cassette was 
rinsed under running water and the gel removed. The gel, a nitrocellulose membrane 
and blotting pads were soaked in 700ml of IX NuPage transfer buffer (50ml 20X 
NuPage transfer buffer, 100ml methanol, 850ml deionised water, 1ml NuPage 
antioxidant) and assembled in a Novex module. The module was locked into the 
lower buffer chamber and filled with transfer buffer. Following transfer at 30V for
1.5 hours, the membrane was shaken gently for 1 hour at room temperature or 
overnight at 4°C with blocking solution (3% BSA (4.5mg) in 150ml IX western 
wash buffer (lOx western wash buffer = 20ml 100% Tween 20, 400ml 5M NaCl and 
200ml 1M TRIS pH 7.5 and diluted to 2 litres with deionised water). 6E10 anti Ap 
antibody at 1:1000 (Senetek via Signet Labs Inc, USA) was added to the membrane 
and left for 1 hour at room temperature prior to a wash with IX wash buffer for a 
duration of 30 minutes, changing the buffer every 5 minutes. The membrane was 
wrapped in foil and incubated at room temperature with Goat anti-mouse IgG affinity 
purified IR dye 800 at 1:6000 (Rockland Immunochemicals Inc., USA). After 1 hour, 
the membrane was kept in the dark and washed with IX wash buffer for a duration of 
30 minutes, changing the buffer every 5 minutes and subsequently analysed using an 
Odyssey Infrared Imaging System (LI-COR Biosciences, USA).
4.2.4 Intra-hippocampal (IH) direct injection surgery
Specific, pathogen free male CD rats (250g) (Charles River, UK) were anaesthetised 
by inhalation of 3% isoflurane in oxygen (Merial animal Health Ltd, Essex, UK). 
Rats were shaved around the crown of the head and the skin sterilised using a 
hibitane/alcohol solution. Lacrilube (Allergan, Buckinghamshire, UK) was applied to
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the eyes to prevent them from drying out during surgery. Animals were secured in a 
stereotaxic frame (David Kopf Instruments, USA) and a midline incision along the 
sagittal suture made in the skin overlying the skull. 0.1ml intra-epicaine (Arnolds, 
Surrey, UK) was injected into the subdermal skin layers to provide post-operative 
local analgesia. A burr hole was drilled in the skull at co-ordinates relative to 
bregma: anterior-posterior: -3.6; medio-lateral: -1.8 and a 26 gauge lOpl Hamilton 
syringe (Hamilton, Birmingham, UK) stereotaxically lowered to a dorso-ventral co­
ordinate o f -3.8. Vehicle or Apl-42 was injected at a speed of 0.2pl min'1 to a final 
volume of 2 pi (lnmol) according to the protocol of Ryu et al, 2004. Following 
injection, the needle was withdrawn and the burr hole sealed with bone wax. The 
skin incision was sutured using vicryl Rapide 4/0 (Johnson & Johnson, USA) and the 
animal was placed back in the home cage with warm bedding and soft mash/baby 
food. The body weights and general health of the rats were monitored daily until 
pre-operative body weight had been reached. Rats were housed under controlled 
conditions at 21-24°C and on a 12-hour light/dark cycle (7am lights on) and fed a 
pellet diet and water ad libitum in an animal facility at GlaxoSmithKline 
Pharmaceuticals, Harlow, Essex, UK. All experimental procedures were conducted 
in accordance with the GlaxoSmithKline local ethics committee and conformed to 
the UK Animals (Scientific Procedures) Act 1986.
4.2.5 Sample collection
At 7 days post intra-hippocampal injection, rats were deeply anaesthetised with 
sodium pentobarbitone (Euthatal® lOOmg kg-1 i.p, Rhone Merieux, Harlow, UK) 
prior to transcardial perfusion with 120ml ice-cold 0.9% sterile saline followed by 
120ml of ice-cold 4% paraformaldehyde. The descending artery was clamped 
throughout this procedure to improve upper-body perfusion. Whole brain was 
removed and stored in 4% paraformaldehyde in a 20ml glass vial for 5 days.
4.2.6 Imm unohistochemistry
A 3mm coronal block was cut from each brain to incorporate the injection site at 
approximately -2.0 through -5.0 relative to bregma and processed into paraffin wax 
using a Shandon Citadel 1000 tissue processor. Each block was embedded in paraffin 
wax using a Shandon Histocentre II embedding centre. Serial sections of 5pM
135
thickness were taken throughout the injection site using a Microm HM 355S rotary 
microtome and dried at room temperature for at least 24 hours before staining. 4 
sections per stain were examined excluding NeuN staining for which between 4 and 
8 sections that spanned the injection site were analysed. Sections were stained for 
general cell morphology (Haematoxylin & Eosin (H&E)), Ap (1E8), neurons (NeuN) 
and macrophage/microglia (EDI) immunohistochemistry. Sections were dewaxed in 
Histoclear (National Diagnostics, UK) and hydrated through 100% industrial 
methylated spirit (IMS), 70% IMS and deionised water. All sections were washed in 
deionised water and a hydrophobic barrier applied above and below the section using 
a PAP pen to prevent the antibody solutions from running off the slide. Slides were 
loaded into an autostainer and treated with a primary antibody as described in section 
4.2.7.1. Sections were then treated with LSAB 1 biotinylated link for 10 minutes, 
LSAB 2 HRP-conjugate for 10 minutes and diaminobenzidine substrate kit for 10 
minutes. Optimax buffer was applied to each section and between each step and 
deionised water applied after the diaminobenzidine step. After staining, sections 
were washed in running tap water for 5 minutes before counter staining in Gills 
haematoxylin for 3 seconds and placed in running tap water to "blue", dehydrated in 
graded followed by absolute IMS, cleared in Histoclear and mounted in DPX (VWR, 
UK). Sections were viewed using a Colourview digital camera attached to an 
Olympus BX41 microscope. Photomicrographs were captured and analysed using 
image analysis software (AnalySIS, Soft Imaging Systems). Sections stained for EDI 
positive cells were viewed using a Leica DC 100 camera attached to a Leitz DMRB 
microscope. Photomicrographs were captured and analysed using Leica Qwin 
software (Leica systems. Buckinghamshire, UK).
4.2.6.1 Primary antibody staining
Amyloid (1E8) staining
Sections received DAKO peroxidase block for 5 minutes followed by primary mouse 
monoclonal antibody 1E8 (raised against 13-27 fragment of beta amyloid) (GSK, 
UK), diluted 1/1000 with antibody diluent, for 30 minutes.
NeuN staining
Sections were incubated for 30 minutes with NeuN antibody (Chemicon 
International, UK) diluted to 1/1000 with antibody diluent.
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Macrophage/Microglia (EDI) staining
Sections were immersed in citrate antigen retrieval buffer (HD Supplies, 
Buckinghamshire, UK) and microwaved (Sanyo supershower wave (Sanyo, UK)) at 
900W (2.5 minutes), 300W (5 minutes) and 300W (5 minutes) for each rack and 
allowed to cool for 20 minutes. Sections were washed 3 times in dH20 for 5 minutes 
and loaded onto an autostainer. The slides were treated with DAKO peroxidase block 
for 5 mins followed by mouse anti-rat CD68 (EDI) Ab (Serotec, UK) at a dilution of 
1/1000 for 30 minutes.
4.2.6.2 Quantification o f immunohistochemical staining
Photomicrographs of sections under an x4 objective were captured and used to 
calculate Ap deposit volume (4 sections), percentage number of EDI positive stained 
cells, number of NeuN positive stained cells within a 700pmetre distance either side 
of the central point of mediolateral damage and the width of hippocampal CA1 or 
dentate gyrus neuronal cell layer missing throughout the injection site. The protocol 
used for quantification of NeuN positive cells in the hippocampus was adapted from 
Ryu et al, (2004) and the protocol for measurement of medio-lateral lesion size was 
taken from Miguel-Hidalgo et al, (1998). The percentage of EDI positive stained 
cells was quantified (4 sections) within a 225cm2 (1.06xl06 pixels) box placed so 
that the central point of mediolateral damage was in the centre of the box.
4.2.6.3 Detection o f fibrillar A fi
Sections were viewed under a x40 objective using a Leica DC500 camera attached to 
a Leica DMR microscope (Leica systems. Buckinghamshire, UK). Photomicrographs 
were captured under differential interference contrast and a polarised light source 
using Leica Qwin software (Leica systems, Buckinghamshire, UK).
4.2.7 Data Analysis
Univariate tests of significance using Statistica™ Version 6.1 (StatSoft, USA) 
calculated the effect of Ap treatment and solvent on the number of NeuN positive 
cells, extent of medio-lateral hippocampal damage and percentage EDI stained area. 
Planned comparisons on the predicted means from the model assessed individual 
Api-42 and AP42-1 effects on these measurements. Results are represented as
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means ± SEM and significance was set at P < 0.05.
4.3 Protocols
4.3.1 Study 9: Western blot analysis o f the expulsion of the Apl-42 fragment
from apparatus
Prior to the commencement of in vivo studies, Study 9 examined the Api-42 forms 
that were expelled from apparatus commonly used for injecting Ap into rodent brain 
tissue. This study also sought to identify the apparatus that could consistently expel 
Api-42 protein and therefore be used most successfully for in vivo studies.
4.3.1.1 Lowest concentration o f aggregated A p i-42 used in vivo
In order to establish if the Api-42 fragment, particularly in its aggregated form, 
could be expelled from apparatus commonly used for administering substances 
directly into rodent brain, I initially assessed the lowest Api-42 concentration 
previously reported as successfully administered into brain tissue (Hare et al, 1999). 
Apl-42 was aggregated by continually stirring a lOOpM solution (0.45ug/ul) of 
soluble Api-42 in PBS at 23°C for 40 hours. Following incubation, the Api-42 
solution was turbid and approximately 80% of the peptide was sedimented by 
centrifugation leaving approximately 20% as supernatant. The supernatant and pellet 
were frozen at -20°C until use. Supernatant and pellet were drawn up either 
polypropylene tubing attached to a metal injector or a lOpl Hamilton syringe.
4.3.1.2 Oligomeric A p i -42 using minipump
Previously, the infusion of oligomeric Api-42 via minipump has resulted in Ap 
deposition and neuroinflammation in rodent brain (Frautschy et al, 2001, Frautschy 
et al, 1996). As an alternative to the injection of aggregated Api-42 via ICV tubing 
or Hamilton syringe, I investigated the expulsion of oligomeric forms of Apl-42 
from a minipump using a protocol described by Frautschy et al, 2001. 
lmg Api-42 in 221.7pi hexa-fluoro-iso-propanol (HFIP) was left to dissolve for 1 
hour at room temperature. The HFIP was allowed to evaporate from 45 pg Ap aliquot 
transferred to sterile eppendorfs. Eppendorfs were transferred to a speedvac and
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centrifuged for 10 minutes at 30°C, sealed with parafilm and stored at -20°C. Each 
45 pg aliquot was reconstituted in lpl DMSO and 100pi 4mM HEPEs buffer and 
sonicated for 3 minutes followed by incubation at 4°C for 24 hours. lOOpl of a 
500pg/ml high density lipoprotein (HDL) solution was added to the Ap solution 
before the minipump and associated tubing was filled and incubated in a 37°C water 
bath for 14 days.
4.3.1.3 Concentrations o f A (31-42 used in vivo to induce neurotoxicity 
Api-42 peptide (lnmol/2pl) was dissolved in 4.43pl 35% acetonitrile and 438.57pl 
sterile 0.1M PBS to produce a 500pM solution (2.25pg/pl (1 nmol)) and left to 
incubate overnight as described in section 4.2.2. Ap solution (5pi) was loaded into a 
lOpl Hamilton syringe or a pipette (control sample) and expelled into PBS to 
produce a 0.2pg/pl solution. Api-42 was also prepared by dissolving lmg Apl-42 in 
148 pi deionised water (3 nmol/2 pi) following the protocol described by Miguel- 
Hidalgo et al, 1998. The solution was stored for 3 hours at room temperature, 4°C 
overnight and room temperature for three hours. Aliquots were incubated at 4°C 
further 21-hour incubation before loading into a lOpl Hamilton syringe or pipette.
As a comparison, Api-42 (dissolved in 443pi sterile 0.1M PBS) was incubated at 
37°C for four days allowing formation of higher molecular weight aggregates and 
oligomeric forms of Ap.
4.3.2 Study 10: A/31-42 in 0.35% acetonitrile/O.lMPBS
A variety of solvents has been used to dissolve Ap including acetonitrile and PBS 
(Winkler et al, 1994; Ryu et al, 2004). Acetonitrile is toxic in its own right and its 
use in vivo must be appropriately validated.
Api-42 peptide was dissolved in 4.43pi 35% acetonitrile and 438.57pl sterile 0.1M 
PBS and left to incubate overnight as described in section 4.2.2. Male CD rats (250g, 
approx 10 weeks of age, n=8 per group) were unilaterally injected with 1 nmol/2 pi 
Apl-42 or sterile PBS alone.
4.3.3 Study 11: Afil-42 in 0.035% acetonitrile/0.1MPBS or 0.1MPBS alone
Api-42 peptide was dissolved in 443pi 0.035% acetonitrile/0.1M PBS solution
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(44.3pl 35% acetonitrile and 44.3ml sterile 0.1M PBS) and left to incubate overnight 
as described in section 4.2.2. Male CD rats (250g, approx 10 weeks of age, n=12 per 
group) were administered bilaterally with 1 nmol/2 pi Apl-42 in 0.035% acetonitrile 
and 1 nmol/2 pi Apl-42 in sterile PBS. The hemisphere injected with acetonitrile 
vehicle was randomised between animals and between surgeons so that n=6 animals 
received Api-42 in 0.035% acetonitrile in the left hemisphere and n=6 animals 
received Api-42 in 0.035% acetonitrile in the right hemisphere. The remaining 
hemisphere was injected with lnmol/2pl Api-42 in sterile PBS.
4.3.4 Study 12: A/31-42 vs. A/342-1 in 0.1MPBS alone
The reverse peptide Ap42-1 was used as a non-fibrillar Ap protein control as 
described by Ryu et al, 2004. Api-42 and AP42-1 peptides were dissolved in sterile 
0.1M PBS solution and left to incubate overnight as described in section 4.2.2. Male 
CD rats (n=12 per group) were unilaterally injected with 1 nmol/2 pi Apl-42 or 
lnmol/2pl AP42-1 or sterile PBS alone.
4.4 Results
4.4.1 Study 9: Western blot comparison o f A p i -42 preparations for direct
hippocampal injection
4.4.1.1 A p i  -42 expulsion: polypropylene tubing and Hamilton syringe 
Western blot analysis of the Ap forms expelled from a lOpl Hamilton syringe or 
plastic tubing attached to a metal injector revealed that Apl-42 is expelled from a 
Hamilton syringe as aggregates (52kDa and above) and as oligomeric (llkDa) and 
monomeric (3kDa) forms (fig 4.2). In contrast, use of polypropylene tubing and 
injector only allowed the expulsion of monomeric and oligomeric forms under both 
pellet and supernatant conditions. The amount of these forms expelled from plastic 
tubing was also greatly reduced relative to that expelled by the Hamilton syringe.
4.4.1.2 Oligomeric A p i  -42 using minipump
Western blot analysis revealed dense bands of oligomeric Ap (>llkDa) in the 
oligomeric control relative to a monomeric control indicating the preparation
140
protocol successfully produced oligomeric Ap (fig 4.3). In the absence of the cannula 
injector positioned on the end of the tubing, diffuse bands of monomeric and 
oligomeric Ap were evident, however, in the presence of the cannula injector, no 
bands of Ap were apparent. Removing a sample of Ap solution from the incubating 
minipump at 14 days indicated a large presence of oligomeric forms although much 
of the Ap solution had also aggregated (>52kDa).
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Figure 4.2: Western blots demonstrating the expulsion of Api-42 forms from Hamilton 
syringe (A) and polypropylene tubing (B).
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Figure 4.3: Western blot demonstrating the expulsion of Api-42 forms from minipump.
4.4.1.3 Concentrations o f Apl-42 used in vivo to induce neurotoxicity
Western blot analysis of Apl-42 prepared following protocols by Miguel-Hidalgo et 
al, 1998 and Ryu et al, 2004 and expelled through a lOpl Hamilton syringe revealed 
the expulsion of monomeric and, to a lesser degree, oligomeric and higher molecular 
weight forms of Api-42 (fig 4.4). The monomeric and oligomeric forms were 
evident as bands between 3 and 19 kDa. Bands of higher molecular weight Api-42 
forms were evident as bands at 185kDa and within the wells of the gel. Forms of 
Apl-42 expelled from a lOpl Hamilton syringe were not different from control 
samples obtained via pipette, suggesting the Hamilton syringe did not limit the 
expulsion of Ap forms into brain tissue. Monomeric forms of a preaggregated Api- 
42 solution were expelled from a lOpl Hamilton syringe, however, oligomeric and 
higher molecular weight aggregates were less evident with diffuse bands of 
aggregated Ap evident in the wells of the gel.
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Figure 4.4: Western blots demonstrating the expulsion o f Api-42 forms from lOjul Hamilton 
syringe using protocols described in the literature (A) or standard preaggregated Api-42 (B).
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4.4.2 Study 10: IH  Apl-42 (lnmol) in 0.35% acetonitrile/0.1MPBS
4.4.2.1 Presence o f amyloid
Staining for the position of the amyloid deposit using 1E8 antibody indicated the 
peptide either remained localised within the dentate gyrus (fig 4.5B), the tract of the 
needle or diffused sideways from the end of the tract through the corpus callosum 
(fig 4.5A).
Figure 4.5: Representative photomicrographs of coronal sections of the CA1 (A) and dentate 
gyms (B) stained for amyloid (1E8) in Apl-42 intra-hippocampal injected rats (n=8 per 
treatment group). Scale bar represents 200pmetres
4.4.2.2 Neurodegeneration
The location of the injection site varied within the hippocampus between the CA1 
and the dentate gyrus (DG) layers. 5/8 vehicle and 5/8 Api-42 injected rats had an 
injection site located within the dentate gyrus (fig 4.6 C & D) whilst remaining rats 
in each treatment group had an injection site located above the CA1 (fig 4.6 A & B). 
Vehicle or Apl-42 solution injected above the CA1 appeared to diffuse down the 
fibres of the corpus callosum. Staining for neuronal cell nuclei using NeuN stain 
indicated a clear demarcation between the injection site and the surrounding tissue 
(fig 4.6). Cell loss was present in all treatment groups and was evident either as a 
complete loss of neurons or the presence of shrunken cells. Cell loss in the dentate 
gyrus (DG) occurred adjacent to the amyloid deposit whilst localisation of the 
deposit along the corpus callosum significantly affected the CA1 granule layer. 
There was no significant effect of Api-42 relative to vehicle treatment on numbers
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of NeuN positive cells within 700pmetres of the lesion centre (fig 4.7) or on the 
extent of mediolateral damage (fig 4.8), regardless of injection site location. 
Differentiating between sub regions of the hippocampus revealed no significant 
effect of Apl-42 treatment relative to vehicle control on NeuN count in dentate gyrus 
(DG) or CA1 of the hippocampus (DG: vehicle -  380.83 ± 90.11 cells, Apl-42 -  367 
± 141.38 cells; CA1: vehicle -  141.13 ± 23.77 cells, Apl-42 -  114.57 ± 26.71 cells. 
Similarly, there was no treatment effect on the extent of mediolateral damage in DG 
or CA1 (DG: vehicle -  1170.26 ± 183.70 cells, Apl-42 -  956.05 ± 372.23 cells; 
CA1: vehicle- 100 ± 0.00 cells, Api-42 -  173.50 ± 89.41 cells).
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Figure 4.6: Representative photomicrographs of coronal sections of the hippocampus stained 
with NeuN in vehicle (A, C) and Api-42 (B, D) intra-hippocampal injected rats (n=8 per 
treatment group). Scale bar represents 200pmetres
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Figure 4.7: Quantification of NeuN positive cells in hippocampus of vehicle and Api-42 
intra-hippocampal injected rats (n=8 per treatment group), data represented as the count of 
NeuN positive stained cells and shows mean ± SEM (planned comparisons following
ANOVA)
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Figure 4.8: Measurement of mediolateral lesion in vehicle and Api-42 intra-hippocampal 
injected rats (n=8 per treatment group), data represented as the mediolateral lesion size in 
pM and shows mean ± SEM (univariate ANOVA followed by planned comparisons)
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4.4.2.3 Neuroinflammation
Staining for activated macrophage (and microglia) at the injection site was localised 
around the vehicle and Api-42 deposit and, to a much lesser extent, within the 
injection tract (fig 4.9). The inflammatory cells surrounding the deposit were a mix 
of large amoeboid macrophage cells and activated microglia.
Macrophage
Microglia
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Figure 4.9: Representative photomicrographs of coronal sections of the hippocampus stained 
for EDI positive macrophage and microglia in vehicle (A, C) and A(31-42 (B, D) intra- 
hippocampal injected rats (n=8 per treatment group). Scale bar represents lOOpmetres
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4.4.3 Study 11: IH Apl-42 (lnmol) in 0.035% acetonitrile/O.lMPBS or 0.1M 
PBS alone
4.4.3.1 Presence o f A f
Apl-42 deposits were located within the corpus callosum across the top of the CA1 
granular layer, through the dentate gyrus or within the needle tract (fig 4.10). There 
was no significant difference in deposit volume within the tissue between PBS and 
acetonitrile based vehicles (fig 4.11). This suggests the maximum amount of Ap was 
expelled from the syringe needle or that acetonitrile, at this concentration, does not 
aid amyloid expulsion.
Ap deposit at
Ap deposit at CA1
Figure 4.10: Representative photomicrographs of coronal sections of the hippocampus 
stained for Ap in 0.1 M PBS alone (A, B) or 0.035% acetonitrile (C, D) in bilateral intra- 
hippocampally injected rats (n=12 per vehicle or AP treatment group). Scale bar represents
200pmetres
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Figure 4.11: Measurement of the average amyloid deposit in the hippocampus of Apl-42 
bilateral intra-hippocampally injected rats (n=12 per vehicle or Ap treatment group), data 
represented as the volume of Ap deposit (pM2) and shows mean ± SEM (univariate ANOVA
followed by planned comparisons)
4.4.3.2 Neurodegeneration
There remained variation in the dorso-ventral location of the injection site as 
reported previously in study 9; however, there were a greater number of animals in 
both vehicle and Apl-42 treatment groups that had a deposit located above the CA1 
granular layer (fig 4.12). The clear demarcation between healthy surrounding CA1 or 
dentate gyrus neurons and the neuronal loss within the injection site allowed 
quantification of healthy cells remaining within 700pm either side of the centre of 
the injection site and the lateromedial measurement of cell loss.
Repeated measures ANOVA revealed there was no overall effect of treatment, F q, 30) 
=2.47, p=0.13, a significant effect of solvent, F (i; 30) =4.41, p<0.05 and a non­
significant trend for an overall interaction between treatment and solvent, F (1, 30) 
=3.05, p=0.09. Post hoc comparisons revealed a significant reduction in NeuN 
positive cells within the injection site, demonstrated as a 25% loss in cells with Api- 
42 treatment in PBS only (p<0.05). Acetonitrile at 0.035%, masked Api-42 induced 
cell loss since a similar number of NeuN positive cells remained following 
acetonitrile, Api-42 in acetonitrile or Apl-42 in PBS (fig 4.13). Acetonitrile vehicle 
resulted in significantly fewer remaining NeuN positive cells than PBS vehicle 
(p=0 .0 1 ) demonstrating a toxic effect of acetonitrile in vivo.
Acetonitrile
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There was no overall treatment effect on the extent of mediolateral damage, F (i, 32) 
=0.57, p=0.46. There was a non-significant trend for an overall interaction between 
treatment and solvent, F (1, 32) =3.27, p=0.08. Post hoc planned comparisons revealed 
that Apl-42 in PBS caused an increase in the extent of mediolateral damage 
demonstrated as a 69% increase above PBS treatment alone (p < 0.05). Utilisation of 
an acetonitrile vehicle masked this effect as evident by the increase in lesion size 
with acetonitrile alone relative to PBS treatment (p<0.05) (fig 4.14).
Figure 4.12: Representative photomicrographs of coronal sections of the hippocampus 
stained for NeuN in vehicle - PBS (A), vehicle - acetonitrile/PBS (B), Apl-42 - PBS (C) 
and Api-42 - acetonitrile/PBS (D) in bilateral intra-hippocampally injected rats (n=12 per 
vehicle or Ap treatment group). Scale bars represent 200pmetres
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Figure 4.13: Quantification of NeuN positive cells in vehicle and Apl-42 bilateral intra- 
hippocampally injected rats (n=12 per vehicle or Ap treatment group), data represented as 
the count of NeuN positive stained cells and shows mean ± SEM. * p <0.05 significantly 
different vs. PBS vehicle (repeated measures ANOVA followed by planned comparisons)
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Figure 4.14: Measurement of mediolateral lesion in vehicle and Api-42 intra-hippocampal 
injected rats (n=12 per vehicle or Ap treatment group), data represented as the mediolateral 
lesion size (pM) and shows mean ± SEM. * p <0.05 significantly different vs. PBS vehicle 
(repeated measures ANOVA followed by planned comparisons)
4.4.3.3 Neuroinflammation
There was an overall treatment effect, F (3, 33) = 12.73, p<0.001 on EDI positive cells 
present within the injection site (fig 4.15). Post hoc planned comparisons revealed 
Api-42 induced a significant 8 8 % (p=0.01) increase when dissolved in PBS alone 
and a significant 64% (p<0.05) increase in EDI positive cells when using a vehicle
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containing 0.035% acetonitrile (fig 4.16).
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Figure 4.15: Representative photomicrographs of EDI staining in hippocampus of vehicle - 
PBS (A) vehicle - acetonitrile/PBS (B), A01-42 - PBS (C) & Ap 1-42 - acetonitrile/PBS (D) 
bilateral intra-hippocampally injected rats (n=12 per vehicle or amyloid treatment group),
scale bar represents lOOpmetres
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Figure 4.16: Quantification of the percentage stained area of EDI positive cells in vehicle 
and Api-42 intra-hippocampal injected rats, data represented as percentage stained area and 
shows mean ± SEM. * p <0.05, ** p <0.01 significantly different vs. respective vehicle 
(repeated measures ANOVA followed by planned comparisons)
4.4.4 Study 12: IHAfil-42 (lnmol) vs. A/342-1 (lnmol) in 0.1MPBS alone
4.4.4.1 Presence o f amyloid
As demonstrated in previous studies, Api-42 deposition was evident within the CA1 
and dentate gyrus regions of the hippocampus. 6/12 animals per treatment group had 
a deposit within the CA1 (fig 4.17). Further investigation revealed that, under 
polarised light, the Congo red stained deposit did not demonstrate the apple-green 
birefringence typical of fibrillar Ap. As a positive control, Congo red stained cortical 
Ap plaques of a heterozygous double mutant APP/PS1 transgenic TASTPM mouse 
(TASTPM developed in GSK, Harlow, UK) revealed apple-green birefringence 
(fig.4.18).
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Ap deposit surrounded 
by immune cells
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Figure 4.17: Representative photomicrographs of coronal sections of the CA1 (A) and 
dentate gyrus (B) stained for amyloid (1E8) in Apl-42 intra-hippocampal injected rats (n=12 
per treatment group). Scale bar represents 200pmetres
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Figure 4.18: Representative photomicrographs of coronal sections of the cortex of a 
TASTPM mouse (A) and the Apl-42 deposit in intra-hippocampal injected rats(n=12 per 
treatment group) (B) under polarised light (x40 magnification)
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4.4.4.2 Neurodegeneration
There was no overall effect of treatment, F (2, 22) = 0.84, p = 0.44, on hippocampal 
cell loss (fig 4.19). The greater variability within the AJ31-42 treatment group, in 
contrast to study 11, meant a loss in statistical significance evident as a non­
significant decrease in NeuN positive cells relative to vehicle (26% loss, p = 0.35) 
and Ap42-1 (29% cell loss, p = 0.84) (fig 4.20). There was a significant overall effect 
of treatment on the extent of mediolateral damage present, F (2, 26) = 4.06, p<0.05. 
Post hoc planned comparisons revealed a non-significant increase in lesion size of 
Apl-42 treated rats relative to vehicle (42% increase, p=0.09) and a significant 
increase relative to AP42-1 (69% increase, p<0.01) (fig 4.21).
DG dama;
DG damage
Figure 4.19: Representative photomicrographs of coronal sections of the hippocampus 
stained for NeuN following intra-hippocampal (n=12) vehicle (A) Ap42-1 (B) and Apl-42
(C), Scale bars represent 200pmetres
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Figure 4.20: Quantification of NeuN positive cells in vehicle and Api-42 intra-hippocampal 
injected rats (n=12), data represented a count of the NeuN positive stained cells and shows as 
mean ± SEM (univariate ANOVA followed by planned comparisons)
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Figure 4.21: Measurement of mediolateral lesion in vehicle and Api-42 intra-hippocampal 
injected rats, data represented as mediolateral lesion size (pM) and shows mean ± SEM. * p 
<0.05 significantly different vs. AP42-1 (univariate ANOVA followed by planned
comparisons)
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4.4.4.3 Neuroinflammation
There was an overall effect of treatment, F 25) = 9.84, p<0.001 on presence of EDI 
positive cells (fig 4.22). Api-42 induced a 100% increase in EDI positive cells 
within the region of interest (p=0.01) relative to vehicle treatment and a 138% 
increase relative to the reverse peptide AP42-1 (p<0.001) (fig 4.23).
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Figure 4.22: Representative photomicrographs of coronal sections of the hippocampus 
stained for EDI positive macrophage and microglia in vehicle (A), AP42-1 (B) and Api-42 
(C) intra-hippocampal injected rats (n=12). Scale bar represents lOOpmetres
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Figure 4.23: Quantification of the percentage stained area of EDI positive cells in vehicle 
and Apl-42 intra-hippocampal injected rats (n=12 per treatment group), data represented as 
percentage stained area and shows mean ± SEM. ** p <0.01, *** p <0.001 significantly 
different vs. Apl-42 (univariate ANOVA followed by planned comparisons)
4.5 Discussion
4.5.1 Delivery o f A p i -42 forms in to roden t brain
Using western blot analysis, the expulsion of Ap from apparatus commonly used to 
deliver Ap into rodent brain was assessed. A lOOpM Ap solution prepared following 
a protocol by O’Hare et al, 1999 and previously described to be successfully injected 
into rat brain was expelled through a Hamilton syringe or plastic tubing attached to a 
metal injector. Diffuse bands indicated little aggregated Api-42, shown to be present 
in pellet and supernatant control samples was released from plastic tubing (fig 4.2). 
The amount of oligomeric and monomeric Ap forms expelled was also decreased. 
This was in contrast to the Ap forms delivered by using a lOpl Hamilton syringe, in 
which monomeric, oligomeric and aggregated forms were successfully expelled 
under both pellet and supernatant conditions (fig 4.2). This confirms that, at lOOpM 
concentration, Ap 1 -42 can be successfully delivered into rodent brain via Hamilton 
syringe, in agreement with data described by O’Hare et al, 1999. This may explain 
why many authors choose to inject Ap into discrete brain regions or the ventricular 
system by using a Hamilton syringe (Song et al, 2001; Ryu et al, 2004; Jantaratnotai
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et al, 2003). Alternatively, the Ap deposition and neuroinflammation in rats and 
mice following ICV minipump infusion of an oligomeric Apl-42/HDL solution has 
also been reported (Harris-white et al, 2004; Craft et al, 2004; Frautschy et al, 2001). 
HDL is thought to aid the delivery of Ap and reduce aggregation (Craft et al, 2004). 
Western blot analysis of Api-42 solution prepared following the protocol by 
Frautschy et al, 2001 and expelled from tubing attached to a minipump revealed no 
Ap form was delivered when assessed after 14 days incubation (fig 4.3). Due to the 
housing of the minipump, tubing and collecting eppendorf at 37°C for 14 days, it is 
possible that Ap could not be detected due to evaporation of the expelled solution, 
hence the possibility that Ap was expelled cannot be discounted and Frautschy et al, 
2001 does describe limited deposition of Ap in brain tissue with this protocol. 
Additional assessment of the remaining Api-42 solution within the minipump after 
14 days incubation revealed the presence of Ap aggregates (fig 4.3). The likelihood 
that Ap contained within a minipump may aggregate easily and limit the deposition 
of AP within the brain tissue highlights the difficulty of using this method for 
delivering significant Ap into the tissue to induce quantifiable neurodegeneration. 
Using this Ap minipump protocol, overt cell death has not yet been described by the 
Frautschy group, although a reduction of synaptophysin, a synaptic-associated 
protein, indicates compromised synaptic density (Craft et al, 2004).
Much published literature describes the direct injection of Ap into rodent brain 
(O’Hare et al, 1999; Weldon et al, 1998; Ryu et al, 2004; 2006; Jantaratnotai et al, 
2003; Miguel-Hidalgo et al, 1998; 2002; Song et al, 2001). Further assessment using 
Apl-42 solutions prepared following protocols by Miguel-Hidalgo et al, 1998 or Ryu 
et al, 2004 and described as neurotoxic in vivo, revealed mainly monomeric and 
some oligomeric Apl-42 were present in control samples and expelled from a 10pl 
Hamilton syringe (fig 4.4). This suggests that, on injection, Ap is delivered into brain 
tissue as soluble Ap forms. Frautschy et al, 1996 suggested that Ap toxicity in brain 
tissue is dependent on Ap remaining in its soluble state, however, Api-42 aggregates 
easily and may aggregate once injected into rodent brain.
4.5.2 Presence o f A p in  brain tissue following intra-hippocampal injection
Following the protocol by Ryu et al, intra-hippocampal injection of Api-42 resulted
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in a deposit located within the CA1, corpus callosum or dentate gyrus of the 
hippocampus (fig 4.5). It is likely that much of the variability observed within these 
studies is due to the inherent variability in injection procedure as, in agreement with 
previous literature, consistent direct injection to one specific sub-region is difficult 
(Miguel-Hidalgo et al, 1998). As in the studies described in this chapter, Miguel- 
Hidalgo et al, 1998 also described that, under polarised light, Api-42 deposits 
stained with Congo red did not demonstrate apple-green birefringence (fig 4.18). 
This indicates that Ap neurotoxicity evident in this model is caused by soluble Ap 
forms rather than fibrillar Ap. Recently, the possibility that soluble Ap causes 
neurotoxicity in brain tissue has been extensively discussed, particularly the role of 
oligomers in Ap neurotoxicity (Chromy et al, 2003; Walsh & Selkoe, 2004; Lacor et 
al, 2004).
4.5.3 A fi- induced neurodegeneration
The purpose of the in vivo studies described in this chapter was to investigate the 
influence of the solvents acetonitrile diluted in PBS and PBS alone on Ap-induced 
neurotoxicity in rat brain. Following this, the neurotoxic effect of Api-42 was 
compared to the reverse peptide, AP42-1. Despite earlier conflicting reports 
regarding the neurotoxic effects of Ap in vivo (Smyth et al, 1994; Winkler et al, 
1994; Games et al, 1992), recent literature has described the neurotoxic effects of the 
Api-42 fragment when directly injected into the hippocampus. Quantification of 
neurodegeneration following protocols previously described by Ryu et al, 2004 and 
Miguel-Hidalgo et al, 1998 revealed a trend for increased neurodegeneration in rats 
treated with Api-42 relative to vehicle and AP42-1 when all treatments were 
dissolved in PBS alone. This was evident as approximately a 25% NeuN positive cell 
loss (fig 4.13) and a 69% increase in the extent of mediolateral damage (fig 4.14). 
The 25% cell loss evident in studies described within this chapter supports 
previously published literature (Ryu et al, 2004); however, this window of cell loss 
was relative to vehicle injected rats. Ryu et al, 2004 described a 28% reduction in 
NeuN count relative to sham rats following intra-hippocampal Api-42 injection into 
the hippocampus although the Api-42 was dissolved in the solvent acetonitrile. 
Synthetic Ap has been dissolved in a number of commonly used solvents including 
dimethylsulfoxide (DMSO) (Mattson et al, 1993), acetonitrile (Yankner et al, 1994,
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Jantaratnotoi et al, 2003; Ryu et al, 2004), water (O’Hare et al, 1999) and saline or 
PBS (Bishop et al, 2003) and the inherent toxicity should be taken into consideration 
when injecting directly into rodent brain tissue. In vitro studies revealed that Ap 
neurotoxicity was influenced by the solvent employed and the peptide aggregation 
state (Pike et al, 1993; Busciglio et al, 1992). Further evidence suggests the solvent 
may alter Ap aggregation state. For example, Mattson et al, 1992 reported the 
potentiation of excitotoxicity by Ap which had been dissolved in DMSO as a stock 
solution and then further diluted in saline. This resulted in predominantly monomeric 
forms of Ap and a lOOx greater toxicity than Ap dissolved in saline, which resulted 
in Ap dimer formation. A comparison of the neurotoxicity resulting from the 
injection of Ap dissolved in various solvents revealed that acetonitrile can cause a 
large degree of toxicity, which is significantly enhanced by either Api-42 or Api-40 
(Waite et al, 1992). There are conflicting reports relating to the influence of 
acetonitrile solvent on Ap-induced neurotoxicity in rodent brain (Ryu et al, 2004, 
Waite et al, 1992, Podlisny et al, 1992). Acetonitrile can be converted to cyanide by 
cytochrome P450 (Freeman & Hayes, 1988). Cyanide toxicity elicits changes in 
calcium homeostasis mediating the influx of calcium into the cell resulting in cell 
death (Waite et al, 1992). Using acetonitrile at either 0.35% (fig 4.7 & 4.8) or 
0.035% (fig 4.13 & 4.14) concentration, failed to result in a window of cell death 
between vehicle and Apl-42 treatment groups which supports a study described by 
Podlisny et al, 1992 in which injections of Api-40 dissolved in 35% acetonitrile into 
primate cerebral cortex did not significantly increase cell loss relative to acetonitrile 
alone. In contrast, Ryu et al, 2004 reported 28% cell loss following the intra- 
hippocampal injection of Api-42 dissolved in an acetonitrile/PBS based solvent 
although it is unclear what final percentage of acetonitrile remained following 
dilution of Apl-42 with 0.1M PBS to a 500pM concentration. The comparison of the 
Api-42 group with sham animals may also suggest that the neurotoxicity was wholly 
or partly due to the effect of acetonitrile since comparing studies described here 
indicated no difference in the magnitude of cell loss between Ap in acetonitrile and 
acetonitrile (vehicle) treated rats.
4.5.4 A p i  -42 - induced neuroinflammation
Previous reports suggest the full length Ap peptide is required to induce
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neuroinflammation, since Api-42 elicits greater inflammation both in vivo (Miguel- 
Hidalgo et al, 1998) and in vitro (Velazquez et al, 1997) than shorter Ap fragments. 
Neuroinflammation has long been considered as a potential mechanism for mediating 
or exacerbating Ap neurotoxicity in AD and recent studies have described the 
induction of an early inflammatory response to oligomeric amyloid in contrast to a 
less profound but chronic inflammatory state elicited by fibrillar Ap (White et al, 
2005). Intra-hippocampal injection of Api-42 increased neuroinflammation, evident 
as the increased presence of microglia and macrophage cells surrounding the Ap 
deposit relative to both acetonitrile and PBS vehicle treatment (fig 4.16). 
Neurodegeneration of hippocampal cells occurred adjacent to the deposit suggesting 
a combination of contact with Ap and the phagocytic activity and release of toxic 
molecules such as cytokines and NO by associated phagocytic cells mediates cell 
death in this model (Minagar et al, 2002). This theory is supported by in vitro 
evidence that in mixed neuron-glia cultures, following incubation with low 
concentrations (l-3pM) of Ap, significant neurotoxicity was evident in contrast to 
neuron-enriched cultures (without microglia) in which no neurotoxicity was observed 
(Qin et al, 2002).
Although Ap is a key characteristic of AD brain tissue, the role of Ap load and 
particularly the relative contribution of different Ap forms in causing or exacerbating 
cell death remain uncertain. Both fibrillar and oligomeric Ap forms have been shown 
to cause neurotoxicity (Howlett et al, 1995; Chromy et al, 2003). The accumulation 
of intraneuronal Api-42 may also significantly contribute to causing overt 
neurodegeneration, particularly on the scale evident in AD (Fernandez-Vizarra et al, 
2004; Masters et al, 1985). In AD brain tissue, microglia can congregate around core 
plaques as they develop and may convert the extracellular soluble Ap released from 
intraneuronal stores to fibrillar Ap plaques (Nagele et al, 2004). Further research 
would clarify whether the soluble Apl-42 deposit present by 7 days after intra- 
hippocampal injection may fibrillise if the study duration was extended. This may 
also have further implications on the neuroinflammation and neurodegeneration 
evident by later timepoints since it is unclear which Ap form is most neurotoxic in 
vivo. Intraneuronal soluble Ap has also been identified as an early neurodegenerative 
change in AD (Fernandez-Vizarra et al, 2004). Intraneuronal soluble Ap may 
significantly contribute to cell death (Wirths et al, 2004) hence the exogenous Ap
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induced neurodegeneration evident in this model is limited since it is unlikely to 
affect intracellular AP levels.
Overall, my thesis thus far has reported the development and validation of IP and 
ICV LPS induced neuroinflammation in rat brain. Assessment of the more AD 
relevant peptide, Apl-42, revealed successful delivery of Api-42 concentrations 
reported to be neurotoxic via injection by Hamilton syringe into rodent brain tissue. 
Intra-hippocampal injection of Api-42 resulted in a significant increase in cell- 
mediated inflammation associated with quantifiable but variable endpoints of 
neurodegeneration observed at 7 days post injection. Thus, the exogenous application 
of Api-42 into rat brain does not provide a robust and reliable in vivo model of AP- 
induced neurodegeneration. An alternative to the exogenous injection of Ap into 
rodent brain is to use APP or APP/PS1 overexpressing transgenic mouse models. 
Transgenic mouse lines overexpressing mutant human APP and PS1 genes, identified 
as genetic mutations important in familial AD, exhibit age-dependent increases in 
extracellular senile and diffuse Ap deposits within specific brain regions including 
the cerebral cortex and hippocampus. Ap deposits are associated with activated 
microglia, reactive astrocytes and increased cytokine expression within brain tissue. 
Despite the presence of Ap deposition, a majority of transgenic models 
overexpressing APP (and PS1) do not exhibit overt neurodegeneration, however, the 
peripheral administration of inflammatory or neurotoxic challenges such as LPS or 
DSP4 to APP and APP/PS1 overexpressing mice has been previously reported to 
modulate Ap load, exacerbate neuroinflammation and induce neurodegeneration 
(Sheng et al, 2003; Bragg et al, 1995; Heneka et al, 2006). Hence, subsequent 
chapters will evaluate the effects of inflammatory or neurotoxic challenges on 
inflammation and neurodegeneration in an APP/PS1 overexpressing transgenic 
mouse model, TASTPM.
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CHAPTER 5 
Single and repeated administration of LPS to TASTPM 
APP/PS1 overexpressing mice
5.1 Introduction
APP and APP/PS1 overexpressing transgenic mouse models have been routinely 
used to characterise the effects of amyloid neuropathology on neuroinflammation 
and neurodegeneration (Price et al, 2000). APP and APP/PS1 overexpressing mice 
demonstrate Ap induced neuroinflammation evident as activated microglia and 
reactive astrocytes associated with increased mRNA expression of pro- and anti­
inflammatory cytokines in brain tissue (Apelt et al, 2001; Abbas et al; 2002; Benzing 
et al, 1999). However, a majority of transgenic models do not exhibit the overt 
neurodegeneration evident in brain tissue of AD patients (Games et al, 2006). More 
recently, newly constructed APP/PS1 transgenic lines have been reported to exhibit 
some level of neurodegeneration in brain ranging from approximately 15 -  50% cell 
loss (Schmitz et al, 2004; Casas et al, 2004; Bondolfi et al, 2002); however, this is 
low relative to the neurodegeneration evident in specific brain regions, particularly 
the entorhinal cortex, of AD brain (Gomez-Isla et al, 1996). Recent evidence derived 
from in vivo animal models (Cunningham et al, 2005; Combrinck et al, 2002; Perry 
et al, 2003) and patient studies (Holmes et al, 2003) suggests systemic infection may 
exacerbate the progression of chronic neurodegenerative diseases such as AD by 
enhancing the production of inflammatory mediators and recruitment of immune 
cells in compromised brain tissue. There is further evidence that peripheral 
administration of LPS can modulate Ap load and neuroinflammation in APP or 
APP/PS1 overexpressing mice (Sheng et al, 2003; Sly et al, 2001; Qiao et al, 2001). 
Much of the current literature describes the quantification of cytokine mRNA (Abbas 
et al, 2002; Lim et al, 2000) in APP overexpressing mice and there is data indicating 
modulation of cytokine protein in brain tissue following IP LPS administration (Sly 
et al, 2001). Exacerbating the pathology of APP/PS1 transgenic models using 
peripheral administration of inflammatory stimuli such as LPS or specific neurotoxic 
agents may therefore provide a suitable model of neuroinflammation and
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neurodegeneration.
5.1.1 Peripheral infection in AD
Severe systemic infections in elderly patients can induce the development of 
delirium, a state of cognitive impairment comprising a loss of memory, 
hallucinations and confusion (Perry et al, 2004). At their time of death, many AD 
patients are suffering from infections of peripheral organs such as the lungs or 
bladder. Holmes et al, 2003 reported that for at least two months following the 
resolution of a systemic infection, patients suffering mild-to-moderate AD exhibited 
greater cognitive decline relative to uninfected patients. A subset of infected patients 
also displayed enhanced ILlp at initial mini-mental state examination (MMSE) 
assessment and subsequent MMSE tests revealed an exacerbated cognitive decline 
relative to other infected AD patients. The induction of a peripheral infection in a 
preclinical model demonstrating amyloid deposition in brain tissue, such as APP/PS1 
overexpressing mice, may enhance pre-existing neuroinflammation. I was also 
interested in examining the consequence of peripheral infection on the occurrence of 
neurodegeneration.
5.1.2 LPS administration to APP (&PS1) overexpressing mice
There are a limited number of reports detailing the effect of LPS administration to 
APP or APP/PS1 overexpressing mice. Differences in route of administration, 
treatment protocols, animal genotype, LPS serotype and sampling timepoint have 
resulted in variability in the in vivo effects of LPS on APP or APP/PS1 
overexpressing mice. Intra-hippocampal LPS, administered after plaque onset, 
resulted in increased number and size of reactive astrocytes and activated microglia 
in Tg2576 transgenic mice with (DiCarlo et al, 2001) and without (Herber et al, 
2004) the presence of a PS 1 transgene. In both reports, there was a corresponding 
decrease in Ap load that was due to a reduction in diffuse amyloid plaques, since 
congophilic deposits remained unaffected (Herber et al, 2004). Additionally, the IP 
administration of LPS (single bolus of 25mg/kg at 13 and 14 months) post plaque 
onset in Tg2576 mice caused a reduction in Ap load (Quinn et al, 2003). Acute 
peripheral administration of LPS also induced cortical and hippocampal ILip in aged 
Tg2576 mice (Sly et al, 2001). This supports evidence that an acute inflammatory
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response in the brain can occur after a peripheral inflammatory challenge and that 
this is exacerbated in animals exhibiting amyloid neuropathology. In contrast, 
chronic administration of LPS either via repeated ICV or IP injection results in an 
increase in Ap load, evident as an increase in Ap and APP positive neurons, Api-40 
and Apl-42 protein, intracellular Ap accumulation (Sheng et al, 2003) or thioflavin- 
S-positive amyloid deposits (Qiao et al, 2001). Interestingly, these authors 
administered LPS before the onset of robust fibrillar amyloid deposition. This 
suggests that pre-existing neuroinflammation caused by chronic administration of an 
inflammatory challenge can exacerbate Ap neuropathology. LPS treatment after 
extensive amyloid deposition may induce clearance of plaques since IP 
administration of LPS after the onset of plaque deposition the brains of Tg2576 mice 
caused a reduction in amyloid plaque burden (Quinn et al, 2003).
5.1.3 The TASTPMAPP/PS1 overexpressing transgenic mouse model
Heterozygous double mutant mice (TASTPM) previously generated by Dr. Jill 
Richardson at GSK, Harlow, UK were used in these studies. TAS10 mice 
(Richardson et al, 2003) carrying the Swedish double familial mutation hAPP695swe 
(K670N; M671L) and backcrossed onto a pure C57BL/6 background and mice 
carrying the PS-1 (Ml46V) mutation were generated at GlaxoSmithKline. Human 
cDNA for APP695 (K670N; M671L) or PS-1 (Ml46V) was inserted into a vector 
and replaced the coding sequence of the murine Thy-1 gene to allow brain-specific 
expression of either transgene as described by Howlett et al, 2004.
TASTPM mice demonstrate age-dependant amyloid neuropathology and cognitive 
impairments (extensively characterised at GSK, Harlow and initially described by 
Howlett et al, 2004). Using immunohistochemical techniques, amyloid deposits were 
observed in the brain tissue of all TASTPM mice by four months of age. Fibrillar Ap 
plaques, when observed under an electron microscope, were not evident until six 
months of age. Female mice displayed more extensive cerebral plaque pathology by 
six and ten months of age relative to male mice. Cortical extracellular Ap plaques 
were surrounded by dystrophic neurites and in close proximity to astrocytes and 
microglia, however, overt neuronal loss was not evident.
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5.1.4 Chapter A ims
This chapter will describe the effects of peripheral administration of LPS to the 
APP/PS1 overexpressing mouse, TASTPM. Using Luminex®, the effects of a
peripheral inflammatory challenge on cytokine expression in brain tissue and plasma
will be investigated. The effect of LPS on amyloid neuropathology, 
neuroinflammation and neurodegeneration will be characterised using 
immunohistochemical techniques.
5.2 Materials & Methods
5.2.1 Animals
Specific, pathogen free male heterozygous double mutant TASTPM and male 
C57BL6/J mice at 2, 5 and 10 months of age (for assessing effects of acute LPS 
administration) and at 4 months of age (for assessing effects of repeated 
administration of LPS) were purchased from Charles River, UK. All mice were 
singly housed under controlled conditions (temperature: 21-24°C, 12-h light/dark 
cycle (7am lights on) and provided with Global Rodent Maintained Diet (Harlan 
Teklad) and water ad libitum. Sheng et al, 2003 described evidence of adverse effects 
1-2 hours following LPS administration, which included shivering. Hence, during 
repeated LPS injection animals were provided with extra bedding. All experimental 
procedures were conducted in accordance with the GlaxoSmithKline local ethics 
committee and conformed to the UK Animals (Scientific Procedures) Act 1986.
5.2.2 Materials
Phosphate buffered saline (PBS) was prepared using PBS tablets obtained from 
Sigma, UK. Lipopolysaccharide (0111 :B4, L2630) was purchased from Sigma, UK. 
Immunostaining machines, PAP pens, the antigen retrieval solution proteinase K, 
peroxidase blocking solution and diaminobenzidine substrate kit were obtained from 
DakoCytomation, UK. Optimax buffer was obtained from A. Menarini, UK. Gills 
haematoxylin stain and citrate buffer was purchased from HD Supplies, UK. The 
sources of additional materials are individually stated.
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5.2.3 Treatment
LPS was allowed to dissolve in filtered PBS in a falcon tube (VWR International, 
UK) for at least 30 minutes before administration.
For single dosing, LPS was dissolved at 600pg/5ml and administered at 5ml/kg. 
This dose was based on previous validation studies assessing a dose response and a 
timecourse of LPS induced cytokine protein in brain and plasma in C57BL6/J mice 
(GSK, Harlow, UK). For repeated dosing, 5mg LPS was dissolved in 100ml of 
filtered PBS and was administered at lOpl/g body weight (0.5pg/g body weight) 
according to a protocol by Sheng et al, 2003. Repeated administration of LPS at
0.5pg/g increased Ap load and neuroinflammation in APPswe transgenic mice 
(Sheng et al, 2003).
5.2.4 Sample collection
Mice were deeply anaesthetised with sodium pentobarbitone (Euthatal® lOOmg kg-1
1.p, Rhone Merieux, Harlow, UK). Trunk blood was collected into a 1.3ml EDTA 
micro-tube (VWR International, UK) via a cut in the right atrium. Mice were 
transcardially perfused with 15ml ice-cooled 0.9% sterile saline. Hemidissected brain 
and microdissected brain regions were stored in preweighed and labelled eppendorfs 
at -80°C. The blood was spun in a microcentrifuge at 6000g for 6 minutes (according 
to a previous protocol, GSK, Harlow) and the straw-coloured plasma fraction 
collected into fresh eppendorfs and stored at -80°C.
5.2.5 Cytokine protein determination
5.2.5.1 Sample preparation
Brain tissues were diluted to the appropriate concentration (5ul/mg tissue) with high 
performance ELISA (HPE) buffer (Sanquin Reagents, Amsterdam) and homogenised 
using a hand-held Ultra-Turrax T8 homogeniser (VWR International, UK). All 
samples were spun in a microcentrifuge (Centrifuge 5415 D, Eppendorf UK Ltd, 
Cambridge, UK) at 16,1 lOg for 2 minutes. The supernatant was removed and stored 
in a fresh eppendorf at -80°C. Brain supernatant and plasma were subsequently 
allowed to defrost and 50pl aliquots of each sample placed into a corresponding well 
on a standard 96-well plate (Nunc, UK) according to a predetermined plate layout.
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All samples were diluted with lOOpl assay buffer (1% BSA in PBS).
®5.2.5.2 Luminex suspension bead array -  cytokine analysis
lOOpl of sample was transferred to a pre-wet (lOOpl of assay buffer added to each 
well and then vacuum filtered) 96-well filter plate (Millipore®, USA). A 5000pg 
standard (Upstate, Hampshire, UK) was reconstituted in 500pi of assay buffer, added 
to a 14600pg standard for M IP-la (Biosource, UK), and serially diluted 1:3 using 
assay buffer to provide an 8 point standard curve (0 to 5000 pg/ml). Samples were 
incubated in the dark overnight at 4°C with 50pl of anti-cytokine conjugated beads 
(60pl of 25x stock solution for each cytokine diluted to lx in total of 5940pl assay 
buffer per plate) multiplexed from individual kits for each cytokine (R & D Systems, 
UK, (MIP-la (Biosource, UK)). Plates were washed three times with 200pl of assay 
buffer, filtered using a vacuum manifold apparatus (Millipore®, USA) and incubated 
with lOOpl of detection antibody (R & D Systems, UK, (MIP-la (Biosource, UK)) 
(60pl stock solution of each cytokine diluted to lx dilution in a total of 11940pi 
assay buffer per plate) in the dark at room temperature for 1 hour. Following three 
washes (200pl assay buffer), each sample was incubated with lOOpl streptavidin 
phycoerythrin - PE (VWR International, UK) (12pl stock solution diluted with 
11,988pl assay buffer) and placed in the dark on a plate shaker at 700rpm for 30 
minutes at room temperature. Plates were analysed by the Luminex®-100™ system 
(Luminex® Corporation, USA) to achieve MFI readings for standard curves and 
cytokines in brain homogenate and plasma. Double discriminator gates were 
positioned from approximately 8,000 to 15,000 to separate singlet and doublet beads. 
Intensity was identified at bead regions 50, 06, 32, 79, 26 for IL-10, IL-ip, IL-6, 
TNF-a and M IP-la respectively. 4/5-parameter logistic regression curves (Hulse et 
al, 2004) of the cytokine standards were calculated using StarStation software and 
the concentrations of unknown samples were determined relative to calculated 
standard curves.
5.2.6 Afi ELISA
Hemidissected brain samples were prepared by adding 1ml 5M guanidine HC1 
(Calbiochem, USA) containing Complete TM protease inhibitor tablet (Roche
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Diagnostics, UK) resulting in approximately 150mg/ml w/v. Each sample was 
homogenised using a Torax/hand held pellet pestle (Sigma, UK) and mixed on a 
shaker for 90 minutes at 4°C. IGEN buffer (50mM Tris HC1, pH7.4, 150mM NaCl, 
0.05% Tween-20+ 1% BSA) was added to each sample at a 1/10,000 dilution and an 
aliquot of the resulting solution removed. The aliquot was vortexed and centrifuged 
at 20000g for 20 mins at 4°C. The supernatant was removed and transferred to a 2ml 
deep polypropylene 96 well block and lOOpl of each sample pipetted in triplicate 
into polypropylene 96 well plates (VWR international, UK). Standard curves for 
human A£40 (0 to 40ng/ml) and A042 (0 to 20 mg/ml) dissolved in guanidine 
containing IGEN buffer were constructed, in triplicate. An antibody/bead mix of 
15ml per plate was prepared using lOpl of 0.66pg/ml biotinylated 6E10 (Signet 
Labs, USA), 4pl ori-tag G210 (A04O) or 8pi 5G5 (AP42) (IGEN® International, 
USA), 125pi streptavidin dynabeads® (Invitrogen Ltd, UK) and 15ml assay buffer 
(50mM Tris HC1, pH7.4, 150mM NaCl, 0.05% Tween-20)+ 1% BSA. 150pl of the 
mix was added to each well and the plate vigorously mixed overnight at room 
temperature. The following day, the plate was read on an IGEN M8 analyser 
(IGEN® International, USA). The Ap ELISA was kindly completed by Peter Soden, 
GSK, Harlow, UK.
5.2.7 Immunohistochemistry
Hemi-dissected brains were immersed fixed in 4% paraformaldehyde for 3 days at 
room temperature and prepared for paraffin wax processing using a Shandon Citadel 
1000 tissue processor and embedded in paraffin wax using a Shandon Histocentre II 
embedding centre. A Microm HM 355S rotary microtome was used to cut at least 40 
semi-serial sections of 5pM thickness were prepared from each sample to include the 
cortex and hippocampus (bregma -1 to -4mm). Slides were dried at room 
temperature for at least 24 hours before staining. 6 sections per stain were assigned 
for amyloid (1E8), neuronal cell nuclei (NeuN), astrocytes (GFAP) and microglia 
(CD68) immunohistochemistry. Sections were dewaxed in Histoclear (National 
Diagnostics, UK) and hydrated through industrial methylated spirit (IMS), 70% IMS 
and deionised water. Sections were washed in deionised water and a hydrophobic 
barrier applied above and below the section using a PAP pen to prevent the antibody 
solution falling off the slide. Slides were loaded into an autostainer and Optimax
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buffer applied. Buffer was added between each step and deionised water applied after 
the diaminobenzidine step. After staining, sections were washed in running tap water 
for 5 minutes before counter staining in Gills haematoxylin for 3 seconds. Sections 
were placed in running tap water to "blue", dehydrated in graded followed by 
absolute IMS, cleared in Histoclear and mounted in DPX (VWR, UK).
5.2.7.1 Amyloid (IE8) Staining
Sections were treated with 85% formic acid (VWR) for 8 minutes then washed 
thoroughly in deionised water and loaded into the automated immunostaining 
machine. Sections received peroxidase block for 5 minutes, primary mouse
monoclonal antibody 1E8 (raised against 13-27 fragment of beta amyloid) (GSK, 
UK) diluted 1 in 1000 in antibody diluent for 30 minutes, prediluted labelled
streptavidin biotin system (LSAB) 1 for 10 minutes, prediluted LSAB 2 for 10
minutes and diaminobenzidine substrate kit for 10 minutes.
5.2.7.2 NeuN
Sections were microwaved in 1 % citrate buffer (pH 6.0) at 900 W for 3Vi minute, 
then twice at 300 W for 5 minutes and left to cool at room temperature for 20 
minutes. Sections received peroxidase block for 5 minutes, primary mouse
monoclonal antibody NeuN (1/1000, antibody diluent) (Chemicon International, UK) 
for 30 minutes, prediluted labelled streptavidin biotin system (LSAB) 1 for 10 
minutes, prediluted LSAB 2 for 10 minutes and diaminobenzidine substrate kit for 10 
minutes.
5.2.7.3 GFAP Staining
Sections were treated with proteinase K for 5 minutes followed by peroxidase block 
for 5 minutes and primary antibody rabbit anti bovine GFAP (1/500, optimax buffer) 
(DakoCytomation, UK) for 30 minutes. Biotinylated goat anti rabbit (1/200, optimax 
buffer) (Vector Laboratories, UK) was added for 30 minutes followed by peroxidase 
ABC kit (Vector Laboratories, UK) for 45 minutes and diaminobenzidine substrate 
kit for 10 minutes.
5.2.7.4 Macrophage (CD68) Staining
Sections were treated with proteinase K for 5 minutes followed by peroxidase block
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for 5 minutes, rat anti mouse CD68 (1/50, antibody diluent) (Serotec, UK) for 30 
minutes, biotinylated anti rat IgG (1/100, optimax buffer) (Serotec, UK) for 30 
minutes followed by peroxidase ABC kit (Vector Laboratories, UK) for 45 minutes 
and diaminobenzidine substrate kit for 10 minutes.
5.2.7.5 Quantification ofA/3 plaque deposition, neuronal cell loss and GFAP
The effect of repeated LPS challenge on immunohistochemical endpoints was 
quantified by using a Leica microscope and Qwin software (Leica systems, 
Buckinghamshire, UK) to calculate percentage area stained for 1E8 positive Ap 
plaques, NeuN positive cells and GFAP positive astrocytes in cortex and 
hippocampus of all mice. CD68 positive macrophage/microglia were not quantified, 
as the staining was too diffuse to accurately obtain contrast against background.
5.2.8 Data Analysis
A general linear mixed model approach using the Proc Mixed procedure in SAS® 
Version 8 (SAS® Institute, UK) assessed the overall effects and interactions of 
treatment genotype and age on cytokine responses in brain tissue within subjects. 
Separate univariate tests of significance using Statistica™ Version 6.1 (StatSoft, 
USA) calculated the overall effect of LPS treatment on plasma cytokine responses, 
Ap load and Ap, NeuN and GFAP immunohistochemical quantification. Planned 
comparisons on the predicted means from the model assessed individual treatment, 
genotype and age effects on acute LPS challenge in TASTPM mice and individual 
treatment and genotype effects on immunohistochemical endpoints. Results are 
represented as means ± SEM and significance was set at P < 0.05. Percentage 
induction refers to the effect of LPS versus vehicle.
5.3 Protocols
5.3.1 Study 13: Acute administration o f LPS in TASTPM mice
Male TASTPM and age-matched C57BL6/J controls were IPly administered with 
filtered PBS or 600jag/kg LPS (5ml/kg) dissolved in filtered PBS at either 2, 5 or 10 
months of age (n=6-9) and euthanased at 2.5 hours post dose as described in section 
5.2.4. These ages were chosen in order to span the progression of Ap
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neuropathology.
5.3.2 Study 14: Inflammation and neurodegeneration following repeated LPS 
administration in TASTPM mice
Male TASTPM mice aged 4 months (prior to onset of fibrillar Ap plaque deposition 
in brain tissue) and age matched C57BL6/J controls (n=10-12) were IPly 
administered with filtered PBS or lOpl/g body weight with 5mg/100ml LPS solution 
weekly for 12 weeks. I chose to begin the administration of LPS to TASTPM mice at 
4 months of age, based on published reports that highlight the possibility that 
initiating a peripheral inflammatory response prior to onset of fibrillar Ap plaque 
deposition could increase neuroinflammation and Ap load (Qiao et al, 2001; Sheng et 
al, 2003). 48 hours following the last IP dose, brain tissue was hemisected for half 
brain for immunohistochemical analysis and the remaining half brain was either 
stored for Ap ELISA, or cortex and hippocampus microdissected for Luminex 
cytokine analysis. Blood was removed via tail tip amputation at 2.5 hours post the 
final IP dose and at 48 hours post the final IP dose as described in section 5.2.4.
S.4 Results
5.4.1 Study 13: Acute LPS administration o f TASTPM mice
5.4.1.1 Cytokine protein in brain
Repeated measures ANOVA indicated an overall effect of treatment, F (i, 72) = 
309.67, p<0.001, age, F (2, 72) = 7.18, p<0.01 and treatment*age, F (2, 72) = 11.47, 
p<0.001 and age*brain region, F (2> 71) = 5.73, p<0.01, interactions on central IL- 6  (fig 
5.1). Cortical and hippocampal IL- 6  was significantly increased in all LPS treated 
groups relative to vehicle controls. Additionally, by 5 months of age, there was a 
significant increase in hippocampal IL- 6  from 0.51 ± 0.175 pg/mg tissue in LPS 
treated C57BL6/J mice to 2.69 ± 0.77 pg/mg tissue in LPS treated TASTPM mice 
(431% increase, p<0.001). Cortical IL- 6  levels also increased in LPS treated 
TASTPM relative to C57BL6/J mice at 5 months of age from 1.1 ± 0.263 pg/mg 
tissue to 1.73 ± 0.41 pg/mg tissue, however this was non-significant (58% increase, p 
= 0.188).
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Repeated measures ANOVA indicated an overall effect of age, F (2, 74) = 74.4, 
p<0.001, and brain region, F (it 74) = 9.94, p<0.01 on central IL-lp (fig 5.2). Post hoc 
planned comparisons revealed a significant age-dependent reduction in central IL-ip 
in C57BL6/J and TASTPM mice (2 vs. 5 & 10 months, p<0.001; 5 vs. 10 months, 
p<0 .0 1 , both genotypes) and a significant difference between cortical and 
hippocampal IL-ip response (p<0.01).
Repeated measures ANOVA indicated an overall effect of age, F (2, 74) -  47.63, 
p<0.001, brain region, F (i, 74) = 12.88, p<0.001 on central TNF-a (fig 5.3). Post hoc 
planned comparisons revealed a significant age-dependent reduction in central TNF- 
a  in C57BL6/J and TASTPM mice (2 vs. 5 & 10 months, p<0.001, both genotypes; 5 
vs. 10 months, p=0.01, C57BL6/J mice) and a significant difference between cortical 
and hippocampal TNF-a response (p<0.001).
Repeated measures ANOVA indicated an overall effect of age, F (2) 69) = 15.07, 
p<0.001, genotype, F (1,69) = 30.26, p<0.001, and an age*genotype interaction, F (2,69) 
= 10.46, p<0.001, on central M IP-la (fig 5.4). There was also a significant effect of 
brain region, F (i; 65) = 16.55, p<0.001, and significant age*brain region, F (2, 55) = 
9.09, p<0.001, and genotype*brain region interactions, F (1,55) = 5.5, p<0.05. Post hoc 
planned comparisons revealed significant age-dependent changes in central MDP-la 
in C57BL6/J (2 vs. 5 months, p<0.001; 2 vs. 10 months, p<0.01; 5 vs. 10 months, 
p<0.05) and TASTPM mice (2 vs. 10 months, p<0.01; 5 vs. 10 months, p<0.001). 
There was also a significant overall difference between cortical and hippocampal 
M IP-la response irrespective of group (p<0.001). By 10 months of age, cortical 
(p<0.01) and hippocampal (p<0.001) M IP-la was significantly increased in vehicle 
treated TASTPM relative to vehicle treated C57BL6/J mice. Cortical and 
hippocampal M IP-la was increased by 5 months (cortical: p<0.01, hippocampal: 
p<0.001) and 10 months (p<0.001, both brain regions) in LPS treated TASTPM 
relative to LPS treated C57BL6/J mice.
Repeated measures ANOVA indicated an overall effect of age, F (2j 74) = 62.38, 
p<0.001, brain region, F (i, 74) = 28.93, p<0.001, and an age*brain region interaction, 
F (2, 74) = 17.62, pcO.OOl on IL-10 (fig 5.5). Post hoc planned comparisons revealed a 
significant age-related increase in central IL-10 in C57BL6/J and TASTPM mice (2 
vs. 5 & 10 months, p<0.001; 5 vs. 10 months, p<0.01, both genotypes) and a 
significant difference between cortical and hippocampal IL-10 response (p<0.001).
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Figure 5.1: IL6 protein in the cortex (A), hippocampus (B) of a C57BL6/J control or 
TASTPM transgenic mouse (n=6-9 per group) by 2.5 hours post a single IP LPS 
administration, data represented as cytokine protein (pg) per milligram of tissue and shows 
mean ± SEM (*** p <0.001 vs. respective vehicle group, +++ p <0.001, ++ p <0.01 vs. 2 
month within treatment, + p <0.05 vs. 5 month within group) (repeated measures ANOVA
followed by planned comparisons)
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Figure 5.2 IL lp  protein in the cortex (A), hippocampus (B) of a C57BL6/J control or 
TASTPM transgenic mouse (n=6-9 per group) by 2.5 hours post a single IP LPS 
administration, data represented as cytokine protein (pg) per milligram of tissue and shows 
mean ± SEM. +++ p <0.00 vs. 5 & 10 month within group, + p <0.05 vs. 5 month within 
group (repeated measures ANOVA followed by planned comparisons)
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Figure 5.3: TNFa protein in the cortex (A), hippocampus (B) of a C57BL6/J control or 
TASTPM transgenic mouse (n=6-9 per group) by 2.5 hours post a single IP LPS 
administration, data represented as cytokine protein (pg) per milligram of tissue and shows 
mean ± SEM. +++ p <0.001, ++ p <0.01, + p <0.05 vs. 2 month within group (repeated 
measures ANOVA followed by planned comparisons)
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Figure 5.4: MIP1 a  protein in the cortex (A), hippocampus (B) of a C57BL6/J control or 
TASTPM transgenic mouse (n=6-9 per group) by 2.5 hours post a single IP LPS 
administration, data represented as cytokine protein (pg) per milligram of tissue and shows 
mean ± SEM. *** p <0.001, ** p <0.01 vs. respective vehicle group, +++ p <0.001 vs. 5 
months within group, ++ p <0.01, + p <0.05 vs. 2 month within group, ^  p <0.01 vs. 5 
month within group, ### p <0.001, ## p <0.01 vs. respective C57BL6/J within age group 
(repeated measures ANOVA followed by planned comparisons)
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Figure 5.5: IL10 protein in the cortex (A), hippocampus (B) of a C57BL6/J control or 
TASTPM transgenic mouse (n=6-9 per group) by 2.5 hours post a single IP LPS 
administration, data represented as cytokine protein (pg) per milligram of tissue and shows 
mean ± SEM. +++ p <0.001, ++ p <0.01 vs. 5 & 10 month within group, AAA p <0.001, ** p 
<0.01, A p <0.05 vs. 5 month within group (repeated measures ANOVA followed by planned
comparisons)
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5.4.1.2 Cytokine protein in plasma
Univariate ANOVA demonstrated an overall effect of treatment on plasma IL-ip (fig 
5.6), F (i? 72) = 65.56, p<0.001, IL- 6  (fig 5.7A), F (i, 72) = 303.35, p<0.001, TNF-a (fig 
5.7B), F (i, 72) = 125.11, p<0.001, M IP-la (fig 5.8A), F (i, 73) = 178.05, p<0.001, and 
IL-10 (fig 5.8B), F (i, 74) = 76.71, p<0.001. There were also significant 
treatment*genotype, F (i, 72) = 9.19, p<0.01 and treatment*age*genotype, F (2, 73) = 
3.13, p<0.05, interactions on IL-lp and M IP-la respectively and an effect of age on 
IL-10, F (2, 74) = 5.78, p<0.01. Plasma IL-6 , IL-ip, TNF-a, M IP-la and IL-10 protein 
was induced by LPS in C57BL6/J and TASTPM mice, although by 5 and 10 months 
of age, the increase in plasma IL-ip in LPS treated TASTPM relative to vehicle 
treated TASTPM mice failed to reach significance at the p<0.05 level (p = 0.09 and p 
= 0.06 respectively). LPS treated TASTPM mice also exhibited a significantly 
stunted IL-ip response relative to LPS treated C57BL6/J controls by 2 months of age 
from 30.49 ± 2.49 pg/ml to 18.06 ± 3.76 pg/ml (40% reduction, p<0.01). Although 
plasma IL-ip was also decreased in LPS treated TASTPM relative to LPS treated 
C57BL6/J mice by 5 and 10 months of age, this failed to reach significance at the 
p<0.05 level (5 months: p = 0.17; 10 months: p = 0.07).
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Figure 5.6: ELip protein in plasma of a C57BL6/J control or TASTPM transgenic mouse 
(n=6-9 per group) by 2.5 hours post a single IP LPS administration, data represented as 
cytokine protein (pg) per millilitre of sample and shows mean ± SEM. ## p <0.01 vs. 2 
month C57BL6/J LPS, *** p <0.001, ** p <0.01 vs. respective vehicle group (univariate 
ANOVA followed by planned comparisons)
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Figure 5.7: IL6 (A) and TNFa (B) protein in plasma of a C57BL6/J control or TASTPM 
transgenic mouse (n=6-9 per group) by 2.5 hours post a single IP LPS administration, data
represented as cytokine protein (pg) per millilitre of sample and shows mean ± SEM. ***
<0.001, * p <0.05 vs. respective vehicle group (univariate ANOVA followed by planned
comparisons)
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Figure 5.8: MIP-la (A) and IL-10 (B) protein in plasma of a C57BL6/J control or TASTPM 
transgenic mouse (n=6-9 per group) by 2.5 hours post a single IP LPS administration, data
represented as cytokine protein (pg) per millilitre of sample and shows mean ± SEM. ***
<0.001, ** p <0.01, * p <0.05 vs. respective vehicle group, +++ p <0.001 vs. 5 month 
TASTPM LPS, + p <0.05 vs. 2 month C57BL6/J VEH (univariate ANOVA followed by
planned comparisons)
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5.4.2 Study 14: Repeated LPS administration o f  TASTPM mice
5.4.2.1 Cytokine protein in brain at 48 hours
Repeated measures ANOVA revealed no overall effect of treatment on IL-6, F (i5 23) = 
0.00, p = 0.97, IL-ip, F (i, 23) = 0.07, p = 0.80, TNF-a, F (i, 23) = 0.50, p = 0.49 or 
MIP-la, F (i, 23) = 0.83, p = 0.37 on cytokine protein in brain tissue 48hrs after the 
final administration of IP LPS (fig 5.9A & B). There was also no overall effect of 
genotype on IL-6, F (1, 23) = 1.88, p = 0.18, IL-lp, F (i;23) = 181, p = 0.19, TNF-a, F 
(i, 23) = 1-77, p = 0.20 or M IP-la, F (i, 23) = 0.79, p = 0.38. An overall 
treatment*genotype interaction was evident in central IL-ip, F (i, 23) = 4.82, p<0.05. 
Planned comparisons revealed vehicle treated TASTPM transgenic mice exhibited 
significantly higher cortical IL-ip relative to vehicle treated C57BL6/J animals 
(p<0.01, 34% increase). The elevation of cortical IL-ip in this group was not 
significant relative to either LPS treated C57BL6/J or transgenic animals.
5.4.2.2 Cytokine protein in plasma at 2.5hrs
Univariate ANOVA analysis of each cytokine revealed an overall effect of treatment 
on plasma IL-ip, F (1, 49) = 17.05, p<0.001, TNF-a, F (1, 49) = 35.22, p<0.001, MIP- 
la , F (i, 49) = 22.74, p<0.001 and IL-6 , F a , 4g) = 34.37, p<0.001 (fig 5.10A & B). 
Levels of plasma IL10 were below the lower limit of detection for all groups. Post 
hoc planned comparisons revealed that LPS administration induced a 120% 
(p<0.001) and a 421% (p<0.001) increase in IL-ip and TNF-a in C57BL6/J and a 
127% (p=0.08) and 257% (p<0.01) increase in IL-ip and TNF-a in TASTPM mice. 
Plasma IL-lp was significantly decreased in LPS treated TASTPM relative to LPS 
treated C57BL6/J mice (p<0.05). IP LPS increased M IP-la and IL- 6  in both 
C57BL6J/ (620% and 18439%, respectively, p<0.001 both groups) and TASTPM 
(455% (p<0.01) and 2083% (p<0.001) respectively) mice.
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Figure 5.9: Effect of repeated IP administration of LPS on cytokine protein in the cortex (A), 
hippocampus (B) of C57BL6/J and TASTPM mice (n=10-12 per group) by 48 hours post the 
last IP LPS administration, data represented as cytokine protein (pg) per milligram of tissue 
and shows mean ± SEM. ** p <0.01 vs. vehicle (repeated measures ANOVA followed by
planned comparisons)
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Figure 5.10: Effect of repeated IP administration of LPS on plasma ILlp, TNFa, and MIPla 
protein (A) and plasma IL6 protein (B) of C57BL6/J and TASTPM mice(n=10-12 per group) 
by 2.5 hours post the last IP LPS administration, data represented as cytokine protein (pg) 
per millilitre of sample and shows mean ± SEM. * p <0.05, ** p <0.01, *** p <0.001 vs. 
vehicle, # p <0.05 vs. C57BL6/J LPS (univariate ANOVA followed by planned
comparisons)
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5.4.23 Cytokine protein in plasma at 48hrs
Univariate analysis of cytokine production by 48 hours following the last IP LPS 
administration revealed no overall effect of treatment on plasma IL-6, F (1,46) = 3.19, 
p = 0.08, IL-ip, F (1,46) = 0.08, p = 0.77, TNF-a, F a ,49) = 1.50, p = 0.31 or MEP-la, 
F (i, 49) = 0.49, p = 0.49 and no overall effect of genotype on plasma IL-6, F (i, 46) = 
2.80, p = 0.10, IL-ip, F (i, 46) = 0.02, p = 0.90, TNF-a, F a , 49) = 0.11, p = 0.74 or 
M IP-la, F (1,49) = 0.16, p = 0.69, cytokine protein (fig 5.11).
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Figure 5.11: Effect of repeated IP administration of LPS on plasma IL6, ILip, TNFa, and 
MIPla protein of C57BL6/J and TASTPM mice (n=10-12 per group) by 48 hours post the 
last IP LPS administration, data represented as cytokine protein (pg) per millilitre of sample 
and shows mean ± SEM (univariate ANOVA followed by planned comparisons)
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5.4.2.4 Cell-mediated neuroinflammation
Repeated measures ANOVA revealed a significant effect of genotype, F (i, 46) = 
50.00, p<0.001 (fig 5.12). There were also significant effects of brain region, F (i>46) 
= 485.82, p<0.001 and a significant brain region*genotype interaction, F (3, 46) = 
22.19, p<0.001. LPS treatment of both C57BL6/J control and TASTPM transgenic 
mice failed to induce a significant increase in GFAP. Vehicle treated and LPS treated 
TASTPM mice exhibited a 635% and a 198% increase in cortical GFAP respectively 
relative to C57BL6/J controls (p<0.001, both groups). Vehicle treated TASTPM 
mice demonstrated a 16% increase (p<0.05) in hippocampal GFAP, however, there 
was no significant increase in hippocampal GFAP in LPS treated TASTPM mice 
relative to C57BL6/J mice (fig 5.13).
A B
Figure 5.12: Representative photomicrographs of coronal sections of the hippocampus and 
cortex stained for GFAP in vehicle TASTPM (A, B) and LPS TASTPM (C, D) mice (n=10- 
12 per group) following repeated IP administration of LPS, scale bar represents 200pmetres
and 50pmetres
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Figure 5.13: Effect of repeated IP administration of LPS on GFAP in the cortex (A) and 
hippocampus (B) in C47BL6/J or TASTPM mice (n=10-12 per group), data represented as 
percentage stained area and shows mean ± SEM. * p <0.05, *** p <0.001 vs. vehicle 
(univariate ANOVA followed by planned comparisons)
Qualitative analysis of the presence of microglia in brain tissue indicated no obvious 
differences in numbers or size of CD68 positive cells (fig 5.14). There was no 
activated microglia present in the C57BL6/J mice.
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Figure 5.14: Representative photomicrographs of coronal sections of the hippocampus and 
cortex stained for CD68 in vehicle TASTPM (A) and LPS TASTPM (B) mice (n=10-12 per 
group) following repeated IP administration of LPS, scale bar represents lOOpmetres
5A.2.5 A p load
Analysis of Ap load in the brain of LPS TASTPM mice revealed an overall effect of 
genotype on Apl-40, F (i, 2i) — 299.48, pO.OOl, and Api-42, F (i5 21) =145.00, 
p<0.001 (fig. 5.15). TASTPM mice exhibited significantly higher Ap load than 
C57BL6/J mice, regardless of treatment. There was no overall effect of treatment on 
Api-40, F (ij2i) = 0.57, p=0.46, or Api-42, F (i>2i) =1.76, p=0.199. There was also no 
difference in numbers of Ap plaques observed by immunohistochemistry between 
vehicle and LPS treated TASTPM mice (fig 5.16 & 5.17).
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Figure 5.15: Effect of repeated IP administration of LPS on brain Api-40 (A) and Api-42 
(B) in TASTPM mice (n=10-12), data represented as pmol of Ap per gram of tissue and 
shows mean ± SEM (univariate ANOVA followed by planned comparisons)
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Figure 5.16: Representative photomicrographs of coronal sections of the cortex stained for 
Ap deposits in vehicle TASTPM (A, B) and LPS TASTPM (C, D) mice (n=10-12 per group) 
following repeated DP administration of LPS, scale bar represents lOOpmetres
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Figure 5.17: Effect of repeated EP administration of LPS on Ap load in the cortex (A), 
hippocampus (B) and whole brain (C) of C57BL6J and TASTPM mice (n=10-12 per group), 
data represented as percentage stained area and shows mean ± SEM (univariate ANOVA
followed by planned comparisons)
5A.2.6 NeuN
There was no effect of genotype, F (i, 47) = 0.00, p=0.95 or LPS treatment, F 47) =
0.18, p=0.68 (fig. 5.18) on neurons as quantified by an assessment of the percentage 
area covered by NeuN positive stained cells in cortical and hippocampal regions (fig 
5.19).
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Figure 5.18: Representative photomicrographs of coronal sections of the hippocampus and 
cortex stained for NeuN positive cells in vehicle C57BL6/J (A, B) and TASTPM (C, D) mice 
and LPS treated C57BL6/J (E, F) and TASTPM (G, H) TASTPM mice (n=10-12 per group), 
scale bar represents 500pmetres (A, C, E, G) and (B, D, F, H) 200jimetres
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Figure 5.19: Effect o f repeated IP administration o f LPS on NeuN staining in the cortex (A) 
and hippocampus (B) o f C57BL6J and TASTPM mice (n=10-12 per group), data represented 
as percentage stained area and shows mean ± SEM (univariate ANOVA followed by planned
comparisons)
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5.5 D iscussion
5.5.1 LPS induced neuroinflammation - APP/PS1 transgenic mice
Administration of a single dose of LPS shown to induce a small increase in central 
cytokine protein in C57BL6/J controls resulted in alteration of the 
neuroinflammatory profile of TASTPM APP/PS1 mutant mice. Interestingly, the 
primary effect of LPS was evident on the chemokine, M IP-la. Cortical and 
hippocampal M IP-la was increased in vehicle treated TASTPM relative to vehicle 
treated C57BL6/J mice by 10 months of age (fig 5.4). Cortical and hippocampal 
M IP-la was increased by 5 months and 10 months in LPS treated TASTPM relative 
to LPS treated C57BL6/J mice (fig 5.4). Central MEP-la remained unaltered in 
C57BL6/J mice, regardless of treatment or age, indicating a genotype-specific 
increase of M IP-la in TASTPM brain tissue. This supports previous literature 
describing the increase of pre-existing M IP-la mRNA expression in brain tissue 
following IP administration of LPS, at an age when Ap plaques and associated 
activated microglia were evident in the brains of APP overexpressing mice (Tg2576) 
(Quinn et al, 2003). Earlier onset of increased M IP-la expression following LPS 
treatment to TASTPM mice may suggest the presence of peripheral inflammation 
can exacerbate a pre-existing neuroinflammatory profile in APP or APP/PS1 
overexpressing mice, particularly since M IP-la was the only cytokine altered in 
vehicle treated TASTPM versus C57BL6/J mice. Repeated IP injection of LPS to 
TASTPM mice from 4 through to 7 months of age did not alter M IP-la protein 
expression in brain tissue, despite evidence that, following repeated LPS treatment, 
plasma M IP-la was increased relative to vehicle treated TASTPM mice (fig 5.8). 
The importance of increased M IP-la protein in the brain of APP and APP/PS1 
overexpressing mice is unclear but it was suggested by Quinn et al, 2003 that it 
might not be linked to Ap plaque load. Acute IP injection of LPS to 2 month 
TASTPM mice failed to increase central MEP-la protein expression relative to LPS 
treated C57BL6/J mice, indicating that peripheral inflammation initiated before onset 
of significant fibrillar Ap plaque deposition does not cause a genotype-specific 
increase in cytokine expression in brain tissue. This suggests an interaction between 
Ap neuropathology and peripheral inflammation is required to enhance the response 
of the brain to peripheral infection.
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Acute LPS injection increased the protein expression of one other cytokine in brain 
tissue. Cortical and hippocampal IL-6 in both C57BL6/J (consistent with validation 
studies) and TASTPM mice at 2, 5 and 10 months of age, was increased following a 
single IP LPS injection (fig 5.1). This indicates central IL-6 expression; unlike MIP- 
1 a, was not genotype specific. Reasons for the increase in hippocampal IL-6 evident 
in 5 month LPS treated TASTPM versus LPS treated C57BL6/J mice are unclear. 
The alteration may be in response to the rapid deposition of Ap occurring at this age 
and may warrant further investigation by characterising central IL-6 expression at 
ages in between the 2 and 5 month timepoints assessed in the current study.
Following acute IP LPS administration, although by 2 months of age, LPS treatment 
significantly increased plasma IL-ip in LPS treated TASTPM versus vehicle treated 
TASTPM mice, plasma IL-ip was attenuated relative to LPS treated C57BL6/J mice 
at this age with a non-significant trend for plasma IL-lp reduction by 5 and 10 
months (fig 5.6). Plasma IL-lp was also decreased in LPS treated TASTPM relative 
to LPS treated C57BL6/J mice following repeated LPS injection (fig 5.10). The 
reason for an abrogation of a peripheral pro-inflammatory response to LPS in 
TASTPM mice is uncertain and is not reported in the current literature so it is 
difficult to determine how this change relates to other APP or APP/PS1 mutant 
transgenic mouse lines. Since the reduction of plasma IL-ip was already evident in 
TASTPM transgenic mice by 2 months of age, before the onset of plaque deposition, 
it is likely that the difference in peripheral immune response between C57BL6/J and 
TASTPM mice following IP LPS injection is due to underlying differences in their 
development rather than an effect of Ap load.
It cannot be discounted that the lack of detectable changes in the expression of other 
cytokines in TASTPM brain tissue following LPS treatment may be due to the 
method of cytokine detection. Previous literature has documented the increase in 
central cytokine mRNA in APP overexpressing mice (Abbas et al, 2002; Lim et al, 
2000; Sly et al, 2001). However, much of the evidence has relied on the 
immunohistochemical detection of cytokine expression, associated with microglia 
and astrocytes, in brain tissue (Abbas et al., 2002; Apelt and Schliebs, 2001; Benzing 
et al., 1999; Mehlhom et al., 2000). Cytokine production by immune cells is 
localised to Ap plaques thus, homogenisation of discrete brain regions may cause
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dilution of the cytokine signal due to the presence of surrounding healthy tissue 
(Quinn et al, 2003). Fold changes in mRNA expression of some cytokines may be 
small, limiting the successful detection of cytokine expression at the protein level by 
Luminex or ELISA techniques.
Immunohistochemical analysis of GFAP positive astrocytes and CD68 positive 
microglia/macrophage in vehicle treated TASTPM versus vehicle treated C57BL6/J 
mice indicated no change in the morphology or number of microglial cells in brain 
tissue (fig 5.14) but a significant increase in cortical and hippocampal GFAP positive 
astrocytes (fig 5.13). Repeated LPS IP injection had no effect on either CD68 or 
GFAP staining by 48 hours following the last LPS injection, indicating the peripheral 
inflammation did not influence cell-mediated neuroinflammation. Previous reports of 
enhanced GFAP expression in APP overexpressing mice following LPS treatment 
are variable. At 1 through to 18 hours, following peripheral LPS injection, GFAP 
mRNA was increased in brain tissue of aged (4 months after Ap plaque onset) 
Tg2576, (Sly et al, 2001). It is unclear whether this rapid increase in GFAP mRNA 
expression is transient and decreases back to basal levels by later timepoints. A more 
in-depth characterisation investigating GFAP mRNA and protein expression in brain 
tissue at acute (1-24 hours) and chronic timepoints following peripheral LPS 
injection may provide more insight into whether increased GFAP mRNA is a 
transient event. Activation of microglia in brain tissue following peripheral LPS 
injection has also been reported in APP overexpressing mice (Sheng et al, 2003), 
however, the effect of LPS on microglia in wildtype mice was not described so it is 
uncertain how this relates to a basal reaction to LPS and whether this was a genotype 
specific change. Certainly, the morphology and numbers of activated microglia 
following repeated LPS injection in the current study suggests peripheral 
inflammation does not affect the chronic cellular neuroinflammatory response.
5.5.2 Modulation o f A p  load by LPS  -  APP/PS1 transgenic mice
Previous studies report alterations of Ap load following peripheral (Quinn et al, 
2003; Sheng et al, 2003) and central injection of LPS (Qiao et al, 2001; DiCarlo et al, 
2001; Herber et al, 2004) and suggest modulation of Ap load depends largely on the 
protocol of LPS administration. Typically, LPS injection after onset of Ap plaque
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deposition results in a reduction in Ap load. Analysis of Api-40 or Api-42 load and 
AP plaque deposition in brain tissue using ELISA and immunohistochemical 
techniques revealed that LPS treatment had no effect following repeated IP injection 
of LPS to TASTPM mice (fig 5.15). This is in contrast to published literature, 
primarily reporting the use of APP overexpressing mice, demonstrating the reduction 
(Quinn et al, 2003; DiCarlo et al, 2001) and increase (Sheng et al, 2003; Sly et al, 
2001) in Ap load, particularly increased intracellular Ap, following IP LPS 
treatment. The lack of Ap modulation following LPS treatment in TASTPM 
APP/PS1 overexpressing mice may be a result of the significantly more rapid Ap 
deposition evident in APP/PS1 models, hence Ap load is already substantial and 
further modulation of Ap levels may be difficult.
5.5.5 LPS induced neurodegeneration -  APP/PS1 transgenic mice
Cortical and hippocampal NeuN positive cells were quantified in C57BL6/J and 
TASTPM brain tissue following repeated IP LPS treatment. LPS had no effect on 
percentage NeuN staining in either cortex or hippocampus (fig 5.18 & 5.19). As 
discussed in section 5.4.2, repeated administration of LPS also failed to modulate Ap 
load in TASTPM brain tissue. Neurodegeneration in AD brain is associated with Ap 
plaques in the entorhinal cortex and hippocampus (Scott et al, 1991; Armstrong, 
2006). A high level of Ap deposition in TASTPM animals does not cause overt 
neurodegeneration and, as LPS treatment did not increase Ap load, Ap-mediated 
neurodegeneration was unlikely. Previously, increased plasma IL-lp levels and 
peripheral infection has been suggested to exacerbate the progression of AD (Holmes 
et al, 2003). The exacerbation of a pre-existing neuroinflammatory profile in 
TASTPM tissue following repeated LPS injection may indicate that the presence of a 
peripheral infection after onset of Ap plaque deposition could exacerbate pre­
existing pathology. Importantly, peripheral infections occur in AD patients during 
later stages of the neurodegenerative pathology suggesting peripheral inflammation 
may exacerbate rather than initiate neurodegeneration. Therefore, it may be difficult 
to induce cell death via a peripherally administered inflammatory insult considering 
the absence of neurodegeneration in vehicle treated TASTPM mice. The induction of 
neuronal cell loss in brain tissue of APP/PS1 overexpressing mice could be further 
investigated via a more chronic injection of LPS either centrally or peripherally. An
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extended duration of treatment may be a more sufficient insult for causing 
neurodegeneration in APP/PS1 overexpressing mice.
In summary, the initial use of Ap peptide to cause neuroinflammation and 
neurodegeneration in rat brain tissue resulted in a variable window of cell death 
unsuitable in a model of Ap-induced neurodegeneration, despite the significant 
increase in neuroinflammation. This prompted an investigation of the use of LPS to 
exacerbate neuroinflammation and possibly induce onset of neurodegeneration in 
APP/PS1 overexpressing TASTPM mice that exhibit robust Ap neuropathology. 
Peripheral LPS administration exacerbated M IP-la, a chemokine evident in the brain 
tissue of vehicle treated TASTPM mice, suggesting peripheral inflammation may 
enhance a pre-existing neuroinflammatory profile rather than initiate extensive 
neuroinflammation or induce neurodegeneration. Although a longer duration of LPS 
treatment may lead to different results, the repeated peripheral administration of an 
inflammatory stimulus to TASTPM mice is unlikely to provide a robust in vivo 
model of neuroinflammation and neurodegeneration, despite relevance to the chronic 
neurodegenerative disease, AD. The idea that a peripheral inflammatory or specific 
neurotoxic challenge may enhance neuroinflammation in TASTPM mice will be 
further investigated in the following chapter. Chapter 6 will describe use of the 
noradrenergic neurotoxin DSP-4 in exacerbating neuroinflammation and potentially 
causing neurodegeneration in TASTPM brain tissue.
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CHAPTER 6 
Repeated DSP-4 administration to TASTPM APP/PS1
transgenic mice
6.1 Introduction
Degeneration of central noradrenergic neurons projecting from the locus coeruleus 
(LC) to terminal regions including the cortex and hippocampus (Mann et al, 1982; 
Mann &Yates, 1983) correlates with duration of illness (Zarow et al, 2003), Ap 
plaque deposition and duration and severity of dementia (Bondareff et al, 1987) in 
AD. Noradrenaline (NA) acts via adrenoceptors and a2 adrenoceptors are 
significantly reduced in the hippocampus of AD patients (Szot et al, 2006). Previous 
reports describe the anti-inflammatory and neuroprotective properties of NA 
including the attenuation of pro-inflammatory cytokine expression and increased 
release of neurotrophic factors (reviewed by Galea et al, 2003; Marien et al, 2004). In 
addition, previous chapters in this thesis have described the anti-inflammatory 
activity of the a2 antagonist, fluparoxan on LPS-mediated pro-inflammatory 
cytokine expression in rodent brain tissue (sections 2.5.3.2 & 3.5.2.2). Hence, 
reduction of NA in brain tissue may exacerbate neuroinflammation in double mutant 
APP/PS1 transgenic TASTPM mice.
6.1.1 Role o f NA in neuroinflammation & neurodegeneration
NA negatively regulates the expression and release of pro-inflammatory cytokines 
(Kaneko et al, 2005; Hu et al, 1991; Dello Russo et al, 2004) and inhibits microglial 
activation (Lee et al, 1992; Loughlin et al, 1993; Chang & Liu, 2000). LPS (i.p) 
administration causes a significant increase in NA in the brain of rats indicating a 
response of NA to an inflammatory stimulus (Linthorst et al, 1998). NA has been 
shown to inhibit the microglial induced cell death of cortical neurons by reducing IL- 
1(3 release from microglia (Madrigal et al, 2005). a2 adrenoceptor antagonists that 
act to increase extracellular NA have been reported to have anti-inflammatory 
actions in vivo (Hasko et al, 1998) and data presented earlier in this thesis (section 
2.5.3.2) also demonstrated the in vivo anti-inflammatory activity of the a2-
201
adrenoceptor antagonist, fluparoxan in brain tissue. Low doses of the noradrenergic 
neurotoxin N - (2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) (50pg/kg) 
potentiated Ap induced neuroinflammation (Heneka et al, 2002 & 2003a) and 
exacerbated microglial activation and inflammatory gene expression (Feinstein et al., 
2004) in APP over expressing mice. Compromising the NA system by DSP-4 
appears to render the brain tissue more susceptible to the pro-inflammatory effects of 
Ap protein (Heneka et al., 2002; Heneka et al., 2003a). NA can protect neurons and 
promote recovery from neurotoxic stimuli including inflammatory and excitotoxic 
insults by enhancing the release of neurotrophic factors and acting as an anti-oxidant 
(Marien et al, 2004). More recent studies published since the completion of the work 
described in this chapter reported increased neuroinflammation and neuronal cell 
death in the hippocampus and cortex of APP23 mice following the peripheral 
injection of DSP-4 (Heneka et al, 2006). Reduction in central NA also increased Ap 
plaque number in the brain tissue of APPV717F (H6) overexpressing mice (Kalinin 
et al, 2006).
6.1.2 Depletion ofNA following DSP4 administration
DSP-4, a tertiary haloalkylamine that can cross the blood-brain barrier, causes 
marked depletion of endogenous NA via inhibition of uptake and decreased NA 
synthesis (Ross et al, 1976; Jaim-Etcheverry & Zieher, 1980). The response of 
central noradrenergic axons to DSP-4 occurs via two phases. The first phase involves 
massive NA depletion via irreversible uptake inhibition and depletion of endogenous 
NA via decreased NA synthesis (Fritschy et al, 1990). The second phase involves a 
reduction in the enzyme dopamine-P-hydroxylase (DpH) and degeneration of NA 
axons (Fritschy et al, 1990). Inhibition of NA uptake and depletion of endogenous 
neuronal NA occurs rapidly and in a dose dependent manner after DSP-4 
administration. Storage and uptake of NA recovers quickly in the periphery but 
continues in the CNS for a long duration and recovery time differs between specific 
brain regions (Wolfinan et al, 1994). The increased affinity of DSP-4 for the NA 
uptake carrier in synaptosomes from LC terminal areas may explain the actions of 
DSP-4 on neuronal projections specifically originating in the LC (Fritschy & 
Grzanna, 1991). Areas innervated by the LC, such as the cortex and hippocampus, 
also demonstrate the greatest NA depletion due to increased NA turnover rate
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relative to other regions (Logue et al, 1985). Degeneration of terminals is associated 
with a gradual loss of noradrenergic cell bodies in the LC with approximately a 30% 
loss of LC neurons within 2 months after a single DSP-4 injection suggesting 
terminal loss induces retrograde degeneration. Six months after DSP-4 
administration, surviving LC neurons were observed to regenerate resulting in the 
reinnervation of specific brain regions including the forebrain, in contrast to a lack of 
regenerative neuronal sprouting in the brainstem and cerebellum (Fritschy & 
Grzanna, 1992).
6.1.3 Chapter Aims
The primary purpose of this investigation was to determine the effect of 
noradrenergic depletion on Ap plaque deposition and neuroinflammation in 
TASTPM transgenic brain tissue. TASTPM mice exhibit high levels of circulating 
AP protein, Ap plaque deposition, neuroinflammation and cognitive and behavioural 
deficits (Howlett et al., 2004) but lack overt neuronal cell death. Depletion of NA 
may exacerbate some of the features of AD and hence the effects of noradrenergic 
depletion on neurodegeneration, normally absent in the TASTPM model, was also 
examined.
6.2 Materials & Methods
6.2.1 Animals
Male TASTPM mice (5 months old) were obtained from GlaxoSmithKline, UK and 
specific, pathogen free male C57BL6/J mice (25g, approx 10 weeks of age) were 
ordered from Charles River, UK or as aged (5 months) animals from Harlan, UK. All 
mice were singly housed (GlaxoSmithKline, Harlow, UK) under controlled 
conditions (temperature: 21-24°C, 12-h light/dark cycle (7am lights on) and provided 
with Global Rodent Maintained Diet (Harlan Teklad) and water ad libitum. Analysis 
of DNA isolated from tail tips removed at termination confirmed genotype status. All 
experimental procedures were conducted in accordance with the GlaxoSmithKline 
local ethics committee and conformed to the UK Animals (Scientific Procedures) Act 
1986.
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6.2.2 Materials
Saline and DSP-4 were obtained from VWR International, UK and Sigma, UK 
respectively. 4% paraformaldehyde was prepared in-house (GSK, UK). All materials 
for HPLC analyses were obtained from VWR International, UK unless otherwise 
stated. Immunostaining machines, PAP pens, proteinase K, peroxidase blocking 
solution and diaminobenzidine substrate kit were all obtained from DakoCytomation, 
UK. Optimax buffer was obtained from A. Menarini, UK. Gills haematoxylin stain 
was purchased from HD Supplies, UK. The sources of additional materials are 
individually stated.
6.2.3 Treatment
Mice were IP injected with either filtered PBS or DSP-4 (5 or 50mg/kg) dissolved in 
filtered PBS (5ml/kg dose volume). DSP-4 in solution is relatively unstable and was 
administered immediately after preparation (Ross, 1976). A number of previous 
reports describe the reduction of NA and loss of LC neurons following a single 
injection of 50mg/kg DSP-4 (Hallman & Jonsson, 1984; Fritschy & Grzanna, 1989; 
Prieto & Giralt, 2001; Fritschy et al, 1990; Fritschy & Grzanna, 1991). A much 
lower dose of 50pg/kg has been previously shown to potentiate Ap induced 
neuroinflammation (Heneka et al, 2002; Heneka et al, 2003) and previous 
unpublished studies highlighted increased incidence of mortality in APP 
overexpressing mice following administration of 50mg/kg DSP-4 (personal 
communication; D. Feinstein, University of Illinois, Chicago, USA). A recent 
publication by Heneka et al, 2006 details the use of 5mg/kg DSP-4 to modulate Ap 
deposition in the brain tissue of APP overexpressing mice.
6.2.4 Sample collection
Mice were deeply anaesthetised with sodium pentobarbital (Euthatal® lOOmg kg-1
i.p, Rhone Merieux, Harlow, UK).
Study 15: cortex, hippocampus and cerebellum were microdissected and placed in 
prelabelled 2ml eppendorfs (VWR International, UK) and stored at -80°C for HPLC 
analysis of NA. The cortex and hippocampus were hemi-dissected to allow the 
assessment of potential differences in the effect of DSP-4 on NA between left and 
right brain hemispheres.
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Study 16: The brain was microdissected: half brain (right), cortex and hippocampal 
(left) samples. Half brain was immerse fixed in 4% paraformaldehyde, left cortex 
samples from 5 animals were placed into sterile biopur® (RNase-free) safe-lock 
eppendorfs (VWR International, UK) and stored at -80°C for RNA quantification. 
Cortex samples from remaining animals and hippocampus from all mice were stored 
into prelabelled 2ml eppendorfs (VWR International, UK) and stored at -80°C for 
high performance liquid chromatography (HPLC) analysis of NA.
6.2.5 Ex-vivo neurochemistry- HPLC
6.2.5.1 Tissue Preparation
Samples were weighed and homogenised in 0.4 M perchloric acid containing sodium 
metabisulphate (0.1% wv'1), EDTA (ethylene diamine tetra acetate 0.01% wv'1) and 
L-cysteine (0.1% wv'1) at a ratio of lOOjil homogenising buffer per mg of tissue 
(giving a tissue concentration of 0.01 g/ml). All samples were centrifuged on 
10,000g at 4°C for 10 minutes and supernatant decanted.
6.2.5.2 High Performance Liquid Chromatography (HPLC)-ECD analysis 
Aliquots (30|il) of supernatant were transferred into micro-volume glass vials for 
HPLC-ECD analysis. The HPLC-ECD protocol was based on previous published 
literature (Lacroix et al, 2004) and in-house validation. Mobile phase consisted of 
0.07M KH2P 04, containing 1.5 mM sodium octylsulphonate and 0.1 mM EDTA.Na2,
MeOH, tetrahydrofuran (87.5:12:0.5%, wv'1). Flow rates for optimal separation and 
detection varied between 2.2 to 2.5 ml/min. Sample aliquots of lOpl each were 
automatically injected onto the columns. Separation was performed using two 
Chromolith Performance columns connected in series (100 x 4.6 mm i.d., 
Lutterworth UK). Eluates were detected using a Decade electrochemical detector 
fitted with a glassy carbon cell (Antec, Leyden, The Netherlands) set at +0.65V 
versus in situ Ag/AgCl reference electrode. Data were collected using Empower 
software (Waters, Milford, MA). The chromatograms were compared with internally 
run NA standard calibrations (concentrations between 1 and lOOng/ml) to identify 
and quantify components. HPLC analysis was kindly completed by Tracey 
Ashmeade, GSK, Harlow, UK.
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6.2.6 Immunohistochemistry
Hemisected brains immersed fixed in 4% paraformaldehyde for 3 days at room 
temperature were processed and embedded into paraffin wax as described in section
5.2.7 and semi-serial sections (5pM thick) taken throughout the LC (bregma -4  to - 
7) and cortical and hippocampal regions (bregma -1 to-4). Sections (2 sections 
unless otherwise stated) were stained for neurons (NeuN) (6 sections), glial fibrillary 
acid protein (GFAP), microglia (CD68) and Ap as described in section 5.2.7. 
Additionally sections were stained for tyrosine hydroxylase (TH). Sections were 
microwaved (Sanyo Showerwave, 1000W) in tris-borate-EDTA buffer, pH 8.3 
(Sigma-Aldrich, UK) for 2.5 minutes at 1000W, 10 minutes at 450W and allowed to 
cool for 20 minutes. Sections received peroxidase block for 5 minutes, primary 
antibody rabbit anti TH, affinity purified (1/500 in antibody diluent, 30 minutes) 
(Chemicon International, UK), biotinylated goat anti rabbit (1/200 in optimax buffer, 
30 minutes) (Vector Laboratories, UK), peroxidase ABC kit (Vector Laboratories, 
UK) for 45 minutes and diaminobenzidine substrate kit for 10 minutes. Sections were 
counter-stained using Gills haematoxylin (3 seconds followed by running tap water), 
dehydrated in IMS (70 to 100%), cleared in Histoclear and mounted in DPX (VWR, 
UK). Sections were viewed using a Colourview digital camera (xlO objective for TH 
sections, x4 objective for 1E8 sections) attached to an Olympus BX41 microscope. 
Photomicrographs for NeuN, GFAP, CD68 and TH were captured and analysed 
using image analysis software (AnalySIS, Soft Imaging Systems, UK). Sections 
stained for 1E8 were viewed using a Leica DC 100 camera attached to a Leitz DMRB 
microscope. Photomicrographs were captured and percentage area stained by 1E8 
was analysed using Leica Qwin software (Leica systems, Buckinghamshire, UK). 
Immunohistochemical staining and analysis was kindly completed by Martin 
Vidgeon-Hart, GSK, Harlow, UK.
6.2.7 TaqMan analyses
Total RNA was isolated from cortex tissues from WT and TASTPM mice using 
TRIZOL® reagent (Invitrogen, USA). Cortical mRNA was quantified following the 
protocol described in section 2.3.8. Primer (F and R) and probe (P) sets were 
designed from sequences in the Genbank database using Primer Express software 
(Perkin-Elmer, UK) (table 6.1). Taqman analysis was kindly completed by Ainsley
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Culbert and Florence Guillot, GSK, Harlow, UK. 
Gene Reagent Sequences
GFAP F; GGAGCTCAATGACCGCTTTG
R; AGCGCCTTGTTTTGCTGCTC 
P; CAGCTACATCGAGAAGGTTCG
TNFa F; TCCAGGCGGTGCCTATGT 
R; GAGCGTGGTGGCCCC 
P; TCAGCCTCTTCTCATTCCTGCTTGTGG
M IP -la  F; AGCTGACACCCCGACTGC
R; GTCAACGATGAATTGGCGTG 
P; TGCTGCTTCTCCTACAGCCGGAAGAT
RANTES F; TCTTGCAGTCGTGTTTGTCAC
R; TCTTGAACCCACTTCTTCTCT 
P; AGGAACCGCCAAGTGTGTGC
IL -lp F; TTGGGCCTCAAAGGAAAGAAT
R; TCTCCAGCTGOAGGGTGG
P; TATACCTGTCCTGTGTAATGAAAGACGGCA CA
IicBa F; CGGAGGACGGAGGACTCGTT 
R; ACTTCCATGGTCAGCGGCT 
P; TGCACTTGGCAATCATCCACGAAGA
Table 6.1: TaqMan reagent sequences
6.2.8 Data Analysis
A general linear mixed model approach using the Proc Mixed procedure in SAS 
Version 8 (SAS® Institute, UK) assessed the effect of DSP-4 treatment on central NA 
levels within C57BL6/J subjects using brain region as a repeated measure. Separate 
ANOVA analyses at each age point were used to calculate the overall effect and 
interactions between genotype and treatment on cortical and hippocampal NA in
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C57BL6/J and TASTPM mice, using brain region as a repeated measure. Separate 
univariate ANOVAs (Statistica™ Version 6.1 (StatSoft, USA)) at each age point 
calculated the overall effect of DSP-4 treatment on each mRNA marker, plaque load 
and LC degeneration. Post hoc planned comparisons assessed individual treatment 
effects for study 15 and individual differences between groups at each age following 
repeated DSP-4 injection to C57BL6/J and TASTPM subjects. Outliers (data points 
outside 2 standard deviations of the mean) were omitted from statistical analysis and 
graphical representation.
6.3 Protocols
6.3.1 Study 15: Acute DSP-4 effects on NA (5mg/kg and 50mg/kg)
24 male C57BL6/J mice (n=8) (Charles River, UK) were IP administered with 0.9% 
saline, 5mg/kg DSP-4 or 50mg/kg DSP-4 dissolved in 0.9% saline (5ml/kg) were 
euthanased 24 hours post treatment via anaesthetic overdose. Since brain tissue 
would be hemidissected in order to provide tissue for a multitude of analyses 
including immunohistochemistry, taqman and HPLC analysis, I compared left and 
right side cortex and hippocampus to investigate the effect of hemisphere on NA 
quantification using HPLC analysis.
6.3.2 Study 16: Repeated administration o f DSP-4 to TASTPM mice
Male TASTPM mice aged 5 months (n=46) (GSK, Harlow, UK) and age matched 
C57BL6/J controls (n=46) (Harlan, UK) were IP administered with 0.9% saline or 
5mg/kg DSP-4 dissolved in 0.9% saline (5ml/kg) monthly. Half of each treatment 
group were euthanased at 8 months of age whilst remaining animals continued 
treatment and were euthanased at 11 months of age via anaesthetic overdose. Brain 
tissue was hemidissected for half whole brain (right) for immunohistochemical 
analysis and the remaining half brain (left) was microdissected for cortex for either 
taqman or HPLC analysis or hippocampus for HPLC analysis alone.
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6.4 R esults
6.4.1 Study 15: acute DSP-4 effects on NA (5mg/kg and 50mg/kg)
Repeated measures ANOVA indicated an overall effect of DSP-4 treatment, F (2, 8) = 
128.66, p<0.001, brain region, F (4> 32) = 7.78, p<0.001 and a significant interaction 
between brain region*treatment, F (g, 32) = 2.88, p<0.05. Acute administration of 
5mg/kg DSP-4 significantly reduced cortical NA by 21% (p=0.01) and 16% (p<0.01) 
in left (fig 6.1 A) and right cortex (fig 6 .IB) respectively whilst 50mg/kg DSP-4 
treatment induced a 90% (left cortex; p<0.001) and 87% (right cortex; p<0.001) NA 
reduction. DSP-4 (5mg/kg) also significantly reduced left hippocampal NA (fig 
6 .1C) by 22% (p<0.01) but failed to significantly reduce right hippocampal NA (fig 
6 .ID). Treatment of 50mg/kg DSP-4 significantly reduced left (p<0.001) and right 
(p<0.001) hippocampal NA by 74% and 89% respectively. 5mg/kg and 50mg/kg 
DSP-4 treatment significantly reduced NA levels in the cerebellum by 12% (p<0.05) 
and 48% (p<0.001) (fig 6.1E).
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Figure 6.1: Comparison of 5mg/kg and 50mg/kg DSP-4 on NA in left cortex (A), right 
cortex (B), left hippocampus (C), right hippocampus (D) and whole cerebellum (E) in male 
C57BL6/J mice (n=8 per group), data represented as noradrenaline (NA) in ng/ml and shows 
mean ± SEM. * p <0.05, ** p <0.01, *** p <0.001 significantly different vs. vehicle 
(repeated measures ANOVA followed by planned comparisons)
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6.4.2 Study 16: Repeated administration o f DSP-4 to TASTPM mice
6.4.2.1 NA depletion following chronic DSP4 treatment
Repeated measures ANOVA analysis on mice at 8 months revealed no significant 
effect of genotype, F = 3.85, p = 0.058, or treatment, F = 3.56, p = 0.067, on
NA (fig 6.2). There was a non-significant trend for DSP-4 treated groups to exhibit 
elevated NA levels, particularly in cortical tissue of TASTPM mice (35% increase 
relative to vehicle TASTPM). There was also a significant elevation of NA in 
hippocampal tissue of C57BL6/J mice (31% increase relative to vehicle C57BL6/J). 
At 11 months, repeated measures ANOVA revealed an overall effect of genotype, F 
(136) = 50.82, p < 0.001, brain region, F ( = 8.71, p < 0.01, and a significant
genotype*treatment interaction, F 36) = 5.9, p < 0.01. Post hoc planned comparisons
revealed a significant reduction in cortical (p<0.01) and hippocampal (p<0.05) NA 
levels in vehicle treated TASTPM transgenic mice relative to vehicle treated 
C57BL6/J mice. Also a significant reduction in cortical (p<0.01) and hippocampal 
(p<0.001) NA levels in DSP-4 treated TASTPM transgenic mice versus DSP-4 
treated C57BL6/J mice. DSP-4 treatment did not significantly affect C57BL6/J mice, 
however, there was a reduction of cortical (p = 0.01) and hippocampal (p<0.05) NA 
levels by 57% and 45% respectively in DSP-4 treated TASTPM transgenic mice 
relative to vehicle treated TASTPM transgenic mice.
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Figure 6.2: N A  depletion in cortex and hippocampus o f  8 month and 11 month DSP-4 and 
vehicle treated C57BL6/J and TASTPM mice (n=12 per group), data represented as 
noradrenaline (NA) in ng/ml and shows mean ± SEM. * p <0.05, ** p <0.01 significantly 
different vs. vehicle treatment, # p <0.05, ## p <0.01, ###p <0.001 significantly different vs. 
C57BL6/J (repeated measures ANOVA followed by planned comparisons at each age point)
2 1 2
13
3
6.4.2.2 Neuroinflammation following chronic DSP-4 treatment
A. Taqman
Taqman PCR was used to analyse mRNA expression of a number of 
neuroinflammatory markers in hemidissected cortical tissue (fig 6.3 & fig 6.4). 
Univariate ANOVA analysis on mRNA expression in 8 month cortex revealed a 
significant effect of genotype on GFAP, F (11?) = 114.68, p < 0.001, TNF-a, F (116) =
13.18, p < 0.01, M IP-la, F (11?)= 682.48, p < 0.001 and RANTES, F (1 = 61.24, p
< 0.001. There was also a significant genotype*treatment interaction on TNF-a, F 
(i 16) = P < M IP-la, F (11?)= 9.43, p < 0.01 and RANTES, F = 8.05, p
< 0.05. Post hoc planned comparisons revealed signicantly increased GFAP, MIP- 
la , and RANTES in TASTPM relative to C57BL6/J mice regardless o f treatment 
(TASTPM versus C57BL6/J, p<0.001 all groups). TNF-a mRNA expression was 
also increased in TASTPM versus C57BL6/J mice after vehicle treatment (p<0.001). 
There was also a trend towards a reduction of GFAP (p = 0.15), TNF-a (p = 0.06) 
and RANTES with a significant reduction of M IP-la (p<0.05) in DSP-4 treated 
TASTPM relative to vehicle treated TASTPM mice.
Univariate ANOVA analysis on mRNA expression in 11 month cortex revealed 
significant genotype effects on GFAP, F = 204.24, p < 0.001, TNF-a, F (115) =
39.05, p < 0.001, M IP-la, F = 1539.18, p < 0.001, RANTES, F = 82.36, p <
0.001, IL-ip, F = 6.60, p < 0.05, and IkBa, F = 24.69, p < 0.001. There was
also an overall treatment effect on IL-1J3, F = 9.63, p < 0.01, and IkBa, F (116) =
8.96, p < 0.01. GFAP (p<0.01, both groups), TNF-a (p<0.001, both groups), M IP-la 
(p<0.01, both groups), RANTES (p<0.001, both groups) were increased in TASTPM 
relative to C57BL6/J mice, regardless of treatment. There was also a significant 
potentiation of IL-lp (p<0.05) in DSP-4 treated TASTPM relative to vehicle treated 
TASTPM and DSP-4 treated C57BL6/J mice at 11 months. There was a non­
significant decrease in IkBa (p=0.06) in DSP-4 treated TASTPM relative to vehicle 
treated TASTPM mice and a significant reduction in IkBa (p<0.05) in DSP-4 treated 
C57BL6/J relative to vehicle treated C57BL6/J mice at 11 months.
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Figure 6.3: Cortical inflammatory mRNA markers in 8 month and 11 month vehicle and 
DSP-4 treated C57BL6/J and TASTPM transgenic mice (n=12 per group), data represented 
as fold increase relative to GAPDH and shows mean ± SEM. * p <0.05, ** p <0.01 vs. 
vehicle treatment, # p <0.05, ## p <0.01, ###p <0.001 vs. C57BL6/J (univariate ANOVA
followed by planned comparisons)
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Figure 6.4: Cortical inflammatory mRNA markers in 8 month and 11 month vehicle and 
DSP-4 treated C57BL6/J and TASTPM transgenic mice (n=12 per group), data represented 
as fold increase relative to GAPDH and shows mean ± SEM. * p <0.05 significantly 
different vs. vehicle treatment, # p <0.05, ###p <0.001 significantly different vs. C57BL6/J 
(univariate ANOVA followed by planned comparisons)
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B. Immunohistochemistry (IHC)
Brains were immunohistochemically processed to identify reactive astrocytes 
(GFAP) (figs 6.5 & 6.6) and activated microglia (CD68) (fig 6.7), as markers of 
neuroinflammation. There was no effect of DSP-4 treatment on the area of microglial 
stain in cortex of TASTPM mice at 8 or 11 months; however, cortical GFAP staining 
for reactive astrocytes was patchy and less dense in DSP4 treated relative to vehicle 
treated TASTPM mice at 8 months. This was supported at the transcriptional level by 
a reduction in cortical GFAP mRNA of DSP-4 treated TASTPM mice at 8 months of 
age (fig 6.3). By 11 months of age, there was no difference in GFAP staining 
between DSP4 treated and vehicle treated TASTPM mice.
GFAP:
8 month DSP-4 C57BL6/J 8 month VEH C57BL6/J
i'Cr&l .A-z • * ■ -sections of the cortex stained
GFAP:
8 month DSP-4 TASTPM 8 month VEH TASTPM
m;. ■ '
■ i p i i w i i  im m  ^ — P — — — tm a
GFAP from 8 month vehicle and DSP-4 treated C57BL6/J and TASTPM transgenic mice 
(n=12 per group), scale bar represents 200pmetres
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Figure 6.6: Representative photomicrographs of sagittal sections of the cortex stained for 
GFAP from 11 month vehicle and DSP-4 treated C57BL6/J and TASTPM transgenic mice 
(n=12 per group), scale bar represents 200jimetres
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Figure 6.7: Representative photomicrographs of sagittal sections of the cortex stained for 
CD68 from 8 and 11 month vehicle and DSP-4 treated TASTPM transgenic mice (n=12 per
group), scale bar represents 200pmetres
6.4.2.3 Amyloid plaque load
Brains were immunohistochemically processed to identify Ap plaques (fig 6.8 & 
6.9). At 8 months of age, repeated measures ANOVA of Ap plaque number at the 8 
month timepoint revealed a significant effect of treatment, F (13g) = 14.01, p < 0.001, 
genotype, F ( = 209.30, p < 0.001 and a significant treatment*genotype
interaction, F (13g) = 14.01, p < 0.001. Post hoc planned comparisons indicated a 
significant reduction in percentage area of Ap in cortex in DSP-4 treated relative to
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vehicle treated TASTPM mice (p<0.01) (fig 6.10). There was no significant 
difference in percentage hippocampal Ap plaque deposition in DSP-4 treated 
TASTPM versus vehicle treated TASTPM mice.
At 11 months, repeated measures ANOVA revealed an overall effect of genotype, F 
(139) = 231.54, p < 0.001, but no effect of treatment, F 39) = 2.22, p = 0.14, on
cortical Ap plaques. There was also an overall effect of genotype, F (1 = 464.53, p
< 0.001, but no effect of treatment, F (139) = 0.74, p = 0.40, on hippocampal Ap
plaques. TASTPM transgenic mice had significantly greater Ap plaques than 
C57BL6.J mice irrespective of treatment (pO.001, all groups).
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Figure 6.8: Representative photomicrographs of sagittal sections of the cortex and 
hippocampus stained for amyloid from 8 month vehicle and DSP-4 treated C57BL6/J and 
TASTPM transgenic mice (n=12 per group), scale bar represents 1mm
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Figure 6.9: Representative photomicrographs of sagittal sections of the cortex and 
hippocampus stained for amyloid from 11 month vehicle and DSP-4 treated C57BL6/J and 
TASTPM transgenic mice (n=12 per group), scale bar represents 1mm
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Figure 6.10: Percentage of amyloid stained area in cortex and hippocampus of 8 month and 
11 month vehicle and DSP-4 treated C57BL6/J and TASTPM transgenic mice, data 
represented as percentage stained area and shows mean ± SEM. ** p <0.01 significantly 
different vs. vehicle TASTPM (univariate ANOVA followed by planned comparisons)
6.4.2.4 Neurodegeneration following chronic DSP-4 treatment
A. Noradrenergic depletion in the LC
Brains were immunohistochemically processed to identify tyrosine hydroxylase (TH) 
as a marker of noradrenergic depletion (fig 6.11 & 6.12). At 8 months of age, there 
was no overall effect of treatment, F (139) = 0.13, p = 0.72, or genotype, F (139) = 0.31,
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p = 0.58 on TH cell count. A separate univariate ANOVA revealed a significant 
effect of treatment, F (138) = 4.47, p = 0.05 at 11 months of age. Post hoc planned
comparisons indicated a significant reduction (19% vs. vehicle TASTPM, p < 0.05) 
in TH staining within the LC (fig 6.13). There was no difference in TH staining of 
the LC between vehicle and DSP-4 treated C57BL6/J control mice.
TH -  11 month:
A VEH C57BL6/J B
Figure 6.11: Representative photomicrographs of sagittal sections of the locus coeruleus 
stained for tyrosine hydroxylase (TH) from 11 month vehicle and DSP-4 treated C57BL6/J 
mice (n=12 per group), scale bar represents 200pmetres (A, B) and lOOpmetres (C, D)
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Figure 6.12: Representative photomicrographs of sagittal sections of the locus coeruleus 
stained for tyrosine hydroxylase (TH) from 11 month vehicle and DSP-4 treated TASTPM 
transgenic mice (n=12 per group), scale bar represents 200pmetres (A, B) and lOOpmetres
(C, D)
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Figure 6.13: TH cell count in the locus coeruleus (LC) of 8 month and 11 month vehicle and 
DSP-4 treated C57BL6/J and TASTPM transgenic mice (n=12 per group), data represented 
as count of tyrosine hydroxylase positive stained cells and shows mean ± SEM. * p <0.05 
significantly different vs. vehicle TASTPM (univariate ANOVA followed by planned
comparisons)
B. Neurodegeneration in hippocampus
A univariate ANOVA demonstrated an overall effect of age, F = 33.69, p <
0.001, on hippocampal NeuN cell count (fig 6.14). There was no overall effect of 
genotype, F (164) = 2.49, p = 0.12, treatment, F (164) = 3.16, p = 0.09, or any
interaction between treatment*genotype, F M) = 0.00, p = 0.99. Post hoc planned 
comparisons revealed that there was a significant difference in cell count between 8 
month and 11 month mice within all treatment groups (p < 0.01, all groups) (fig 
6.15).
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NeuN:
8 month DSP-4 TASTPM 8 month VEH TASTPM
NeuN:
11 month DSP-4 TASTPM 11 month VEH TASTPM
Figure 6.14: Representative photomicrographs of sagittal sections of the hippocampus 
stained for NeuN from 8 and 11 month vehicle and DSP-4 treated TASTPM transgenic mice 
(n=12 per group), scale bar represents and lOOpmetres
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Figure 6.15: NeuN cell count in the hippocampus of 8 month (A) and 11 month (B) vehicle 
and DSP-4 treated C57BL6/J and TASTPM transgenic mice (n=12 per group), data 
represented as count of NeuN stained positive cells and shows mean ± SEM
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6.5 D iscussion
6.5.1 Acute effect o f DSP-4 on NA (5mg/kg and 50mg/kg)
The reduction of central NA by high doses (50mg/kg) of the noradrenergic specific 
neurotoxin DSP-4 has been reported in detail (Jonsson et al, 1981; Hallman & 
Jonsson, 1984; Prieto & Giralt, 2001) and appears specific to axons originating from 
the locus coeruleus (LC) (Fritschy & Grzanna, 1991). DSP-4 treatment subsequently 
causes an acute and selective degeneration of central NA axonal terminals (Fritschy 
et al, 1990) leading to a loss of NA cell bodies in the LC (Fritschy & Grzanna,).
The data described in this experiment confirms that DSP-4 can cause an acute 
reduction of NA in the main LC terminal regions i.e. hippocampus, cortex and 
cerebellum (fig 6.1) using a well-published dose of 50mg/kg DSP-4 (Hallman & 
Jonsson, 1984; Fritschy & Grzanna, 1989; Prieto & Giralt, 2001; Fritschy et al, 1990; 
Fritschy & Grzanna, 1991). As detailed in the methods section of this chapter, 
previous literature revealed multiple IP injections of 50pg/kg DSP-4 was sufficient 
to potentiate neuroinflammation in rats cortically injected with Apl-42 (Heneka et 
al, 2002; Heneka et al, 2003). Through personal communication with Dr D Feinstein, 
a dose of 5mg/kg was considered appropriate to enhance neuroinflammation but 
minimise the incidence of mortality of TASTPM mice. An acute administration of 
5mg/kg DSP-4 significantly reduced cortical, hippocampal and cerebellar NA 
concentrations (fig 6.1) indicating chronic treatment at this dose would successfully 
lower NA levels in TASTPM mice. A cortical NA reduction induced by both DSP-4 
doses was evident irrespective of hemisphere; however, although a significant 
reduction was elicited by 50mg/kg DSP-4 in both sides of the hippocampus a 
decrease in NA in the right hand side using 5mg/kg DSP4 was absent. This may be 
due to a lower hippocampal NA concentration apparent in vehicle treated animals 
relative to other brain regions and the increased variance evident in right hand side 
hippocampal samples.
6.5.2 Repeated administration o f DSP-4 to TASTPM mice
The most prominent neuronal loss evident in AD occurs in the LC (Zarow et al,
2003) and correlates with the duration and severity of dementia (Bondareff et al, 
1987). Previous literature also describes the potentiation of neuroinflammation in
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vivo following noradrenergic depletion by administration of DSP-4 (Heneka et al, 
2002; Heneka et al, 2003; Feinstein et al, 2002; Song et al, 1999; Feinstein et al, 
2004; Wenk et al, 2003). This evidence suggests NA depletion may exacerbate the 
neuroinflammatory actions of amyloid and subsequently enhance neurodegeneration. 
Hence, I investigated the effects of NA depletion elicited by repeated peripheral 
injection of DSP-4 on neuroinflammation, amyloid plaque load and 
neurodegeneration.
6.5.2.1 Neuroinflammation
The anti-inflammatory actions of NA are mediated through the modulation of the 
pro-inflammatory cytokine expression and release from microglia (Russo et al, 2004; 
Loughlin et al, 1993) and can protect cortical neurons against microglial induced cell 
death by inhibiting the release of IL-lp (Madrigal et al, 2005). In contrast, low doses 
of the noradrenergic neurotoxin N - (2-chloroethyl)-N-ethyl-2-bromobenzylamine 
(DSP-4) (50pg/kg) have been reported to exacerbate microglial activation and 
inflammatory gene expression (Feinstein et al., 2004) in APP over expressing mice. 
The present studies demonstrate that modulation of the NA system by repeated 
peripheral administration of the noradrenergic neurotoxin DSP-4 can influence the 
expression of neuroinflammatory markers in APP/PS1 mice. At 8 months of age, 
vehicle treated TASTPM mice displayed an increased neuroinflammatory profile 
demonstrated by a trend for increased cortical mRNA expression of the pro- 
inflammatory cytokine TNF-a and the chemokine M IP-la relative to DSP-4 treated 
TASTPM mice (fig 6.3). There was also a trend towards increased GFAP (p = 0.15) 
in vehicle treated TASTPM relative to DSP-4 treated TASTPM mice (fig 6.3). The 
reduction in GFAP cortical mRNA expression in DSP-4 treated TASTPM mice was 
further supported by patchy cortical GFAP staining relative to strong staining evident 
in C57BL6/J mice (fig 6.5). Interestingly, the trend for an increased 
neuroinflammatory profile in vehicle versus DSP-4 treated TASTPM mice may 
relate to the prevention of a natural decline in cortical extracellular NA observed in 
the vehicle TASTPM transgenic group as a trend towards a reduction in cortical NA 
levels (fig 6.2). A 3 month treatment of 5 mg/kg DSP-4, administered once a month, 
did not decrease extracellular cortical or hippocampal NA levels (fig 6.2) in 
TASTPM mice and did not cause the degeneration of TH-immunopositive cell
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bodies in the LC (fig 6.13). The effect of low (5mg/kg) doses of DSP-4 on NA levels 
in brain tissue has not been reported but the administration of a high dose of DSP-4 
(50mg/kg) causes significant reduction in NA levels (Hallman & Jonsson, 1984). It is 
relevant to the current studies that a 50mg/kg dose of DSP-4 has also been shown to 
result in the acute increase of extracellular NA efflux in rat brain (Hughes & 
Stanford, 1998). Hence, the short term (3 months) repeated peripheral administration 
of DSP-4 at a 5mg/kg dose may not result in a reduction of central NA levels in the 
brain tissue of DSP-4 treated TASTPM mice. Furthermore, since NA exerts anti­
inflammatory actions (Hu et al, 1991), the short term increases in cortical NA levels, 
in the absence of LC damage, may explain the reduction of neuroinflammatory 
markers evident in DSP-4 versus vehicle treated TASTPM brain tissue.
Continued administration of DSP-4 resulted in a significant reduction of TH-positive 
cells in the LC by 11 months (fig 6.13) associated with a significant reduction in 
cortical and hippocampal NA levels relative to vehicle treated TASTPM mice (fig 
6.2). There was no reduction in NA levels in C57BL6/J control mice at any 
timepoint. The noradrenergic depletion caused by repeated injection of 5mg/kg DSP4 
for 6 months to TASTPM mice resulted in the potentiation of cortical IL-ip mRNA 
expression (fig 6.4) and a reduction in IicBa mRNA (fig 6.4), an intracellular 
inhibitory kinase responsible for regulating translocation o f the transcription factor 
NF-kB, important in mediating transcription of target genes. Repeated administration 
of DSP-4 for 6 months did not increase IL-ip mRNA in C57BL6/J control mice. 
Long-term (6 months) administration of DSP-4 at a low dose (5mg/kg) results in the 
exacerbation of A p-induced neuroinflammation evident in APP/PS1 transgenic mice 
via the reduction in extracellular cortical and hippocampal NA levels and the loss of 
TH-positive cell bodies in the LC. The current data support evidence that sufficient 
depletion of the noradrenergic system by DSP-4 treatment can increase inflammatory 
gene expression and particularly that of IL-lp (Heneka et al, 2002; Feinstein et al.,
2004). Neuroinflammation is associated with Ap plaques in AD brain tissue 
(McGeer et al, 1994). The acute increase in cortical NA levels (fig 6.2) in DSP-4 
treated TASTPM mice by 8 months of age also resulted in a significant reduction in 
cortical amyloid plaque load (fig 6.10), which correlates with the significant decrease 
in cortical GFAP staining (fig 6.5) and mRNA expression (fig 6.3). Recent literature 
published after completion of the current study demonstrated that twice monthly
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dosing of 5mg/kg DSP-4 to mutant V717F APP mice over a 6 month period 
exacerbated Ap plaque burden and GFAP staining in brain tissue (Kalinin et al, 
2006). These data described here support evidence that NA can modulate Ap 
deposition and associated neuroinflammation.
6.5.2.2 Neurodegeneration
Recent data has revealed a significant exacerbation of neuronal cell death in the 
hippocampus, cortex and subiculum of APP23 mice following 50mg/kg DSP4 
(Heneka et al, 2006). Here, using a lower 5mg/kg DSP-4 dose repeatedly 
administered monthly for 3 or 6 months, neurodegeneration in the hippocampus, 
quantified as NeuN cell count, was not evident (fig 6.15). It is difficult to compare 
between the study described in this chapter and that reported by Heneka et al, 2006 
since a different DSP-4 protocol and transgenic line was used. The lack of neuronal 
cell death in TASTPM mice following DSP-4 treatment may be explained by the 
difference in DSP-4 dose and protocol reported by Heneka et al, 2006 to that used in 
this study. Heneka et al, 2006 reported a 50-60% reduction in TH staining in the LC 
following two doses of 50mg/kg DSP-4 in contrast to the 19% observed following 
repeated administration of 5mg/kg DSP4 in the current study. A greater magnitude of 
noradrenergic depletion in the LC is subsequently more likely to affect terminal 
regions such as the hippocampus. It is also interesting, however, that control APP23 
mice exhibited significant neurodegeneration in the brain regions studied relative to 
wildtype controls. Hence, DSP-4 treatment significantly exacerbated pre-existing cell 
death in the brain tissue of APP23 mice. A lack of quantifiable neurodegeneration in 
the brain tissue of TASTPM transgenic mice prior to the administration of DSP-4 
may suggest that peripheral injection of DSP-4 exacerbates pre-existing cell death 
rather than initiating the occurrence of neurodegeneration in the rodent brain. To 
address this issue, further work should directly compare the occurrence and 
magnitude of cell death in brain tissue following DSP-4 administration (using the 
same protocol) in APP transgenic lines that usually exhibit or fail to exhibit pre­
existing neurodegeneration. The injection of DSP-4 prior to and after the occurrence 
of pre-existing cell death in APP transgenic animals may also further elucidate the 
role of noradrenergic depletion in initiating or exacerbating neurodegeneration.
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Overall, the current studies provide novel information regarding the effects o f NA 
modulation on neuroinflammation, amyloid load and neurodegeneration in APP/PS1 
transgenic mice, particularly following the short-term treatment o f DSP-4 at 
relatively low doses (5mg/kg). Altering the DSP-4 protocol to induce a more 
significant loss of TH staining in the LC, similar to that reported by Heneka et al, 
2006, may enhance the possibility of increasing Ap plaque deposition and 
neuroinflammation and causing neurodegeneration in TASTPM brain tissue. I have 
been able to begin a further study at GSK, Harlow to investigate modulation of 
neuroinflammation and the occurrence of neurodegeneration in TASTPM brain 
tissue. I am using the DSP-4 protocol described by Heneka et al, 2006. This will 
clarify further the potential of noradrenergic depletion in TASTPM transgenic mice 
to provide markers of neuroinflammation and neurodegeneration.
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CHAPTER 7 
General Discussion & Conclusions
7.1 Discussion
The progression of Alzheimer’s disease (AD) is characterised by Ap plaque 
formation, neuroinflammation and neurodegeneration. Current therapies for AD are 
restricted to symptomatic relief and do not, at present, modulate the pathological 
progression of the disorder. Putative anti-inflammatory and neuroprotective agents 
for AD need to be tested preclinically in rodent in vivo models that demonstrate 
robust and reproducible markers of neuroinflammation and neurodegeneration. This 
thesis explored the development of rodent in vivo models of neuroinflammation and 
neurodegeneration and investigated markers of neuroinflammation and 
neurodegeneration in brain tissue. This involved using a range of in vivo and in vitro 
techniques including IP or ICV injection of LPS, intranuclear injection of Ap, 
western blotting to assess the presence of different Ap forms, oral administration of 
anti-inflammatory agents, immunohistochemical analysis of Ap deposits, neurons 
and immune cells in rodent brain, Luminex® analysis of cytokine and other 
intracellular proteins in brain tissue and lastly, the colorimetric assessment of plasma 
iNOS activity.
7.L I Luminex9  -  cytokine detection in plasma and brain tissue
Cytokines are key mediators of inflammation (reviewed by Cohen & Cohen, 1996) 
and are present in AD brain tissue (Griffin et al, 1995; Grammas et al, 2001; 
Luterman et al, 2000). Thus, the detection and quantification of cytokine expression, 
particularly in brain tissue, is an important readout for in vivo models of 
neuroinflammation. Although the detection of mRNA expression can provide 
information on gene activity, the post transcriptional events leading to protein 
production are not taken into account (reviewed by Lockhart & Winzeler, 2000). 
Hence, the simultaneous detection of cytokine protein is more informative than 
relying on quantification of mRNA expression. The advantage of analysing a wide 
range of cytokines within a single sample via Luminex® ensures that the balance
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fbetween pro- and anti-inflammatory responses can be clearly identified within each 
individual animal. For example, treatment with a putative anti-inflammatory agent 
may increase anti-inflammatory readouts as well as decrease pro-inflammatory 
cytokine expression.
There are currently only two published papers, by the same author, reporting the 
detection of cytokine protein in rodent (mouse) tissue (Goujon et al, 1996; 1997). A 
majority of the published literature relies on the quantification of cytokine mRNA 
expression in brain tissue following IP LPS injection (Gayle et al, 1998; Castanon et 
al, 2004). Since the completion of this current thesis, Roche et al, 2006 have reported 
the detection, by ELISA, of significantly increased IL-ip protein associated with a 
small increase in TNF-a protein in rat brain tissue following IP LPS injection. This 
recent study supports the data that I have obtained using Luminex®. I report a 
significant increase in IL-1 (3 protein throughout rat brain tissue and an inconsistent 
increase in TNF-a and IL-1 a  within various brain regions including the 
hippocampus, cortex and hypothalamus (fig 2.3). Roche et al (2006) investigated 
TNF-a protein at a 2 hour timepoint. The present studies described within this thesis 
focus primarily on a 6 hour timepoint, suggesting that the detection of various 
cytokine proteins is dependent upon the timepoint chosen for study as the time- 
dependant profile of protein production will differ between cytokines. This also has 
implications on the cytokine protein changes evident in brain tissue following ICV 
LPS injection. Administration of LPS via ICV injection significantly increased the 
expression of TNF-a, IL-1 a  and IL-1 [3 protein in brain tissue (fig 3.1 & 3.5). At the 
2 hour timepoint studied, hippocampal cytokine protein was of a greater magnitude 
than cortical cytokine protein. LPS initially activates microglia in hippocampal and 
thalamic areas (Nicholson & Renton, 2001) following ICV administration so that, by 
2 hours post LPS, higher levels of cytokine protein are observed in the hippocampus 
relative to the cortex. In contrast to the wide range of plasma cytokines increased by 
IP LPS including IFN-y, IL-10, IL-la, IL-ip, IL-6 and TNF-a by 6 hours (fig 2.3), 
ICV LPS increased production of IL-ip, IL-6 and TNF-a only (fig 3.3. & 3.6). 
Disparity between the range and levels of plasma cytokine protein induced by IP or 
ICV LPS injection may also relate to differences in the timepoints investigated for 
each administration route.
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7.1,2 Communication o f inflammation between the brain and periphery
I adapted the Luminex® system to detect changes in phosphorylated IkB cx, p38 and 
JNK in brain tissue following IP LPS, providing the first report of the detection of 
phosphorylated intracellular proteins by Luminex®. The phosphorylation of 
intracellular proteins involved in LPS-mediated signalling pathways in brain tissue 
suggests a centrally derived response to peripherally administered LPS. Previous 
literature has reported the possible mechanism by which LPS circulating in blood 
may elicit neuroinflammation (Nadeau & Rivest, 1999). The receptor for LPS, 
TLR4, is located on microglia found at areas of weak blood brain barrier (BBB) 
including the circumventricular organs (CVOs), leptomeninges and choroid plexus 
(ChP) of the brain (Vallieres & Rivest, 1997). Activation of TLR4 causes 
translocation of N F -kB and activation of MAPK pathways resulting in transcription 
of target genes within microglia, firstly at the CVOs, and subsequently throughout 
the brain tissue (Herkenham et al, 1998). Following IP LPS, Luminex® detection of 
intracellular protein phosphorylation revealed that, in agreement with the literature, 
the LPS-mediated inflammatory response occurred through early N F -kB activation 
via phosphorylation of the inhibitory factor, IkB<x in hippocampal brain tissue at 2 
hours following IP LPS (fig 2.8) (Krappmann et al, 2004). N F -kB activation also 
resulted in decreased cortical JNK phosphorylation by 2 hours following IP LPS (fig 
2.8). This supports recent published data indicating N F -kB  has anti-apoptotic 
properties by suppressing JNK activity (Bubici et al, 2006). Phosphorylation of p38 
kinase was increased by 6 hours following IP LPS (fig 2.8) indicating that this is a 
late event in relation to LPS-mediated N F -kB  activation within the IP LPS model, 
which, as is discussed later, has implications on the efficacy of p38 inhibitors in this 
model. To my knowledge, this is the first report describing the utilisation of 
Luminex® suspension bead arrays for detecting intracellular protein phosphorylation 
in rodent brain tissue and illustrates the broader application of this technology for 
detection of proteins in ex vivo tissue. It cannot be discounted that LPS-mediated 
activation of N F -kB and MAPK pathways in the brain following peripheral LPS 
administration may be due to entry of LPS into the brain through the BBB and the 
subsequent action of LPS on immune cells in brain tissue rather than those localised 
at CVOs. Although there is a molecular weight dependent breakdown of the BBB 
following IP LPS this is limited to access of molecules approximately <340Da in
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size (Singh et al, 2004). Interestingly, following an ICV injection of LPS there is 
rapid diffusion of LPS across the BBB into blood (Chen et al, 2000). There is a 
possibility that the indwelling cannula implanted in the brain tissue, necessary for 
ICV administration of LPS, may damage blood vessels within the brain adequately 
for LPS to diffuse into blood quickly. This warrants further investigation by 
assessing the transport across the BBB of dextran molecules more akin to the 
molecular weight of LPS. This will help establish whether entry of LPS into the brain 
following IP or out of the brain following ICV LPS is possible and how much the 
central and peripheral profiles resulting from IP or ICV LPS injection are influenced 
by diffusion of LPS through the BBB.
7.1.3 LPS models o f neuroinflammation -  utility for compound screening
Cytokine protein can be detected in rat brain tissue following IP LPS injection but 
since the inflammatory response is communicated from blood to brain, any reduction 
in the peripheral immune response caused by an anti-inflammatory agent may have a 
knock-on effect to the brain, preventing central cytokine production. Hence, although 
anti-inflammatory activity of a novel agent can be assessed following IP LPS 
injection, the central efficacy of anti-inflammatory agents is difficult to determine. 
The ICV LPS model provides a central inflammatory response evidenced by 
increased protein production of several cytokines. The ICV model is low throughput 
because, in rat; stereotaxic surgery is needed to fix an indwelling cannula or to 
directly inject LPS via Hamilton syringe. The IP and ICV LPS models should be 
used in conjunction to assess putative anti-inflammatory compounds. I assessed the 
effects of the glucocorticoid dexamethasone (DEX), the a l  adrenoceptor antagonist, 
fluparoxan and the p38 inhibitor, GW569293 on LPS-induced cytokine protein 
production.
Glucocorticoids modulate cytokine production by numerous mechanisms as 
previously described in section 1.4.2 of this thesis. DEX is a standard glucocorticoid 
drug used routinely in preclinical models of inflammation and has been reported to 
attenuate plasma cytokine expression following IP LPS injection (Mengozzi et al, 
1994). DEX can reduce LPS-induced cytokine mRNA expression within brain tissue; 
however, the subsequent effect of DEX on cytokine protein readouts had not yet 
been quantified (Satta et al, 1998; Jacobs et al, 1997; Kakizaki et al, 1999). Pre-
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treatment with DEX significantly inhibited the central and peripheral production of 
pro-inflammatory cytokines following IP LPS administration (fig 2.5 & 2.6). Since 
the central efficacy of glucocorticoid was difficult to assess in the IP LPS model, I 
analysed the efficacy of DEX further using the ICV LPS model. This indicated 
peripheral pre-treatment with DEX could fully inhibit hippocampal IL-ip and 
attenuate cortical and hippocampal IL-1 a  and TNF-a following ICV administration 
of 5pg LPS (fig 3.5).
The LPS models have demonstrated peripheral treatment of DEX can inhibit both 
peripheral and centrally derived inflammation. The efficacy of DEX in both the IP 
and ICV LPS models also indicates that, used in conjunction, both models can 
provide valuable information on anti-inflammatory agents.
I further assessed the utilisation of these models using the a2-adrenoceptor 
antagonist, fluparoxan. The role of NA in AD and the action of NA on adrenoceptors 
was described in section 1.8 of this thesis. NA can down-regulate pro-inflammatory 
cytokines (Kaneko et al, 2005). a2 adrenoceptor antagonists act as anti-inflammatory 
agents by increasing NA levels. Pre-treatment with fluparoxan prior to IP LPS 
caused a significant reduction in LPS-induced plasma TNF-a and IL-ip (fig 2.14) 
and attenuated hippocampal IL-ip and cortical IL-1 a  (fig 2.11). This significant 
anti-inflammatory effect of fluparoxan pre-treatment led to the further assessment of 
fluparoxan in the ICV LPS model. Peripherally administered fluparoxan significantly 
attenuated ICV LPS-induced cortical and hippocampal IL-ip and TNF-a and 
reduced cortical IL-1 a  (fig 3.7). These data are the first to demonstrate the anti­
inflammatory properties of a a2-adrenoceptor antagonist fluparoxan, on IL-1 a , IL- 
ip  and TNF-a protein in both plasma and brain tissue. It also indicates the 
importance of NA in the modulation of neuroinflammation. This may have important 
implications in the search for efficacious anti-inflammatory agents suitable for the 
treatment of inflammatory based neurological disorders including AD.
Previous literature describes the anti-inflammatory actions of p38a inhibitors in 
numerous in vivo models of inflammation (Barone et al, 2001; Legos et al, 2001; 
reviewed by Kaminska, 2005). MAP kinase pathways, particularly, p38 kinase, are 
also thought to be involved in LPS-mediated intracellular signalling (Lee & Young, 
1996; Nolan et al, 2003). I had previously demonstrated that, at timepoints used to 
assess cytokine readouts, p38 phosphorylation in cortex occurred by 6 hours
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following IP LPS (fig 2.8). This event was later than IicBa phosphorylation which 
occurred in hippocampus by 2 hours. Hence, involvement of MAP kinase pathways 
may occur as a late event in brain tissue during LPS-induced transcription of target 
genes following IP LPS injection. These data are consistent with a report by Nolan et 
al, 2003 that described the increased phosphorylation in cortex and hippocampus of 
p38 kinase, detected by western blot. The p38 pathway may have a greater 
contribution to the long-term effects of LPS-induced inflammation since the early 
increase in IicBa phosphorylation reveals acute effects in brain tissue caused by the 
peripheral injection of LPS are mediated via NF-kB. Agonism of a2 adrenoceptors 
can induce NF-kB transcriptional activity suggesting an a l  adrenoceptor antagonist 
may inhibit NF-kB transcription of target genes (Lymperopoulos et al, 2006). 
Dexamethasone has also been reported to inhibit NF-kB translocation (Quan et al, 
2000), providing further evidence that agents that can affect the activity of LPS- 
mediated NF-kB activity may subsequently influence the production of pro- and anti­
inflammatory cytokines. It was interesting that subsequent studies demonstrated that 
p38a inhibition failed to modulate cytokine protein production in both the IP and 
ICV LPS models, leading to the hypothesis that, in models demonstrating 
phosphorylation of p38 kinase as a late event and the main transcription of cytokines 
occurring via NF-kB activation, p38 inhibitors fail to influence cytokine expression. 
Previous literature also indicates that p38 activity may be cell-specific, differentially 
affecting cytokine release between different cell types (Van den Blink et al, 2001; 
Zhang et al, 1997). Further investigation to establish the specific immune cells 
activated in plasma and brain tissue following IP LPS injection and a correlation with 
known p38 activity on different cell types is required. It is important to consider the 
mechanism of action of anti-inflammatory agents when investigating their activity 
using LPS models. Agents that may affect cytokine protein production by altering 
gene transcription may not be efficacious in IP or ICV LPS models if they are unable 
to modulate NF-kB activity.
7.1.4 Injection o f  exogenous A f t  in vivo
There are many in vivo models described in the literature that involve the use of a 
variety of Ap fragments, Ap preparations and methods of delivering Ap into rodent 
brain tissue (Miguel-Hidalgo et al, 1998; Craft et al, 2004; Nakagawa et al, 2004;
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Ryu et al, 2004). This huge variation in the literature has led to conflicting reports 
regarding the neuroinflammatory and neurotoxic effects following injection of Ap 
into rodent brain. At low (100pM) concentrations of Api-42, it was revealed that 
ICV tubing with a metal injector attachment was unlikely to be a suitable method for 
Ap delivery (fig 4.2). In contrast, Api-42 (lOOpM) was successfully delivered as 
monomeric, oligomeric and aggregated forms via Hamilton syringe (fig 4.2). 
Previous literature indicates that most researchers prefer to use a Hamilton syringe 
when administering Ap into rodent brain tissue (Song et al, 2001; Ryu et al, 2004). A 
team led by Sally Frautschy routinely use minipumps to chronically infuse 
oligomeric Ap (Frautschy et al, 2001; Craft et al, 2004, Harris-white et al, 2004). The 
analysis of an oligomeric Ap solution expelled from the tubing of a minipump 
revealed that little Api-42 solution was delivered, particularly in the presence of the 
metal cannula (fig 4.3). Oligomeric forms were present in the control sample and a 
sample removed from the minipump but the solution contained within the minipump 
also consisted of Ap aggregates. This suggests the oligomeric Ap solution may 
aggregate over time, which would have implications on the success of the oligomeric 
Ap delivery due to issues with the amount of oligomeric Ap available within the 
minipump and the potential blocking of the plastic minipump tubing by rapidly 
forming Ap aggregates. Interestingly, Ap solutions that had previously been shown 
to cause neurotoxicity in rodent brain tissue when injected via Hamilton syringe 
(Ryu et al, 2004, Miguel-Hidalgo et al, 1998) consisted of mostly monomeric and 
some oligomeric forms of Apl-42. Pre-aggregating Api-42 solutions described in 
these reports resulted in the increased presence of aggregated Ap in a control sample; 
however, this could not be successfully expelled through a Hamilton syringe (fig 
4.4). Hence, Ap aggregates appear difficult to expel successfully from any apparatus 
routinely used to apply agents into brain tissue in vivo. These current novel data 
implies that there are limitations to examining Ap mediated neuroinflammation or 
neurodegeneration in vivo as the direct injection via a Hamilton syringe is restricted 
to the delivery of soluble forms of Api-42.
There is a further concern regarding the successful delivery of Ap into rodent brain 
in vivo. Some authors describe the deposition of injected Ap within brain tissue 
(Miguel-Hidalgo et al, 1998; Weldon et al, 1998); however, in contrast many do not
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report whether the Ap solution injected has been successfully delivered into the brain 
(Jantaratnotai et al, 2003; Ryu et al, 2004; Heneka et al, 2002; Games et al, 1992). In 
agreement with previous literature, viewing Congo red stained Ap deposits under 
polarised light revealed that the Ap did not form fibrils once in the brain tissue (fig 
4.18); therefore, neurotoxicity occurred in response to the presence of soluble Ap 
(Miguel-Hidalgo et al, 1998). Although Ap deposition in brain tissue is a prominent 
feature of AD, it is still unclear whether Ap plaques are causative for the disease. The 
current studies demonstrate that the delivery of Api-42 into rodent brain tissue is 
restricted to soluble forms and that soluble Ap, by 7 days post injection, does not 
fibrillise in the tissue. This suggests it will be difficult to consistently assess the role 
of fibrillised Ap in vivo since it is difficult to achieve reliable delivery and the Ap 
deposit may not aggregate over a short study duration. The argument against a role 
for insoluble Ap in neurotoxicity includes evidence that Ap plaque load does not 
strongly correlate with the progression and severity of cognitive deficits in AD and 
does not cause significant neurodegeneration in mouse with mutant APP or APP and 
PS-1 overexpression (Games et al, 2006). More recently, the levels of soluble 
oligomeric forms of Ap have been shown to correlate with disease severity and 
induce neurotoxicity (Watson et al, 2005; De Felice et al, 2004).
7.1.5 Afi models o f neuroinflammation & neurodegeneration
As stated previously, there is contradictory evidence regarding the neurotoxicity of 
Ap in vivo and much of the variability may result from differences between the Ap 
fragments and method of administration used. However, the solvent employed to 
dissolve and prepare the Ap can also vary widely (Winkler et al, 1994; O’Hare et al, 
1999; Waite et al, 1992, Ryu et al, 2004). In the current studies, Ap was dissolved in 
PBS which caused approximately a 25% hippocampal cell loss (fig 4.13) and 69% 
mediolateral damage (fig 4.14) relative to vehicle treated animals. This effect was 
similar to that achieved by Ryu et al, 2004 in which Ryu et al described the 
comparison of Ap injected rats with non injected shams. In contrast to Ryu et al, 
2004, the current studies revealed that Apl-42 dissolved in acetonitrile, at either 0.35 
or 0.035%, caused toxicity that was similar to the neurotoxic effect of acetonitrile 
injection alone (fig 4.7 & 4.13). This highlights the importance of comparing an Ap 
injected animal to vehicle injection rather than non injected sham rats. The data
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described in this thesis suggests that Api-42 does not exacerbate acetonitrile driven 
cell death and that acetonitrile causes significant neurotoxicity in vivo, even when 
administered in relatively small quantities. This disagrees with a previous report 
suggesting that Ap may potentiate the toxicity of 35% acetonitrile in vivo (Waite et 
al, 1992) but this study described the injection of 3nmol human Api-40 or rat A pi- 
42 in contrast to the lnmol human Apl-42 used in these current studies. Acetonitrile 
is believed to cause calcium driven neurotoxicity and due to the nature of this in vivo 
model, direct application of an acetonitrile based vehicle onto hippocampal cells in 
vivo is likely to cause a large degree of neurotoxicity (Waite et al, 1992).
In contrast to the variable and inconsistent neurotoxicity induced by injection of Ap, 
significant neuroinflammation was observed around the injection site. Quantification 
of microglial and macrophage staining revealed a clear increase in 
neuroinflammation following injection of Api-42 when using either PBS alone of 
acetonitrile/PBS as a vehicle (fig 4.16). This indicates that Api-42 causes significant 
neuroinflammation whilst acetonitrile elicits neurotoxicity via an alternative 
mechanism (i.e. calcium-mediated neurotoxicity). The macrophage and microglia 
were surrounding the extracellular deposit and cell loss was evident only adjacent to 
the deposit (fig 4.15). This is similar to that seen in AD brain tissue since activated 
microglia surround extracellular senile plaques (McGeer et al, 1994). The role of 
microglia in mediating Ap-induced cell death is unclear. Activated microglia 
phagocytose extracellular Ap deposits and may attack the surrounding healthy tissue. 
Microglia can also release neurotoxic reactive species that cause further damage 
(Minager et al, 2002). It is possible that the toxicity evident in an exogenous Ap 
injection model occurs via an inflammatory-driven mechanism comprising the 
release of toxic agents by microglia and macrophage surrounding the Ap deposit. 
Certainly, the direct injection of soluble AP primarily caused robust and quantifiable 
neuroinflammation with a small window of neurodegeneration. In vitro evidence 
suggests that the presence of microglia and the corresponding release of reactive 
oxygen species enhance Ap neurotoxicity, particularly when cells are incubated with 
low concentrations of Ap (Qin et al, 2002). Ryu et al, 2004 reported that 
minocycline, an antibiotic with anti-inflammatory properties in vivo, attenuated 
neuroinflammation and neurodegeneration following intra-hippocampal injection of 
soluble Apl-42 into rat brain tissue lending support that extracellular Ap induced
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neurotoxicity may be mediated by an inflammatory mechanism. In addition, 
intracellular soluble Ap pools have also been suggested to significantly contribute to 
cell death (Wirths et al, 2004). Recent evidence suggests a role for microglia in 
converting extracellular soluble Ap deposits, originally released from intraneuronal 
soluble Ap stores, into fibrillar Ap (Nagele et al, 2004). The role of extracellular 
insoluble Ap in AD remains uncertain and whilst fibrillised Ap will contribute to 
neuronal cell death in brain tissue, some argue that core plaques may also be 
neuroprotective by sequestering toxic Ap from intracellular pools of soluble Ap (Yan 
et al, 1996). Recently generated transgenic models of APP/PS1 overexpression 
exhibit intraneuronal Ap that correlates with neuronal loss in brain tissue further 
supporting a role for intraneuronal Ap in neurodegeneration. Although intraneuronal 
Ap may increase the window of cell death observed in an in vivo model of Ap 
mediated cell death, it is unlikely that this will be achieved by injection of exogenous 
Ap into rodent brain. Furthermore, the nature of the direct injection procedure in 
vivo and the resulting variability in neurotoxicity may only provide inconsistent 
readouts of neuronal cell death that are unsuitable for compound screening. This is in 
contrast to the significant Ap mediated neurotoxicity seen in vitro as the incubation 
of neuronal cells with Ap has been reported to cause significant cell death (Yankner 
et al, 1990) and neuronal cell culture assays are used to assess the activity of putative 
neuroprotective agents (Ban et al, 2006). The disparity between in vitro and in vivo 
models investigating Ap-mediated neurotoxicity is likely to be due to a wide variety 
of factors including differences between the amount of Ap administered to cause cell 
death in vitro or in vivo, variation of the Ap aggregation rate between an in vitro and 
in vivo setting and, importantly, the lack of cell-cell interactions in vitro. Taken 
together, previous literature and the current studies suggest that the magnitude of 
neurotoxicity observed in vitro has yet to be consistently detected in rodent in vivo 
Ap injection/infusion models. An in vivo Ap injection rodent model is more likely to 
be useful in the screening of putative anti-inflammatory agents for AD since robust 
changes in neuroinflammation were evident in the current studies.
In addition to Ap, another feature of AD is the intracellular aggregation of the 
microtubule associated protein tau as neurofibrillary tangles (NFTs) (Blennow et al, 
2006). This pathological characteristic is not considered in models of Ap induced
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neuroinflammation or neurodegeneration but NFTs have been shown to correlate 
with neuronal cell loss (Gomez-Isla et al, 1997) in AD. Previous studies have been 
conducted to investigate the effect of Ap injection on NFT numbers in the brain 
tissue of tau transgenic mice (Gotz et al, 2001). Triple (APP/PSl/tau) transgenic 
mice have also been generated (Oddo et al, 2006) but interestingly, recent data using 
these mice suggests that the presence of intraneuronal Ap precedes evidence of Ap 
plaques or tau pathology and correlates with deficits in synaptic plasticity (Cole et al, 
2006). Future studies using models that combine Ap and tau pathology will further 
elucidate the role of intracellular and extracellular Ap and NFTs in 
neurodegeneration and neuroinflammation.
7.1.6 APP & APP/PS1 transgenic mouse models
Cytokines are present in the plasma, cerebrospinal fluid and brain tissue of AD 
patients (McGeer & McGeer, 2002). It remains controversial whether this 
inflammatory response is causal or consequential in the pathology of the disease 
(Perry et al, 2004). It is, therefore, interesting that peripheral infection can enhance 
cognitive decline and increase signs of neuroinflammation in AD patients (Holmes et 
al, 2003) suggesting a role for peripheral infection in the exacerbation of AD brain 
pathology. Early reports of APP or APP/PS1 transgenic mouse models were useful 
for the assessment of cognition and behaviour, amyloid neuropathology and 
neuroinflammation but apart from the neurodegeneration exhibited in the APP23 
mouse line, most fail to demonstrate any overt neuronal loss (Stein & Johnson, 2002; 
Higgins & Jacobsen, 2003). Challenging transgenic mice with peripherally 
administered inflammatory or neurotoxic agents is a relatively new approach 
supported by early evidence that IP LPS administration to animals injected with 
prion protein exacerbates neuropathology and behavioural endpoints (Cunningham et 
al, 2005). This demonstrates the use of LPS to enhance pathology in other models of 
neurodegeneration. There has been little comprehensive assessment of the effect of 
peripheral LPS in APP/PS1 transgenic models, particularly investigating the 
production of cytokine protein (Sly et al, 2001) rather than mRNA cytokine readouts 
(Abbas et al, 2002; Lim et al, 2000). Quantification of cytokine protein in plasma and 
brain tissue following an acute peripheral LPS challenge in the APP/PS1 model 
TASTPM revealed an exacerbation of a pre-existing neuroinflammatory profile. 
Vehicle treated TASTPM mice exhibited increased central M IP-la by 10 months of
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age (fig 5.4). Following IP LPS challenge, increased central M IP-la became evident 
from 5 months of age and maintained at 10 months in TASTPM brain tissue (fig 5.4). 
Acute LPS challenge did not significantly cause any other alteration in the 
neuroinflammatory profile of the TASTPM mouse. Chronic LPS did not exacerbate 
neuroinflammation or cause neurodegeneration in the TASTPM model. It cannot be 
discounted that the lack of any overt effect of repeated administration of LPS 
peripherally may be due to the duration of the treatment or the dose of LPS chosen. 
Certainly, throughout the long duration of a chronic neurodegenerative disorder like 
AD, a persistent peripheral infection may eventually cause neurodegeneration or 
cause significant exacerbation of pre-existing pathology. The earlier detection of 
M IP-la in TASTPM brain tissue following a single acute dose of LPS would 
suggest that, providing the magnitude of the peripheral inflammatory response were 
sufficient, it can exacerbate pre-existing neuroinflammation.
In addition, administration of the noradrenergic neurotoxin DSP-4 to TASTPM mice 
resulted in the modulation of inflammatory endpoints (fig 6.3 & 6.4) and Ap 
deposition (fig 6.8 -  6.10). Unexpected increases in hippocampal and cortical NA 
levels (fig 6.2) in TASTPM mice after 3 monthly injections with DSP-4 was 
associated with a decrease in AP plaque deposition and an attenuation of cytokine 
and chemokine mRNA expression in TASTPM brain tissue. This is consistent with 
previous reports describing the potentiation of inflammation and Ap deposition 
following significant noradrenergic depletion (Heneka et al, 2002; Kalinin et al, 
2006). Since the completion of this current study, Heneka et al 2006 reported that 
DSP-4 administration exacerbated cell loss and neuroinflammation in the brain tissue 
of APP23 mice. The APP23 mouse line has been previously reported to demonstrate 
significant neurodegeneration (Bondolfi et al, 2002). The TASTPM model does not 
demonstrate significant overt cell death. This implies that for a toxic peripheral 
challenge to induce a significant effect on cell death, a transgenic model must be 
chosen that has significant pre-existing neurodegenerative pathology.
7.1.7 Conclusion and future studies
This thesis has presented studies investigating the development of rodent in vivo 
models comprising markers of neuroinflammation and neurodegeneration pertinent
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to AD. Although a single acute injection of Ap or LPS or the administration of a 
peripheral insult to APP/PS1 overexpressing transgenic mice does not constitute a 
model of AD, particularly since these are relatively short duration studies in contrast 
to the chronic progressive nature of AD, the data described here have strong 
implications on the future development of in vivo models for screening putative 
therapeutic strategies for AD.
These data and more recent published studies suggest that administering a peripheral 
inflammatory or neurotoxic insult to mice with overexpression of mutant APP or 
APP/PS1 may provide robust and quantifiable markers of neuroinflammation and 
neurodegeneration suitable for screening novel agents. Heneka et al (2006) reported 
that the administration of a higher dose of DSP-4 (50mg/kg) to APP23 mice that 
exhibit neurodegeneration correlating with the presence of intraneuronal Ap 
exacerbates neuroinflammation and neurodegeneration. As a consequence of this 
recent publication and the data reported in this thesis, access to TASTPM mice has 
allowed me to continue this line of research. I will be investigating 
neuroinflammation (by immunohistochemistry and Luminex®) and 
neurodegeneration in TASTPM brain tissue at 8 and 11 months of age following IP 
administration of two 50mg/kg doses of DSP-4 (given a week apart) at 5 months of 
age. It will be interesting to determine whether administration of DSP-4 (50mg/kg), 
to an APP/PS1 transgenic mouse line that does not exhibit pre-existing 
neurodegeneration or significant intraneuronal Ap, results in the potentiation of 
neuroinflammation and initiates neurodegeneration. The novel data described in this 
thesis will focus the development of in vivo models to approaches most likely to 
provide robust markers of neuroinflammation and neurodegeneration in the future for 
the successful screening of novel disease modifying agents for AD.
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